1 00:00:05,160 --> 00:01:00,400 >>WELCOME TO NHLBI COUNCIL 2 00:01:00,400 --> 00:01:02,280 >> I'LL QUICKLY GO OVER THE 3 00:01:02,280 --> 00:01:06,440 AGENDA SO WE KNOW WE HAVE 4 00:01:06,440 --> 00:01:09,560 SCHEDULED FOR OUR MEETING TODAY 5 00:01:09,560 --> 00:01:13,080 SO WE'LL BEGIN WITH DR. GIBBONS' 6 00:01:13,080 --> 00:01:17,680 REPORT ALONG WITH DR. CLAUDIA 7 00:01:17,680 --> 00:01:19,160 KEMPER AND WE'LL REVIEW THE 8 00:01:19,160 --> 00:01:21,680 NHLBI CONCEPTS FOR CLEARANCE 9 00:01:21,680 --> 00:01:23,280 DISCUSSED AT THE MEETING BEFORE 10 00:01:23,280 --> 00:01:24,560 WE END THE OPEN SESSION. 11 00:01:24,560 --> 00:01:26,160 IT'S A PACKED AGENDA SO I THINK 12 00:01:26,160 --> 00:01:29,080 WE SHOULD GO AHEAD AND GET 13 00:01:29,080 --> 00:01:29,320 STARTED. 14 00:01:29,320 --> 00:01:31,160 PATRICK GIBBONS, WE'RE ANXIOUS 15 00:01:31,160 --> 00:01:34,560 TO HEAR YOU'RE REPORT. 16 00:01:34,560 --> 00:01:44,880 >> THANKS VERY MUCH. 17 00:01:51,120 --> 00:01:54,960 >> AS IS OUR CUSTOM I'LL ADDRESS 18 00:01:54,960 --> 00:01:58,960 OUR ACCOUNTABLE STEWARDSHIP 19 00:01:58,960 --> 00:02:00,560 ELEMENTS AS WELL AS SCIENTIFIC 20 00:02:00,560 --> 00:02:01,200 OPPORTUNITIES ARE EXHIBITING OUR 21 00:02:01,200 --> 00:02:08,080 PRIORITIES. 22 00:02:08,080 --> 00:02:10,640 FIRST A REVIEW OF WHERE WE ARE 23 00:02:10,640 --> 00:02:16,400 WITH THE FISCAL YEAR 2022 24 00:02:16,400 --> 00:02:16,640 BUDGET. 25 00:02:16,640 --> 00:02:20,680 FIRST YOU'LL NOTE A NOTE OF 26 00:02:20,680 --> 00:02:23,360 APPRECIATION FOR THE BIPARTISAN 27 00:02:23,360 --> 00:02:26,000 SUPPORT OF NIH PARTICULARLY OVER 28 00:02:26,000 --> 00:02:29,200 THE LAST SEVERAL YEARS THAT HAS 29 00:02:29,200 --> 00:02:31,880 YIELDED YEAR OVER YEAR INCREASES 30 00:02:31,880 --> 00:02:34,560 THAT HAVE HELPED US STAY JUST 31 00:02:34,560 --> 00:02:45,040 ABOVE AND AHEAD OF INFLATION. 32 00:03:01,320 --> 00:03:04,800 WITH SARS COV2 INFECTION AND 33 00:03:04,800 --> 00:03:05,760 HIGHLIGHTING AREAS OF CONCERN 34 00:03:05,760 --> 00:03:09,960 RELATED TO THE NEXT GENERATION. 35 00:03:09,960 --> 00:03:17,760 A FEW IMPORTANT THEMES THAT WERE 36 00:03:17,760 --> 00:03:19,080 NOTEWORTHY WAS COMORBIDITY AND 37 00:03:19,080 --> 00:03:21,040 MORTALITY THAT INTERSECTS WITH 38 00:03:21,040 --> 00:03:23,720 HEALTH DISPARITIES RESEARCH. 39 00:03:23,720 --> 00:03:25,280 CLIMATE CHANGE AND HEALTH AS 40 00:03:25,280 --> 00:03:28,040 WELL AS HOW WE'RE DEALING WITH 41 00:03:28,040 --> 00:03:28,880 THE STRUCTURAL RACISM AND ENDING 42 00:03:28,880 --> 00:03:31,520 HARASSMENT. 43 00:03:31,520 --> 00:03:34,600 TOWARD THAT END, THE CONGRESS 44 00:03:34,600 --> 00:03:37,400 DID APPROPRIATE AN INCREASE 45 00:03:37,400 --> 00:03:42,160 ABOVE FY21 TO NIH OVER ALL AND 46 00:03:42,160 --> 00:03:46,320 FORTUNATELY THE NHLBI WAS PART 47 00:03:46,320 --> 00:03:48,960 OF THAT RISING TIDE WITH AN 48 00:03:48,960 --> 00:03:55,080 INCREASE OF 3.9% OVER ALL AND OF 49 00:03:55,080 --> 00:03:58,480 PARTICULAR NOTE OF A BASE 50 00:03:58,480 --> 00:03:59,760 INCREASE OF THE SEAL PROGRAM 51 00:03:59,760 --> 00:04:02,520 COMMUNITY ENGAGED ALLIANCE 52 00:04:02,520 --> 00:04:07,440 AGAINST COVID DISPARITIES THAT 53 00:04:07,440 --> 00:04:10,960 NHLBI CO-LED WITH THE NIMHD AS 54 00:04:10,960 --> 00:04:12,560 PART OF THE TRANS-NIH EFFORT TO 55 00:04:12,560 --> 00:04:16,360 PROMOTE COMMUNITY-ENGAGED 56 00:04:16,360 --> 00:04:17,400 RESEARCH AS PART OF THE PANDEMIC 57 00:04:17,400 --> 00:04:18,600 RESPONSE WITH A PARTICULAR FOCUS 58 00:04:18,600 --> 00:04:20,640 ON UNDER SERVED COMMUNITIES, 59 00:04:20,640 --> 00:04:23,800 COMMUNITIES OF COLOR THAT WERE 60 00:04:23,800 --> 00:04:24,440 DISPROPORTIONATELY AFFECTED BY 61 00:04:24,440 --> 00:04:26,480 THE PANDEMIC. 62 00:04:26,480 --> 00:04:28,240 ALSO NOTABLE IN THE 63 00:04:28,240 --> 00:04:30,800 APPROPRIATION NOT ONLY WAS THAT 64 00:04:30,800 --> 00:04:35,000 $45 BILLION FOR NIH OVER ALL, 65 00:04:35,000 --> 00:04:37,640 AGAIN A PARTICULAR CALL OUT TO 66 00:04:37,640 --> 00:04:41,160 AN INCREMENT GIVEN TO SUPPORT 67 00:04:41,160 --> 00:04:42,240 MATERNAL MORBIDITY AND MORTALITY 68 00:04:42,240 --> 00:04:45,440 RESEARCH PARTICULARLY THE 69 00:04:45,440 --> 00:04:47,760 IMPROVE PROGRAM A TRANS-NIH 70 00:04:47,760 --> 00:04:49,320 INITIATIVE FOCUSSED IN ON 71 00:04:49,320 --> 00:04:51,440 MATERNAL HEALTH WITH EMPHASIS ON 72 00:04:51,440 --> 00:04:54,520 THE STRIKING RACIAL ETHNIC 73 00:04:54,520 --> 00:04:57,400 DISPARITIES IN MATERNAL HEALTH 74 00:04:57,400 --> 00:04:59,600 THAT THE NHLBI IS PARTICIPATING 75 00:04:59,600 --> 00:05:02,840 IN GIVEN OUR PORTFOLIO. 76 00:05:02,840 --> 00:05:06,280 SIMILARLY, A $1 BILLION 77 00:05:06,280 --> 00:05:08,160 ALLOCATION TO ARPA-H AS A NOVEL 78 00:05:08,160 --> 00:05:16,480 ENTITY IN HHS. 79 00:05:16,480 --> 00:05:18,800 ARE THIS ENABLES US TO PURSUE 80 00:05:18,800 --> 00:05:24,320 SOME PRIORITIES IN PROMOTING 81 00:05:24,320 --> 00:05:24,960 INVESTIGATOR-INITIATED SCIENCE. 82 00:05:24,960 --> 00:05:29,800 AND WE'VE TRIED TO MAINTAIN A 83 00:05:29,800 --> 00:05:37,280 STEADY CONSISTENT PREDICTIVE AND 84 00:05:37,280 --> 00:05:39,480 SUSTAINABLE PRIORITY FOR OUR RO1 85 00:05:39,480 --> 00:05:41,480 INVESTIGATORS SEEKING TO 86 00:05:41,480 --> 00:05:46,520 MAINTAIN A SUCCESS RATE IN THE 87 00:05:46,520 --> 00:05:47,040 20s. 88 00:05:47,040 --> 00:05:47,800 IT DIPPED A LITTLE BIT BELOW 89 00:05:47,800 --> 00:05:52,520 THAT THIS YEAR BUT AS YOU MAY 90 00:05:52,520 --> 00:05:55,040 NOTICE, THAT THE SUCCESS RATE IS 91 00:05:55,040 --> 00:05:59,040 A FRACTION OR A RATIO OF 92 00:05:59,040 --> 00:06:00,160 APPLICATIONS TO AWARDS. 93 00:06:00,160 --> 00:06:02,680 YOU'LL SEE THAT THERE'S A 94 00:06:02,680 --> 00:06:03,280 PARTICULAR INCREASE IN THE 95 00:06:03,280 --> 00:06:05,640 NUMBER OF APPLICATIONS WE 96 00:06:05,640 --> 00:06:09,800 RECEIVED OVER THE LAST FOUR 97 00:06:09,800 --> 00:06:10,880 YEARS. 98 00:06:10,880 --> 00:06:16,560 IT'S FAIRLY SUBSTANTIAL, 2942 IN 99 00:06:16,560 --> 00:06:23,800 2018 AND 3700 IN 2022. 100 00:06:23,800 --> 00:06:25,480 THAT INCREASE IN APPLICATIONS 101 00:06:25,480 --> 00:06:28,240 HOPEFULLY IS INDICATIVE OF A 102 00:06:28,240 --> 00:06:29,760 VIBRANT COMMUNITY OF SCIENTISTS 103 00:06:29,760 --> 00:06:32,800 WITH A LOT OF GREAT IDEAS. 104 00:06:32,800 --> 00:06:34,360 THE CHALLENGE THAT OUR 105 00:06:34,360 --> 00:06:36,200 APPROPRIATION HASN'T QUITE KEPT 106 00:06:36,200 --> 00:06:38,840 UP WITH THAT EXUBERANT RESPONSE 107 00:06:38,840 --> 00:06:42,560 EVEN THOUGH WE'RE STILL GIVING 108 00:06:42,560 --> 00:06:45,480 OUT MORE AWARDS OVER ALL THAT 109 00:06:45,480 --> 00:06:46,680 HAS RESULTED IN A SLIDE DIP IN 110 00:06:46,680 --> 00:06:50,520 THE SUCCESS RATE. 111 00:06:50,520 --> 00:06:54,120 WE'RE SEEKING TO SUSTAIN AND 112 00:06:54,120 --> 00:06:56,360 MAINTAIN SUCCESS RATE FOR 113 00:06:56,360 --> 00:06:57,360 EARLY-STAGE INVESTIGATORS WITH 114 00:06:57,360 --> 00:06:59,800 THE 10-POINT HANDICAP AND ABOVE 115 00:06:59,800 --> 00:07:03,520 THE 15% THIS TIME THAT YIELDED A 116 00:07:03,520 --> 00:07:05,800 SUCCESS RATE IN THE MID 30s WE 117 00:07:05,800 --> 00:07:08,960 TRY TO MAINTAIN AS WELL AS A 118 00:07:08,960 --> 00:07:11,000 ROBUST SUCCESS RATE FOR OUR K 119 00:07:11,000 --> 00:07:14,600 AWARDS AS PART OF OUR COMMITMENT 120 00:07:14,600 --> 00:07:21,760 TO THE NEXT GENERATION. 121 00:07:21,760 --> 00:07:24,440 LET ME PIVOT FROM STEWARDSHIP TO 122 00:07:24,440 --> 00:07:29,760 ADVANCING SCIENTIFIC PRIORITIES. 123 00:07:29,760 --> 00:07:32,760 FIRST AND FOREMOST, I WANT TO 124 00:07:32,760 --> 00:07:37,080 GIVE A PARTICULAR SHOUT OUT AND 125 00:07:37,080 --> 00:07:41,880 ACKNOWLEDGEMENT, RECOGNITION, TO 126 00:07:41,880 --> 00:07:42,800 OUR BELOVED SCIENTIFIC DIRECTOR 127 00:07:42,800 --> 00:07:46,240 DR. BALABAN WHO HAS MADE THE 128 00:07:46,240 --> 00:07:48,120 DECISION TO STEP DOWN AS 129 00:07:48,120 --> 00:07:48,880 SCIENTIFIC DIRECTOR. 130 00:07:48,880 --> 00:07:50,600 HE'S NOT LEAVING US, HE'S GOING 131 00:07:50,600 --> 00:07:58,360 TO KEEP HIS LAB BUT AFTER 20 132 00:07:58,360 --> 00:07:59,720 YEARS AS SCIENTIFIC DIRECTOR 133 00:07:59,720 --> 00:08:00,920 HE'S STEPPING DOWN FROM THAT 134 00:08:00,920 --> 00:08:06,560 POSITION AND ACCORDINGLY WE'VE 135 00:08:06,560 --> 00:08:07,160 INITIATED A SEARCH PROCEEDING 136 00:08:07,160 --> 00:08:09,560 QUITE WELL ACCORDING TO OUR 137 00:08:09,560 --> 00:08:10,560 TIMETABLE. 138 00:08:10,560 --> 00:08:12,720 WE ARE CONFIDENT WE'LL BE ABLE 139 00:08:12,720 --> 00:08:16,600 TO ENABLE BOB TO RETURN TO HIS 140 00:08:16,600 --> 00:08:18,560 LAB IN THE VERY NEAR FUTURE. 141 00:08:18,560 --> 00:08:21,960 BOB HAS DONE A FABULOUS JOB AS 142 00:08:21,960 --> 00:08:22,440 SCIENTIFIC DIRECTOR. 143 00:08:22,440 --> 00:08:25,520 I THINK HE'S BEEN A MODEL AS A 144 00:08:25,520 --> 00:08:28,800 SCIENTIFIC DIRECTOR AND ACHIEVED 145 00:08:28,800 --> 00:08:29,720 AND ACCOMPLISHED SO MUCH. 146 00:08:29,720 --> 00:08:34,160 IN PART RELATED BECAUSE HE'S A 147 00:08:34,160 --> 00:08:34,920 TERRIFIC SCIENTIST AND THIS IS 148 00:08:34,920 --> 00:08:38,040 AN ATTEMPT TO GIVE HIM A SHOUT 149 00:08:38,040 --> 00:08:40,680 OUT OF THE SCIENTIFIC 150 00:08:40,680 --> 00:08:42,360 ACHIEVEMENTS THAT HE HAS. 151 00:08:42,360 --> 00:08:44,960 HE'S NOT ONLY BRILLIANT BUT A 152 00:08:44,960 --> 00:08:47,800 SMART MAN BECAUSE WHEN WE HAD 153 00:08:47,800 --> 00:08:50,040 ONE-ON-ONES HE OFTEN SHARES WITH 154 00:08:50,040 --> 00:08:52,280 ME WHAT'S GOING ON IN HIS LAB 155 00:08:52,280 --> 00:08:56,320 AND WHAT HE'S EXCITED ABOUT AND 156 00:08:56,320 --> 00:08:59,600 ONE OF THE CHALLENGES OF BEING 157 00:08:59,600 --> 00:09:01,320 DIRECTOR OF NHLBI A NEEDED FIX 158 00:09:01,320 --> 00:09:03,880 FOR SCIENTIFIC DATA ON A 159 00:09:03,880 --> 00:09:05,160 RECURRENT BASIS. 160 00:09:05,160 --> 00:09:08,120 JOB'S A RELIABLE SOURCE FOR THAT 161 00:09:08,120 --> 00:09:11,800 AND JUST GETTING INSIGHTS IN HIS 162 00:09:11,800 --> 00:09:13,960 FASCINATION WITH MITOCHONDRIAL 163 00:09:13,960 --> 00:09:15,840 BIOLOGY HAS BEEN FUN AND I'VE 164 00:09:15,840 --> 00:09:17,760 BEEN BLOWN AWAY BY HIM SHARING 165 00:09:17,760 --> 00:09:18,800 HIS WORK. 166 00:09:18,800 --> 00:09:20,720 IT'S REALLY STATE OF THE ART IN 167 00:09:20,720 --> 00:09:26,440 TERMS OF USING OPTICAL 168 00:09:26,440 --> 00:09:28,840 TECHNIQUES AND ISOLATED HOUSE 169 00:09:28,840 --> 00:09:32,440 HEART TO TRACK WITH NMR SPECTRA 170 00:09:32,440 --> 00:09:35,720 AND THE METABOLISM OF THE HEART 171 00:09:35,720 --> 00:09:38,920 IN AN ELEGANT WAY EVEN THE 172 00:09:38,920 --> 00:09:43,320 HISTORIC STANLEY SURNOOFF WOULD 173 00:09:43,320 --> 00:09:44,960 BE PROUD IS STILL GOING OFF ON 174 00:09:44,960 --> 00:09:47,800 AT THE NIH AND AT THE LEVEL OF 175 00:09:47,800 --> 00:09:50,400 ELEGANCE WE'RE CAPABLE IN 2022. 176 00:09:50,400 --> 00:09:54,480 AND BOB'S LAB TAKING A SYSTEMS 177 00:09:54,480 --> 00:09:57,000 APPROACH AND PROTEOMICS, 178 00:09:57,000 --> 00:09:59,160 ETCETERA, HAS REVEALED SOME 179 00:09:59,160 --> 00:10:00,240 ASTOUNDING THINGS IN TERMS OF 180 00:10:00,240 --> 00:10:03,920 THE MITOCHONDRIA OF THE HEART 181 00:10:03,920 --> 00:10:10,800 AND THE NETWORKS AND RETICULA 182 00:10:10,800 --> 00:10:13,640 AND MAYBE THAT'S WHAT WE'LL MAKE 183 00:10:13,640 --> 00:10:17,880 HIM DO IS GIVE A TALK AND SHARE 184 00:10:17,880 --> 00:10:18,560 OBSERVATIONS. 185 00:10:18,560 --> 00:10:22,800 SUFFICE TO SAY IT'S THAT BURNING 186 00:10:22,800 --> 00:10:24,360 CURIOSITY AND ENERGY THAT'S MADE 187 00:10:24,360 --> 00:10:27,960 HIM AN EXCEPTIONAL SCIENTIFIC 188 00:10:27,960 --> 00:10:28,200 DIRECTOR. 189 00:10:28,200 --> 00:10:30,120 HIS LEGACY WILL JOIN THOSE OF 190 00:10:30,120 --> 00:10:40,680 THE SARNOFFS WHO GRACE THE DIR. 191 00:10:44,880 --> 00:10:46,560 THE INCREDIBLE LEGACY IS THE 192 00:10:46,560 --> 00:10:48,560 ENVIRONMENT CREATED IN OUR 193 00:10:48,560 --> 00:10:53,040 PROGRAM THOUGH I'M BIASSED I AM 194 00:10:53,040 --> 00:10:55,880 UNABASHEDLY WOULD SAY THE BEST 195 00:10:55,880 --> 00:10:58,240 PROGRAM AT NIH. 196 00:10:58,240 --> 00:11:01,240 CERTAINLY PUNCHING ABOVE ITS 197 00:11:01,240 --> 00:11:01,920 WEIGHT. 198 00:11:01,920 --> 00:11:03,920 IT'S ALL ABOUT THE PEOPLE HE'S 199 00:11:03,920 --> 00:11:06,560 RECRUITED AND RETAINED OVER HIS 200 00:11:06,560 --> 00:11:10,880 20-YEAR TENURE. 201 00:11:10,880 --> 00:11:12,800 IN PARTICULAR I'VE ALWAYS CHIDED 202 00:11:12,800 --> 00:11:15,760 HIM HIS JOB IS TO CREATE THE 203 00:11:15,760 --> 00:11:18,320 ENVIRONMENT, THE NEST, IN WHICH 204 00:11:18,320 --> 00:11:22,520 THESE YOUNG INVESTIGATORS CAN 205 00:11:22,520 --> 00:11:22,840 THRIVE. 206 00:11:22,840 --> 00:11:25,960 HE'S RECRUITED AN INCREDIBLE 207 00:11:25,960 --> 00:11:28,760 BEVY OF THEM AND YOU CAN SEE A 208 00:11:28,760 --> 00:11:33,160 DIVERSE GROUP, INCREDIBLY 209 00:11:33,160 --> 00:11:34,000 TALENTED DOING RESEARCH ACROSS 210 00:11:34,000 --> 00:11:35,880 AN INCREDIBLE SPECTRUM OF 211 00:11:35,880 --> 00:11:39,520 SCIENCE AND DISCIPLINES AND 212 00:11:39,520 --> 00:11:42,560 AGAIN HE MAKES US ALL PROUD BY 213 00:11:42,560 --> 00:11:46,560 THE IRP OF THE RESEARCH PROGRAM 214 00:11:46,560 --> 00:11:50,280 HE'S CREATED HERE AND THAT IS 215 00:11:50,280 --> 00:11:52,880 REALLY EXEMPLIFIED BY THESE FINE 216 00:11:52,880 --> 00:11:53,920 INVESTIGATORS AND DURING JUNE 217 00:11:53,920 --> 00:11:57,760 COUNCIL AS MANY ARE FAMILIAR, 218 00:11:57,760 --> 00:11:59,880 THAT'S THE TIME THAT WE TAKE 219 00:11:59,880 --> 00:12:02,520 PARTICULAR NOTE OF COUNCIL IN 220 00:12:02,520 --> 00:12:07,160 WHICH WE SHARE THE READOUTS AND 221 00:12:07,160 --> 00:12:09,800 EVALUATION OF OUR INTRAMURAL 222 00:12:09,800 --> 00:12:11,880 INVESTIGATORS AS THEY UNDER GO 223 00:12:11,880 --> 00:12:14,120 THEIR QUADRENNIAL REVIEWS BY THE 224 00:12:14,120 --> 00:12:17,720 BOARD OF SCIENTIFIC COUNSELORS 225 00:12:17,720 --> 00:12:19,480 IN WHICH THEIR PROGRESS IS 226 00:12:19,480 --> 00:12:21,080 EVALUATED AS PART OF THE 227 00:12:21,080 --> 00:12:23,480 STEWARDSHIP OF THE INTRAMURAL 228 00:12:23,480 --> 00:12:23,720 PROGRAM. 229 00:12:23,720 --> 00:12:26,520 ON THE RIGHT YOU CAN JUST SEE A 230 00:12:26,520 --> 00:12:32,840 BRIEF LIST OF SOME OF THE 231 00:12:32,840 --> 00:12:36,200 ACCOMPLISHMENTS THAT BOB BALBAN 232 00:12:36,200 --> 00:12:41,320 HAS MADE IN TRANSFORMING AND 233 00:12:41,320 --> 00:12:42,760 REENGINEERING AND PUTTING THE 234 00:12:42,760 --> 00:12:45,040 INTRAMURAL PROGRAM ON AN 235 00:12:45,040 --> 00:12:46,200 INCREDIBLE TRAJECTORY. 236 00:12:46,200 --> 00:12:48,960 BOB, YEAR ETERNALLY GRATEFUL TO 237 00:12:48,960 --> 00:12:50,720 YOUR SERVICE TO THE NHLBI AND 238 00:12:50,720 --> 00:12:52,200 RESEARCH PROGRAM AND YOUR 239 00:12:52,200 --> 00:12:53,880 SCIENCE AND SCIENTIFIC 240 00:12:53,880 --> 00:12:55,880 LEADERSHIP NOT ONLY IN THE 241 00:12:55,880 --> 00:12:56,840 INTRAMURAL PROGRAM BUT ACROSS 242 00:12:56,840 --> 00:12:58,560 THE INTRAMURAL RESEARCH PROGRAM 243 00:12:58,560 --> 00:13:00,320 OF THE NIH AND YOUR 244 00:13:00,320 --> 00:13:01,840 CONTRIBUTIONS TO THE SCIENTIFIC 245 00:13:01,840 --> 00:13:02,320 COMMUNITY SO THANK YOU. 246 00:13:02,320 --> 00:13:12,520 THANK YOU. 247 00:13:21,640 --> 00:13:25,400 AS A TASTE OF THE SCIENCE WE 248 00:13:25,400 --> 00:13:28,960 WANT TO HIGHLIGHT DR. CLAUDIA 249 00:13:28,960 --> 00:13:30,080 KEMPER AND WE LOOK FORWARD TO 250 00:13:30,080 --> 00:13:34,640 HER TALK LATER ON. 251 00:13:34,640 --> 00:13:45,240 SHE KIND OF BLEW ME AWAY WITH A 252 00:13:45,240 --> 00:13:46,400 COMPLIMENT SYSTEM AND 253 00:13:46,400 --> 00:13:47,000 TRANSFORMED MY THINK OF THAT 254 00:13:47,000 --> 00:13:57,160 SYSTEM. 255 00:14:09,040 --> 00:14:11,560 WE'RE TRYING TO TRANSLATE 256 00:14:11,560 --> 00:14:12,720 DISCOVERY SCIENCE IN A PUBLIC 257 00:14:12,720 --> 00:14:13,640 HEALTH IMPACT PARTICULARLY AT 258 00:14:13,640 --> 00:14:16,000 THE COMMUNITY LEVEL AND AT THE 259 00:14:16,000 --> 00:14:17,800 LEVEL OF GLOBAL HEALTH 260 00:14:17,800 --> 00:14:25,320 PARTICULARLY AS IT RELATES TO 261 00:14:25,320 --> 00:14:27,680 THE SOCIAL ECOLOGICAL MODEL THAT 262 00:14:27,680 --> 00:14:28,800 APPRECIATES THINGS NOT ONLY AT 263 00:14:28,800 --> 00:14:34,560 THE MOLECULAR LEVEL AND GENETIC 264 00:14:34,560 --> 00:14:37,480 S BUT THE INDIVIDUAL LEVEL, 265 00:14:37,480 --> 00:14:42,920 CULTURE, FAMILY, COMMUNITY, 266 00:14:42,920 --> 00:14:46,960 ENVIRONMENT AND ALL THOSE ARE 267 00:14:46,960 --> 00:14:51,120 CRITICAL TO HEALTH AND DISEASE 268 00:14:51,120 --> 00:14:52,240 AS SOCIAL DETERMINATES OF HEALTH 269 00:14:52,240 --> 00:14:53,360 AND AS WE LOOK AT HEALTH EQUITY 270 00:14:53,360 --> 00:14:55,280 AND DISPARITIES AND GLOBAL 271 00:14:55,280 --> 00:14:57,400 HEALTH, THESE CONSTRUCTS ARE 272 00:14:57,400 --> 00:14:58,680 CRITICALLY IMPORTANT TO INCLUDE 273 00:14:58,680 --> 00:15:00,960 IN HOW WE THINK ABOUT OUR 274 00:15:00,960 --> 00:15:02,800 RESEARCH AGENDA AND OUR RESEARCH 275 00:15:02,800 --> 00:15:10,040 PROGRAM PORTFOLIO. 276 00:15:10,040 --> 00:15:12,160 TOWARD THAT END, ONE OF THE 277 00:15:12,160 --> 00:15:14,520 OUTCOMES OF THE MOST RECENT AND 278 00:15:14,520 --> 00:15:20,040 NIH RESPONSE TO THE PANDEMIC HAS 279 00:15:20,040 --> 00:15:25,000 BEEN THE UNDER SCORE HOW A VIRUS 280 00:15:25,000 --> 00:15:26,480 THAT ATTACKS THE BODY, 281 00:15:26,480 --> 00:15:29,000 PARTICULARLY THE LUNG AND LINING 282 00:15:29,000 --> 00:15:30,960 OF THE BLOOD VESSELS AND END 283 00:15:30,960 --> 00:15:34,040 THELIUM HAS AN IMPACT THAT HAS A 284 00:15:34,040 --> 00:15:37,080 SOCIAL DIMENSION. 285 00:15:37,080 --> 00:15:38,440 THERE'S A REASON WHY THERE'S 286 00:15:38,440 --> 00:15:42,680 CERTAIN RACIAL ETHNIC GROUPS 287 00:15:42,680 --> 00:15:44,240 THAT ARE DISPROPORTIONATELY 288 00:15:44,240 --> 00:15:46,720 AFFECTED BY THE PANDEMIC. 289 00:15:46,720 --> 00:15:48,680 IT'S NOT NECESSARILY RELATED TO 290 00:15:48,680 --> 00:15:50,280 THE STRUCTURE OF THEIR ACE 2 291 00:15:50,280 --> 00:15:51,640 RECEPTOR THE VIRUS USE TO INVADE 292 00:15:51,640 --> 00:15:55,840 THE CELLS BUT REFLECTS THESE 293 00:15:55,840 --> 00:15:57,000 OTHER SOCIAL DETERMINATES OF 294 00:15:57,000 --> 00:15:58,360 HEALTH AND IMPACT. 295 00:15:58,360 --> 00:16:00,280 AND IT'S CRITICAL THAT IF WE'RE 296 00:16:00,280 --> 00:16:02,560 GOING TO TURN DISCOVERY SCIENCE 297 00:16:02,560 --> 00:16:05,400 INTO PUBLIC HEALTH IMPACT, THAT 298 00:16:05,400 --> 00:16:09,440 WE HAVE A RESEARCH PORTFOLIO AND 299 00:16:09,440 --> 00:16:11,800 PLATFORM THAT'S ABLE TO ADDRESS 300 00:16:11,800 --> 00:16:15,080 THREATS TO COMMUNITY HEALTH SUCH 301 00:16:15,080 --> 00:16:16,760 AS THESE. 302 00:16:16,760 --> 00:16:19,520 AND SO AS PART OF I THINK THE 303 00:16:19,520 --> 00:16:20,760 LESSONS LEARNED OF THE PANDEMIC 304 00:16:20,760 --> 00:16:26,320 IS WE NEED PLATFORMS THAT ARE 305 00:16:26,320 --> 00:16:30,240 ABLE TO ADVANCE HEALTH EQUITY BY 306 00:16:30,240 --> 00:16:31,920 ENGAGING COMMUNITIES MOST 307 00:16:31,920 --> 00:16:35,800 VULNERABLE AND THAT FOR ANY 308 00:16:35,800 --> 00:16:39,680 GIVEN THREAT A VARIOUS, CLIMATE 309 00:16:39,680 --> 00:16:43,520 CHANGE OR FRANKLY SOME 310 00:16:43,520 --> 00:16:44,680 NON-COMMUNICABLE DISEASES 311 00:16:44,680 --> 00:16:46,560 DISPROPORTIONATELY AFFECT THESE 312 00:16:46,560 --> 00:16:49,280 COMMUNITIES AND IT COMES FROM 313 00:16:49,280 --> 00:16:50,880 INCLUDING THE DIMENSIONS OF 314 00:16:50,880 --> 00:16:51,880 SOCIAL DETERMINATES OF HEALTH 315 00:16:51,880 --> 00:16:54,400 AND TARGETING OUR RESEARCH TO 316 00:16:54,400 --> 00:16:56,520 LOCAL NEEDS. 317 00:16:56,520 --> 00:16:57,240 LEVERAGING COMMUNITY PLATFORMS 318 00:16:57,240 --> 00:17:02,560 AND PROMOTE BEING INCLUSIVE 319 00:17:02,560 --> 00:17:03,840 COMMUNES AND THOSE AFFECTED 320 00:17:03,840 --> 00:17:05,480 WITHIN THOSE COMMUNITIES AS PART 321 00:17:05,480 --> 00:17:09,760 OF OUR RESEARCH AGENDA AND 322 00:17:09,760 --> 00:17:11,360 FINALLY GOING THAT LAST MILD TO 323 00:17:11,360 --> 00:17:11,960 PROMOTE UPTAKE FOR COMMUNITY 324 00:17:11,960 --> 00:17:17,920 BENEFIT. 325 00:17:17,920 --> 00:17:22,520 TOWARD THAT END THE ALLIANCE 326 00:17:22,520 --> 00:17:23,920 AGAINST COVID DISPARITIES 327 00:17:23,920 --> 00:17:26,520 EXERCISED PRINCIPLES OF 328 00:17:26,520 --> 00:17:27,720 COMMUNITY-ENGAGED RESEARCH AND 329 00:17:27,720 --> 00:17:29,920 BUILDING ON PARTNERSHIPS WITH 330 00:17:29,920 --> 00:17:31,480 COMMUNITIES AND ADDRESSING THE 331 00:17:31,480 --> 00:17:35,160 INFORMATION, PROMOTING 332 00:17:35,160 --> 00:17:35,960 INFORMATION AND AWARENESS AND 333 00:17:35,960 --> 00:17:39,560 ALL PROMOTES AN INCREASE IN 334 00:17:39,560 --> 00:17:40,960 TRUST IN SCIENCE THAT YET AGAIN 335 00:17:40,960 --> 00:17:44,240 THIS PANDEMIC HAS TAUGHT US WE 336 00:17:44,240 --> 00:17:45,600 CANNOT TAKE LIGHTLY. 337 00:17:45,600 --> 00:17:47,640 INDEED IT'S THE CRITICAL ELEMENT 338 00:17:47,640 --> 00:17:48,720 OF OUR SURVIVAL. 339 00:17:48,720 --> 00:17:50,240 IT'S BEEN ONE OF THE FACTORS 340 00:17:50,240 --> 00:17:52,320 THAT IMPEDED OUR ABILITY TO PUT 341 00:17:52,320 --> 00:18:01,120 THIS VIRUS BEHIND US. 342 00:18:01,120 --> 00:18:05,960 AND IT'S CRITICAL TO THE 343 00:18:05,960 --> 00:18:11,800 DISCOVERY SCIENCE YIELDS. 344 00:18:11,800 --> 00:18:15,480 TO THAT END WE'RE REFINE THE 345 00:18:15,480 --> 00:18:18,520 INITIATIVE THAT CREATES A 346 00:18:18,520 --> 00:18:19,680 RESEARCH PLATFORM TO ADVANCE 347 00:18:19,680 --> 00:18:23,120 HEALTH EQUITY BUILDING ON THE 348 00:18:23,120 --> 00:18:33,600 EXPERIENCE OF CEAL AND THE 349 00:18:35,760 --> 00:18:38,440 TECHNOLOGY ASSISTANCE CENTER AND 350 00:18:38,440 --> 00:18:40,840 SERVING AS AN UMBRELLA OF THE 351 00:18:40,840 --> 00:18:43,880 PLATFORM WHICH WE RECENTLY BEGAN 352 00:18:43,880 --> 00:18:49,240 TO INCORPORATE PRIMARY CARE 353 00:18:49,240 --> 00:18:53,200 RESEARCH NETWORKS PARTICULARLY 354 00:18:53,200 --> 00:18:55,880 THOSE EMBEDDED WITHIN 355 00:18:55,880 --> 00:18:58,240 COMMUNITIES OR OFTEN UNDER 356 00:18:58,240 --> 00:18:59,960 SERVED LEVERAGING FEDERALLY 357 00:18:59,960 --> 00:19:02,480 QUALIFIED HEALTH CENTERS, WHERE 358 00:19:02,480 --> 00:19:05,440 THERE'S AN ETHOS OF COMMUNITY 359 00:19:05,440 --> 00:19:06,520 ENGAGEMENT AS PART OF THEIR 360 00:19:06,520 --> 00:19:10,560 DELIVERY OF PRIMARY CARE IN SUCH 361 00:19:10,560 --> 00:19:12,840 THE INTERVENTIONS CAN PENETRATES 362 00:19:12,840 --> 00:19:17,960 THE COMMUNITIES WHERE THESE 363 00:19:17,960 --> 00:19:20,200 INDIVIDUALS LIVE, WORK AND PLAY 364 00:19:20,200 --> 00:19:22,560 AND A MULTI-LEVEL APPROACH TO 365 00:19:22,560 --> 00:19:25,840 ADDRESSING HEALTH INEQUITIES. 366 00:19:25,840 --> 00:19:29,440 SIMILARLY THE PLATFORM HAS 367 00:19:29,440 --> 00:19:31,160 INNOVATED INCORPORATING A 368 00:19:31,160 --> 00:19:34,480 CONSULTATIIVE RESOURCE THAT CAN 369 00:19:34,480 --> 00:19:39,640 PROMOTE TAILORED GUIDANCE FOR 370 00:19:39,640 --> 00:19:41,080 INCLUSIVE PARTICIPATION IN 371 00:19:41,080 --> 00:19:43,120 RESEARCH AND TRIALS AND BEST 372 00:19:43,120 --> 00:19:45,720 PRACTICES FOR COMMUNITY-ENGAGED 373 00:19:45,720 --> 00:19:48,360 RESEARCH, TRAINING MODULES AND 374 00:19:48,360 --> 00:19:49,360 GUIDANCE FOR EXAMPLE FOR 375 00:19:49,360 --> 00:19:52,520 COMMUNITY HEALTH WORKERS AND A 376 00:19:52,520 --> 00:19:55,360 VARIETY OF TOOLS, TOOL KITS, 377 00:19:55,360 --> 00:19:57,600 RESOURCES AND TIP SHEETS. 378 00:19:57,600 --> 00:19:59,960 FINALLY, A KEY COMPONENT OF THE 379 00:19:59,960 --> 00:20:02,280 PLATFORM RELATES TO THE 380 00:20:02,280 --> 00:20:07,560 IMPORTANCE OF COMMUNICATION, 381 00:20:07,560 --> 00:20:12,000 EDUCATION, BI-DIRECTIONAL 382 00:20:12,000 --> 00:20:13,880 KNOWLEDGE EXCHANGE AND THE TOOLS 383 00:20:13,880 --> 00:20:15,680 NECESSARY FOR THAT TO HAPPEN 384 00:20:15,680 --> 00:20:18,000 THAT'S CULTURALLY COMPETENT AND 385 00:20:18,000 --> 00:20:21,360 ENGAGES AND ADDRESSES THE NEEDS 386 00:20:21,360 --> 00:20:25,600 OF A VARIETY OF SETTINGS, RURAL, 387 00:20:25,600 --> 00:20:30,280 AMERICAN INDIAN, LATINO, 388 00:20:30,280 --> 00:20:33,120 AFRICAN, PACIFIC ISLANDER, 389 00:20:33,120 --> 00:20:33,400 ETCETERA. 390 00:20:33,400 --> 00:20:39,320 TOWARD THAT END, WE'VE BEEN 391 00:20:39,320 --> 00:20:40,960 EXERCISING THIS PLATFORM IN 392 00:20:40,960 --> 00:20:43,120 WHICH WE LEARNED IN CEAL WHERE 393 00:20:43,120 --> 00:20:45,840 WE LEARNED TO INTEGRATE VARIOUS 394 00:20:45,840 --> 00:20:51,320 ELEMENTS INCLUDING THE 395 00:20:51,320 --> 00:20:54,560 PRACTICE-BASED RESEARCH NETWORK 396 00:20:54,560 --> 00:20:56,200 COMPONENT TO ENGAGE THE CLINIC 397 00:20:56,200 --> 00:20:58,560 AND THE COMMUNITY FOR ISSUES 398 00:20:58,560 --> 00:21:01,640 SUCH AS TESTING OR FINDING OUT 399 00:21:01,640 --> 00:21:03,600 WHO'S AT RISK AND NEEDS A BOOST 400 00:21:03,600 --> 00:21:08,560 AND THE STRATEGIES NECESSARY TO 401 00:21:08,560 --> 00:21:10,520 ENSURE THOSE COMMUNITIES ARE 402 00:21:10,520 --> 00:21:11,840 AFFECTIVELY PROTECT FROM THE 403 00:21:11,840 --> 00:21:12,160 VIRUS. 404 00:21:12,160 --> 00:21:14,000 LEVERAGING ASSETS AND 405 00:21:14,000 --> 00:21:16,080 CAPABILITIES WITHIN THE 406 00:21:16,080 --> 00:21:22,520 COMMUNITY AND BUTTRESSING THEM 407 00:21:22,520 --> 00:21:27,120 WHERE THEY NEED TO AND ADDRESS 408 00:21:27,120 --> 00:21:28,600 SPECIFIC CONTEXTUAL NEEDS OF THE 409 00:21:28,600 --> 00:21:30,600 COMMUNITY TO PROTECT THEMSELVES. 410 00:21:30,600 --> 00:21:32,880 WE HOPE TO EXTEND THIS MODEL 411 00:21:32,880 --> 00:21:33,840 BEYOND COVID. 412 00:21:33,840 --> 00:21:38,560 ONE EXAMPLE WOULD BE A 413 00:21:38,560 --> 00:21:41,160 COLLABORATION AND COALITION ON 414 00:21:41,160 --> 00:21:46,480 THE EFFORT IN MATERNAL HEALTH IN 415 00:21:46,480 --> 00:21:52,200 WHICH A COMMUNITY-ENGAGED 416 00:21:52,200 --> 00:21:53,720 PROGRAM IS PART OF THE EFFORT 417 00:21:53,720 --> 00:21:56,200 AND MAY PROVIDE THE LINKAGES 418 00:21:56,200 --> 00:21:58,040 BETWEEN PATIENTS AND PROVIDERS 419 00:21:58,040 --> 00:22:00,480 IN A WAY THAT WOMEN BOTH BEFORE, 420 00:22:00,480 --> 00:22:02,040 DURING AND AFTER PREGNANCY CAN 421 00:22:02,040 --> 00:22:05,800 BE PUT ON THE BEST POSSIBLE 422 00:22:05,800 --> 00:22:07,840 TRAJECTORY TO NOT ONLY HAVE A 423 00:22:07,840 --> 00:22:11,160 HEALTHY PREGNANCY AND BABY AND 424 00:22:11,160 --> 00:22:20,360 BE ON A PATHWAY TO OPTIMAL 425 00:22:20,360 --> 00:22:23,880 CARDIOVASCULAR HEALTH. 426 00:22:23,880 --> 00:22:26,000 ONE EMERGING APPLICATION IS IN 427 00:22:26,000 --> 00:22:32,680 THE SPACE OF CLIMATE AND HEALTH. 428 00:22:32,680 --> 00:22:35,920 EMERGING TRANS-NIH INITIATIVE 429 00:22:35,920 --> 00:22:41,480 LED BY NIEHS WHERE NIH WILL BE 430 00:22:41,480 --> 00:22:42,400 RESPONDING TO THE EXISTENTIAL 431 00:22:42,400 --> 00:22:46,160 THREATS OF CLIMATE AND HEALTH 432 00:22:46,160 --> 00:22:48,000 AND LEVERAGING THE STRATEGY OF 433 00:22:48,000 --> 00:22:51,440 GOING TO THE COMMUNITIES AND 434 00:22:51,440 --> 00:22:53,920 ENGAGING THEM IN HOW TO ADDRESS, 435 00:22:53,920 --> 00:22:57,760 ADAPT AND BECOME RESILIENT TO 436 00:22:57,760 --> 00:23:00,600 THE AFFECTS OF CLIMATE AND 437 00:23:00,600 --> 00:23:01,160 CLIMATE CHANGE THROUGH THE 438 00:23:01,160 --> 00:23:11,360 PLATFORM. 439 00:23:13,680 --> 00:23:14,800 LET ME CLOSE WITH ANOTHER 440 00:23:14,800 --> 00:23:19,240 EXAMPLE OF THAT ENGAGEMENT THAT 441 00:23:19,240 --> 00:23:21,480 EXTENDS OUR PORTFOLIO INTO THE 442 00:23:21,480 --> 00:23:26,880 SPACE OF COMMUNITY ENGAGEMENT 443 00:23:26,880 --> 00:23:28,280 AND SCIENCE TO HAVE PUBLIC 444 00:23:28,280 --> 00:23:30,000 HEALTH IMPACT. 445 00:23:30,000 --> 00:23:32,360 CLEARLY THAT'S AN AREA IN WHICH 446 00:23:32,360 --> 00:23:38,560 THE GLOBAL HEALTH AGENDA IS A 447 00:23:38,560 --> 00:23:44,680 KEY AND WE APPRECIATE THE 448 00:23:44,680 --> 00:23:48,000 LEADERSHIP WHO I HOPE WILL BE 449 00:23:48,000 --> 00:23:49,400 ABLE TO PRESENT TO COUNCIL AT 450 00:23:49,400 --> 00:23:52,240 SOME JUNCTURE AS ONE OF OUR LEAD 451 00:23:52,240 --> 00:23:52,840 COORDINATORS OF OUR GLOBAL 452 00:23:52,840 --> 00:23:59,800 HEALTH EFFORT. 453 00:23:59,800 --> 00:24:02,480 THIS IS AN AREA WHERE AS ALL OF 454 00:24:02,480 --> 00:24:03,920 YOU KNOW, CARDIOVASCULAR DISEASE 455 00:24:03,920 --> 00:24:07,840 AND NON-COMMUNICABLE DISEASE AND 456 00:24:07,840 --> 00:24:10,240 CHRONIC RESPIRATORY DISEASES ARE 457 00:24:10,240 --> 00:24:13,320 RISING ON A GLOBAL SCALE AND 458 00:24:13,320 --> 00:24:16,640 STARTING TO SQUEEZE OUT THOSE 459 00:24:16,640 --> 00:24:17,400 COMMUNICABLE CAUSES OF MORBIDITY 460 00:24:17,400 --> 00:24:18,000 AND MORTALITY THROUGHOUT THE 461 00:24:18,000 --> 00:24:26,040 WORLD. 462 00:24:26,040 --> 00:24:29,920 IT'S IMPORTANT THE NHLBI BE A 463 00:24:29,920 --> 00:24:33,400 GLOBAL LEADER OF NATIONAL HEART, 464 00:24:33,400 --> 00:24:34,560 LUNG AND BLOOD INSTITUTE 465 00:24:34,560 --> 00:24:35,640 RESEARCH RELATED TO CHRONIC LUNG 466 00:24:35,640 --> 00:24:39,200 DISEASE AND IMPACT OF AIR 467 00:24:39,200 --> 00:24:42,000 POLLUTION AS WELL AS BIO MASS 468 00:24:42,000 --> 00:24:45,560 BURNING AND INTERNAL AIR 469 00:24:45,560 --> 00:24:47,440 POLLUTION, IF YOU WILL. 470 00:24:47,440 --> 00:24:50,080 THE RISING RATES OF HYPERTENSION 471 00:24:50,080 --> 00:24:51,200 AND CARDIOVASCULAR DISEASE 472 00:24:51,200 --> 00:24:53,320 THROUGHOUT THE WORLD. 473 00:24:53,320 --> 00:24:56,280 AND PARTICULARLY HAVING IMPACT 474 00:24:56,280 --> 00:24:58,360 ON LOW AND MIDDLE INCOME 475 00:24:58,360 --> 00:25:01,600 COUNTRIES AND CERTAINLY FAMILIAR 476 00:25:01,600 --> 00:25:04,440 WITH OUR BLOOD DISEASE PORTFOLIO 477 00:25:04,440 --> 00:25:06,480 THAT HAS A GLOBAL COMPONENT NOT 478 00:25:06,480 --> 00:25:11,480 ONLY IN BLOOD SAFETY, 479 00:25:11,480 --> 00:25:12,920 HEMORRHAGE, BUT SICKLE CELL 480 00:25:12,920 --> 00:25:23,360 DISEASE AND OTHERS AND HU 481 00:25:33,520 --> 00:25:35,240 HUMEOGLOBENOPATHIES AND THERE'S 482 00:25:35,240 --> 00:25:36,000 A PORTFOLIO THAT GOES THROUGHOUT 483 00:25:36,000 --> 00:25:40,360 THE WORLD. 484 00:25:40,360 --> 00:25:41,080 THOUGH THERE'S A STRATEGIC FOCUS 485 00:25:41,080 --> 00:25:41,920 ON WHERE WE CAN HAVE THE 486 00:25:41,920 --> 00:25:46,720 GREATEST IMPACT. 487 00:25:46,720 --> 00:25:49,200 WE BELIEVE THAT'S IN THE 488 00:25:49,200 --> 00:25:54,000 DEVELOPING WORLD AND LOW AND 489 00:25:54,000 --> 00:26:00,000 MIDDLE INCOME COUNTRIES WITH THE 490 00:26:00,000 --> 00:26:04,280 RISE OF COMMUNICABLE DISEASES, 491 00:26:04,280 --> 00:26:06,560 CARIBBEAN, SOUTH AFRICA AND 492 00:26:06,560 --> 00:26:09,680 SOUTHEAST ASIA. 493 00:26:09,680 --> 00:26:11,400 HERE YOU SEE THE PROBLEM 494 00:26:11,400 --> 00:26:12,960 STATEMENT, IF YOU WILL. 495 00:26:12,960 --> 00:26:17,440 IN THIS CASE RELATED TO 496 00:26:17,440 --> 00:26:19,280 HYPERTENSION THE W.H.O. CALLED 497 00:26:19,280 --> 00:26:20,920 THE BEST BUY IN TERMS OF 498 00:26:20,920 --> 00:26:22,520 INTERVENTIONS THAT CAN HAVE THE 499 00:26:22,520 --> 00:26:23,960 GREATEST IMPACT. 500 00:26:23,960 --> 00:26:27,800 JUST BY HOPEFULLY EXTENDING WHAT 501 00:26:27,800 --> 00:26:30,160 WE ALREADY KNOW WORKS AND ABOUT 502 00:26:30,160 --> 00:26:31,560 WHAT WE KNOW ABOUT HYPERTENSION 503 00:26:31,560 --> 00:26:34,560 AND AWARENESS, TREATMENT AND 504 00:26:34,560 --> 00:26:36,240 CONTROL. 505 00:26:36,240 --> 00:26:37,920 UNFORTUNATELY IN HIGH-INCOME 506 00:26:37,920 --> 00:26:42,040 COUNTRIES WE'VE HAD SUCCESS IN 507 00:26:42,040 --> 00:26:45,240 PROMOTING THOSE ELEMENTS AND YET 508 00:26:45,240 --> 00:26:48,040 YOU LOOK AT AREAS OF THE WORLD 509 00:26:48,040 --> 00:26:50,800 LIKE SUB-SAHARAN AFRICA AND AN 510 00:26:50,800 --> 00:26:53,120 EVER RISING OF UNDIAGNOSED, 511 00:26:53,120 --> 00:26:55,240 UNAWARE, UNTREATED HYPERTENSION. 512 00:26:55,240 --> 00:26:58,520 THAT'S WHERE I BELIEVE THE NHLBI 513 00:26:58,520 --> 00:27:02,240 NEEDS TO MAKE A DIFFERENCE. 514 00:27:02,240 --> 00:27:06,960 TOWARD THAT END, A PROGRAM OF 515 00:27:06,960 --> 00:27:09,680 PROGRAMS HAVE BEEN STOOD UP BY 516 00:27:09,680 --> 00:27:16,440 GEORGE MENSA THAT HAS THE HOME 517 00:27:16,440 --> 00:27:25,920 OF THE GLOBAL HEALTH AGENDA. 518 00:27:25,920 --> 00:27:28,720 A KEY PART OF THE LEADERSHIP WAS 519 00:27:28,720 --> 00:27:29,680 FORGING INTERNATIONAL 520 00:27:29,680 --> 00:27:31,280 COLLABORATIONS NOT THE LEAST OF 521 00:27:31,280 --> 00:27:34,560 WHICH WAS THE GLOBAL ALLIANCE 522 00:27:34,560 --> 00:27:35,840 FOR GLOBAL DISEASE THAT INCLUDES 523 00:27:35,840 --> 00:27:39,360 A VARIETY OF FUNDERS AROUND THE 524 00:27:39,360 --> 00:27:44,760 WORLD THAT HAVE COALESCED TO 525 00:27:44,760 --> 00:27:48,560 COLLABORATE AROUND STUDIES AND 526 00:27:48,560 --> 00:27:50,400 RESEARCH PROGRAMS ON CHRONIC 527 00:27:50,400 --> 00:27:51,080 DISEASES. 528 00:27:51,080 --> 00:27:54,040 WITH GEORGE'S LEADERSHIP, HE WAS 529 00:27:54,040 --> 00:27:59,840 ABLE TO PUT HYPERTENSION AS A 530 00:27:59,840 --> 00:28:02,120 MAJOR PRIORITY FOR THE COALITION 531 00:28:02,120 --> 00:28:03,320 AND ADDRESSED LUNG DISEASE, 532 00:28:03,320 --> 00:28:06,040 DIABETES AND MENTAL HEALTH AND 533 00:28:06,040 --> 00:28:11,920 OTHER CONCERNS AND CONDITIONS. 534 00:28:11,920 --> 00:28:14,200 TOWARD THAT END, ONE OF THE 535 00:28:14,200 --> 00:28:16,320 STUDIES THE NHLBI FUNDED, THIS 536 00:28:16,320 --> 00:28:21,720 IS AN EXAMPLE RELATED TO 537 00:28:21,720 --> 00:28:23,960 HYPERTENSION INVOLVED A 538 00:28:23,960 --> 00:28:27,760 COMMUNITY WIDE STUDY IN PERU 539 00:28:27,760 --> 00:28:34,200 BASED ON A STEP WEDGE CLUSTER 540 00:28:34,200 --> 00:28:37,160 DESIGN WHERE HOPEFULLY I GOT 541 00:28:37,160 --> 00:28:42,040 THAT RIGHT, GEORGE, THERE WAS A 542 00:28:42,040 --> 00:28:42,760 SUBSTITUTION OF A SALT 543 00:28:42,760 --> 00:28:44,800 SUBSTITUTE AFTER A LOT OF 544 00:28:44,800 --> 00:28:46,200 ENGAGEMENT AND EDUCATION AND 545 00:28:46,200 --> 00:28:49,400 AWARENESS MOVING TO DIFFERENT 546 00:28:49,400 --> 00:28:52,840 VILLAGES AS PART OF THE CLUSTER 547 00:28:52,840 --> 00:28:56,680 DESIGN AND INDEED WAS ABLE TO 548 00:28:56,680 --> 00:28:58,400 DEMONSTRATE THE SALT SUBSTITUTE 549 00:28:58,400 --> 00:29:01,720 REDUCED THE INCIDENTS OF 550 00:29:01,720 --> 00:29:03,360 HYPERTENSION IN THE VILLAGES 551 00:29:03,360 --> 00:29:05,560 ACCORDING TO THE MODELLING THEY 552 00:29:05,560 --> 00:29:09,400 DID BASED ON TIME SEQUENCE AND 553 00:29:09,400 --> 00:29:14,480 CLUSTERING AS WELL NOTICEABLE 554 00:29:14,480 --> 00:29:16,000 DECREASE IN BLOOD PRESSURE 555 00:29:16,000 --> 00:29:18,040 SUGGESTING THE COMMUNITY-WIDE 556 00:29:18,040 --> 00:29:22,720 INTERVENTION COULD HAVE GREAT 557 00:29:22,720 --> 00:29:30,560 IMPACT SIMILARLY, MOVING FROM 558 00:29:30,560 --> 00:29:32,640 CARDIOVASCULAR TO BLOOD 559 00:29:32,640 --> 00:29:34,560 DISORDERS WE SEE AN OPPORTUNITY 560 00:29:34,560 --> 00:29:42,520 TO TRANSLATE WHAT WE KNOW IN 561 00:29:42,520 --> 00:29:43,560 SICKLE CELL DISEASE WE'VE BEEN 562 00:29:43,560 --> 00:29:46,240 BLESSED TO WATCH THE EVER 563 00:29:46,240 --> 00:29:47,160 DECLINING MORTALITY PARTICULARLY 564 00:29:47,160 --> 00:29:49,200 AMONG CHILDREN IN THE LAST 40 565 00:29:49,200 --> 00:29:49,560 YEARS. 566 00:29:49,560 --> 00:29:52,120 IT'S BEEN QUITE SUBSTANTIAL 567 00:29:52,120 --> 00:29:55,880 RELATED IN LARGE PART TO 568 00:29:55,880 --> 00:29:57,600 DIAGNOSIS, NEWBORN SCREENING AND 569 00:29:57,600 --> 00:30:01,240 PROPHYLAXIS AND TRANSFUSIONS, 570 00:30:01,240 --> 00:30:03,240 PNEUMOVAX, ETCETERA, ALL THESE 571 00:30:03,240 --> 00:30:09,720 THINGS THAT CAN HELP REDUCE 572 00:30:09,720 --> 00:30:12,320 CHILDHOOD MORTALITY FROM SICKLE 573 00:30:12,320 --> 00:30:12,800 CELL DISEASE. 574 00:30:12,800 --> 00:30:15,200 AS WE LOOK FORWARD TO CHILDREN 575 00:30:15,200 --> 00:30:21,480 IN THE U.S. EXPERIENCING LONG 576 00:30:21,480 --> 00:30:22,480 SURVIVAL OF CHILDHOOD THIS IS 577 00:30:22,480 --> 00:30:24,000 NOT THE CASE IN OTHER PARTS OF 578 00:30:24,000 --> 00:30:26,560 THE WORLD. 579 00:30:26,560 --> 00:30:29,320 YOU CAN SEE WHERE MOST CHILDREN 580 00:30:29,320 --> 00:30:31,240 WITH SICKLE CELL RESIDE, AFRICA 581 00:30:31,240 --> 00:30:33,600 BEING A LEADING PLACE, WEST 582 00:30:33,600 --> 00:30:35,160 AFRICA IN PARTICULAR WHERE 583 00:30:35,160 --> 00:30:36,720 THERE'S MORE BIRTHS BUT 584 00:30:36,720 --> 00:30:42,040 UNFORTUNATELY YOU CAN ALSO SEE 585 00:30:42,040 --> 00:30:52,520 THE STRIKING DIFFERENCE IN 586 00:30:53,160 --> 00:30:53,800 SICKLE CELL DISEASE AND IN 587 00:30:53,800 --> 00:30:57,200 AFRICA THE RATES ARE 50% TO 80% 588 00:30:57,200 --> 00:31:00,280 OF MORTALITY OF 5-YEAR-OLDS IN 589 00:31:00,280 --> 00:31:00,880 SUB-SAHARAN AFRICA. 590 00:31:00,880 --> 00:31:05,440 THIS IS SOMETHING WE PREVENTED 591 00:31:05,440 --> 00:31:07,680 IN OUR COUNTRY AND BELIEVE WE 592 00:31:07,680 --> 00:31:12,400 CAN DO THAT IN SAHARA AFRICA AS 593 00:31:12,400 --> 00:31:12,960 WELL. 594 00:31:12,960 --> 00:31:15,320 TO THAT END OUR BLOOD DIVISION 595 00:31:15,320 --> 00:31:18,440 LED EFFORTS TO ENGAGE SCIENTISTS 596 00:31:18,440 --> 00:31:21,440 IN AFRICA. 597 00:31:21,440 --> 00:31:23,080 TERRIFIC LEADERS LIKE JULIE 598 00:31:23,080 --> 00:31:25,680 CONNIE AND OTHERS LEADING 599 00:31:25,680 --> 00:31:27,480 NETWORKS BUILDING THAT 600 00:31:27,480 --> 00:31:30,000 CAPABILITY TO DO NEWBORN 601 00:31:30,000 --> 00:31:33,840 SCREENING AND TO CONDUCT 602 00:31:33,840 --> 00:31:35,880 CLINICAL RESEARCH, FORM A 603 00:31:35,880 --> 00:31:37,400 REGISTRY AND CONDUCTING CLINICAL 604 00:31:37,400 --> 00:31:40,640 TRIALS AND DEMONSTRATED THE 605 00:31:40,640 --> 00:31:44,800 CAPABILITY TO ADMINISTER AGENTS 606 00:31:44,800 --> 00:31:48,360 LIKE HYDROXY UREA IN PROTOCOLS 607 00:31:48,360 --> 00:31:51,640 AND ARE CREATING A CONTINENTAL 608 00:31:51,640 --> 00:31:53,800 NETWORK OF INVESTIGATORS AND 609 00:31:53,800 --> 00:31:55,520 CAPABILITIES THAT SHOULD 610 00:31:55,520 --> 00:31:57,520 HOPEFULLY MAKE A DENT IN THAT 611 00:31:57,520 --> 00:31:58,520 CHILDHOOD MORTALITY IN THE NEAR 612 00:31:58,520 --> 00:32:07,640 TERM. 613 00:32:07,640 --> 00:32:09,440 FINALLY, WE HOPE THAT 614 00:32:09,440 --> 00:32:10,560 INFRASTRUCTURE IN WHICH WE 615 00:32:10,560 --> 00:32:14,600 FINALLY TRANSLATE WHAT WE KNOW 616 00:32:14,600 --> 00:32:19,880 WORKS AT THE SETTINGS LIKE 617 00:32:19,880 --> 00:32:22,520 SUB-SAHARAN AFRICA WHERE THEY 618 00:32:22,520 --> 00:32:25,280 WILL INNOVATE CONTEXTUAL 619 00:32:25,280 --> 00:32:26,360 SOLUTIONS THAT EFFECTIVELY 620 00:32:26,360 --> 00:32:30,040 ENABLE THEM TO IDENTIFY WHO HAS 621 00:32:30,040 --> 00:32:32,120 SICKLE CELL THESE AND HOW TO 622 00:32:32,120 --> 00:32:34,360 MORE EFFECTIVELY TREAT THEM IN 623 00:32:34,360 --> 00:32:37,000 THEIR CONTEXT. 624 00:32:37,000 --> 00:32:38,960 WE HOPE THEY'LL ALSO BE THE 625 00:32:38,960 --> 00:32:41,240 LANDING PLACE, THE HOME OF NEW 626 00:32:41,240 --> 00:32:44,720 TECHNOLOGIES THAT CAN BE 627 00:32:44,720 --> 00:32:45,000 CURATIVE. 628 00:32:45,000 --> 00:32:49,480 WE'RE HOPING AND PLANNING AND 629 00:32:49,480 --> 00:32:53,520 INDEED YOU'LL HOPEFULLY SEE A 630 00:32:53,520 --> 00:32:58,400 MANIFEST OF PROGRAMS ENABLE 631 00:32:58,400 --> 00:33:00,600 ADVANCEMENT OF CURATIVE 632 00:33:00,600 --> 00:33:02,240 THERAPIES IN THIS COUNTRY AND 633 00:33:02,240 --> 00:33:04,920 NOT ONLY IN THE CONTEXT YOU 634 00:33:04,920 --> 00:33:05,720 WHERE HAVE SOPHISTICATED 635 00:33:05,720 --> 00:33:10,320 CHILDREN'S HOSPITALS THAT ARE 636 00:33:10,320 --> 00:33:16,640 NEEDED TO HAVE CELL THERAPY, 637 00:33:16,640 --> 00:33:17,360 GENETIC THERAPY FOR SICKLE CELL 638 00:33:17,360 --> 00:33:20,040 DISEASE BUT TO MAKE A 639 00:33:20,040 --> 00:33:21,920 TRANSFORMATIVE TECHNOLOGY LEAP 640 00:33:21,920 --> 00:33:24,040 SUCH THAT WE CAN THINK OF A LESS 641 00:33:24,040 --> 00:33:26,280 TOXIC REGIMENT AND THE ABILITY 642 00:33:26,280 --> 00:33:29,880 TO BUILD GENE EDITING MACHINERY 643 00:33:29,880 --> 00:33:36,160 TO HONE TO TISSUES. 644 00:33:36,160 --> 00:33:38,520 FOR EXAMPLE, HEMATOPOIETIC STEM 645 00:33:38,520 --> 00:33:40,440 CELLS ONE WAY WE ENVISION MAKE A 646 00:33:40,440 --> 00:33:43,920 BLOOD TRANSFUSION WILL BE GIVEN 647 00:33:43,920 --> 00:33:45,400 IN RURAL GEORGIA OR RURAL GHANA 648 00:33:45,400 --> 00:33:48,600 AND THIS IS PART OF OUR AGENDA 649 00:33:48,600 --> 00:33:50,560 FOR THE FUTURE PART OF WHICH 650 00:33:50,560 --> 00:33:53,440 WE'RE DOING IN COLLABORATION 651 00:33:53,440 --> 00:33:54,440 WITH THE GATES FOUNDATION THAT 652 00:33:54,440 --> 00:33:56,240 WE HOPE TO BUILD ON THAT 653 00:33:56,240 --> 00:33:59,280 INFRASTRUCTURE OF TAKING WHAT WE 654 00:33:59,280 --> 00:34:02,080 KNOW WORKS, TAKING SUB-SAHARAN 655 00:34:02,080 --> 00:34:05,920 AFRICA AND DEVELOPING A LEAPFROG 656 00:34:05,920 --> 00:34:08,760 TECHNOLOGY THAT COULD BE 657 00:34:08,760 --> 00:34:10,120 ACTUALLY ACCESSIBLE AND SAFE IN 658 00:34:10,120 --> 00:34:11,720 THAT CONTEXT AS WELL. 659 00:34:11,720 --> 00:34:12,520 THAT'S THE TECHNOLOGY CHALLENGE 660 00:34:12,520 --> 00:34:14,560 WE HOPE TO TAKE ON IN THE NEXT 661 00:34:14,560 --> 00:34:20,960 FIVE YEARS. 662 00:34:20,960 --> 00:34:22,960 PART OF THAT MEANS WE NEED AN 663 00:34:22,960 --> 00:34:26,560 ECO SYSTEM TO MAKE THAT 664 00:34:26,560 --> 00:34:29,200 POSSIBLE. 665 00:34:29,200 --> 00:34:30,360 ACADEMIA, GOVERNMENT, YOU ARE 666 00:34:30,360 --> 00:34:33,600 SISTER AGENCIES LIKE CMS TO 667 00:34:33,600 --> 00:34:36,800 ENSURE WE HAVE FDA AND 668 00:34:36,800 --> 00:34:38,520 REGULATORY AND BIO TECH AS PART 669 00:34:38,520 --> 00:34:39,400 OF THE COMMERCIALIZATION OF 670 00:34:39,400 --> 00:34:45,960 THESE TECHNOLOGIES. 671 00:34:45,960 --> 00:34:46,600 WE'RE ENCOURAGED BY THE PROGRESS 672 00:34:46,600 --> 00:34:51,760 BEING MADE. 673 00:34:51,760 --> 00:34:54,400 WE HOPE TO BUILD A COMMUNITY OF 674 00:34:54,400 --> 00:34:57,320 PRACTICE TO ADVANCE HEART, LUNG 675 00:34:57,320 --> 00:34:59,520 BLOOD RESEARCH, SAVE LIVES 676 00:34:59,520 --> 00:35:01,240 AROUND THE WORLD. 677 00:35:01,240 --> 00:35:02,600 LEVERAGING THIS APPROACH 678 00:35:02,600 --> 00:35:04,040 FOCUSSING ON THE MOST VULNERABLE 679 00:35:04,040 --> 00:35:05,560 COMMUNITIES IN THE U.S., AROUND 680 00:35:05,560 --> 00:35:10,960 THE WORLD WHERE SCIENCE CAN MAKE 681 00:35:10,960 --> 00:35:12,960 A DIFFERENCE AND SAVE LIVES BY 682 00:35:12,960 --> 00:35:14,520 ENGAGING IN COLLABORATORS, 683 00:35:14,520 --> 00:35:17,040 PARTNERSHIPS, COMMUNITIES, 684 00:35:17,040 --> 00:35:19,400 DEVELOPING INFRASTRUCTURE 685 00:35:19,400 --> 00:35:23,680 CAPACITY, TRAINING, TO TACKLE 686 00:35:23,680 --> 00:35:26,440 THE BEST BUYS, THE DISORDERS WE 687 00:35:26,440 --> 00:35:29,320 KNOW WE CAN TREAT IN THESE 688 00:35:29,320 --> 00:35:30,560 CONTEXT TO HAVE THE GREATEST 689 00:35:30,560 --> 00:35:34,960 IMPACT. 690 00:35:34,960 --> 00:35:36,040 WITH THAT I THANK YOU FOR YOUR 691 00:35:36,040 --> 00:35:40,960 ATTENTION. 692 00:35:40,960 --> 00:35:43,120 >> THANK YOU, DR. GIBBONS. 693 00:35:43,120 --> 00:35:44,880 THAT WAS VERY INTERESTING AND I 694 00:35:44,880 --> 00:35:46,520 HOPE THE COUNCIL HAS MAYBE SOME 695 00:35:46,520 --> 00:35:54,080 COMMENTS OR QUESTIONS. 696 00:35:54,080 --> 00:35:55,360 IF YOU DO HAVE COMMENTS OR 697 00:35:55,360 --> 00:35:56,360 QUESTIONS YOU CAN PUT THEM IN 698 00:35:56,360 --> 00:36:00,440 THE CHAT OR RAISE YOUR HAND. 699 00:36:00,440 --> 00:36:07,480 YOU CAN USE THE REACTION BUTTON. 700 00:36:07,480 --> 00:36:09,800 >> THANK YOU, DR. GIBBONS. 701 00:36:09,800 --> 00:36:12,040 THIS HAS BEEN A WHIRLWIND TO SEE 702 00:36:12,040 --> 00:36:13,880 THE BREADTH OF ACTIVITY THE 703 00:36:13,880 --> 00:36:16,000 NHLBI IS PROMOTING AND 704 00:36:16,000 --> 00:36:16,280 SUPPORTING. 705 00:36:16,280 --> 00:36:17,680 IN PARTICULAR I THINK I JUST 706 00:36:17,680 --> 00:36:20,880 WANTED TO OFFER THE POSITIVE 707 00:36:20,880 --> 00:36:23,280 FEEDBACK I'M PLEASED TO SEE 708 00:36:23,280 --> 00:36:24,720 THERE'S A GLOBAL FOCUS AS WELL 709 00:36:24,720 --> 00:36:27,520 BECAUSE WHAT IS HAPPENING AROUND 710 00:36:27,520 --> 00:36:28,960 THE WORLD WILL INFLUENCE US IN 711 00:36:28,960 --> 00:36:30,040 THE UNITED STATES. 712 00:36:30,040 --> 00:36:31,800 IT WAS NICE TO SEE THE GLOBAL 713 00:36:31,800 --> 00:36:32,880 FOCUS AND THE WORK GOING ON IN 714 00:36:32,880 --> 00:36:36,440 EACH OF THE MAJOR DIVISIONS. 715 00:36:36,440 --> 00:36:44,680 >> THANK YOU FOR THAT COMMENT. 716 00:36:44,680 --> 00:36:46,120 >> THERE'S NOTHING LIKE A 717 00:36:46,120 --> 00:36:49,680 PANDEMIC TO REINFORCE HOW 718 00:36:49,680 --> 00:36:53,360 CONNECTED WE ARE. 719 00:36:53,360 --> 00:36:56,200 ALL TE TOPICS, CLIMATE CHANGE, 720 00:36:56,200 --> 00:36:57,720 ETCETERA, REENFORCE THAT 721 00:36:57,720 --> 00:36:59,960 CONNECTIVITY AND WHERE IT'S 722 00:36:59,960 --> 00:37:00,240 CRITICAL. 723 00:37:00,240 --> 00:37:02,560 AS PART OF A HEALTH EQUITY 724 00:37:02,560 --> 00:37:03,920 AGENDA THAT IS GOING TO TAKE ALL 725 00:37:03,920 --> 00:37:06,000 OF TO US CARE FOR ALL OF US 726 00:37:06,000 --> 00:37:09,440 BECAUSE WE'RE ALL IN THIS 727 00:37:09,440 --> 00:37:10,440 TOGETHER. 728 00:37:10,440 --> 00:37:14,200 THANKS FOR THAT, MERCEDES. 729 00:37:14,200 --> 00:37:15,280 >> DOES ANYBODY ELSE HAVE ANY 730 00:37:15,280 --> 00:37:16,320 QUESTION OR SOMETHING THEY WANT 731 00:37:16,320 --> 00:37:18,040 TO BRING TO THE CONVERSATION 732 00:37:18,040 --> 00:37:23,880 BEFORE WE MOVE ON? 733 00:37:23,880 --> 00:37:25,080 >> OKAY. 734 00:37:25,080 --> 00:37:28,040 DR. GIBBONS, I THINK YOU WERE 735 00:37:28,040 --> 00:37:29,720 VERY CLEAR IN YOUR PRESENTATION 736 00:37:29,720 --> 00:37:33,840 SO WE DO HAVE OUR SPEAKER FROM 737 00:37:33,840 --> 00:37:35,360 THE D.I.R. NEXT ON THE AGENDA, 738 00:37:35,360 --> 00:37:38,560 DR. KEMPER IS A SENIOR 739 00:37:38,560 --> 00:37:40,800 INVESTIGATOR AND SECTION CHIEF 740 00:37:40,800 --> 00:37:42,080 AT THE NATIONAL HEART, LUNG AND 741 00:37:42,080 --> 00:37:43,040 BLOOD INSTITUTE AT THE NATIONAL 742 00:37:43,040 --> 00:37:44,800 INSTITUTES OF HEALTH AND SHE IS 743 00:37:44,800 --> 00:37:47,480 ALSO AN ADJUNCT PROFESSOR OF THE 744 00:37:47,480 --> 00:37:51,040 UNIVERSITY OF LUBECK, GERMANY. 745 00:37:51,040 --> 00:37:56,560 HER RESEARCH FOCUSES ON 746 00:37:56,560 --> 00:37:58,400 NON-CANONICAL ROLES OF 747 00:37:58,400 --> 00:38:00,480 PHYSIOLOGY AND DISEASE AND A 748 00:38:00,480 --> 00:38:01,520 RECIPIENT OF AN INVESTIGATOR 749 00:38:01,520 --> 00:38:05,520 TRUST AND MERIT AWARD FOR 750 00:38:05,520 --> 00:38:08,440 EXCELLENCE IN SCIENCE FROM AND 751 00:38:08,440 --> 00:38:10,680 TWO AWARDS IN SCIENCE FROM THE 752 00:38:10,680 --> 00:38:14,800 NHLBI AND AN ELECTED MEMBER OF 753 00:38:14,800 --> 00:38:17,560 THE HENRY KUNKEL SOCIETY AND 754 00:38:17,560 --> 00:38:18,560 SERVES ON A SCIENTIFIC BOARD AND 755 00:38:18,560 --> 00:38:22,560 IS THE CURRENT PRESIDENT OF THE 756 00:38:22,560 --> 00:38:24,080 INTERNATIONAL COUNCILMAN'S 757 00:38:24,080 --> 00:38:24,600 SOCIETY. 758 00:38:24,600 --> 00:38:26,160 TODAY SHE'LL SPEAK TO US ABOUT 759 00:38:26,160 --> 00:38:29,960 LOCATION MATTERS, UNEXPECTED 760 00:38:29,960 --> 00:38:36,920 ROLES FOR HEALTH AND DISEASE. 761 00:38:36,920 --> 00:38:38,520 I HOPE WE CAN ALL WELCOME 762 00:38:38,520 --> 00:38:39,960 DR. KEMPER. 763 00:38:39,960 --> 00:38:50,320 >> THANK YOU, LAURA. 764 00:38:52,080 --> 00:38:53,440 >> CAN EVERYBODY SEE MY SLIDES? 765 00:38:53,440 --> 00:38:54,960 >> YES, PERFECT. 766 00:38:54,960 --> 00:39:00,840 >> I'D LIKE TO THANK THE NHLBI 767 00:39:00,840 --> 00:39:03,040 LEADERSHIP TO FOR INVITING AND 768 00:39:03,040 --> 00:39:04,280 THE COUNCIL FOR COMING AND 769 00:39:04,280 --> 00:39:08,520 LISTENING TO WHAT I'M DOING. 770 00:39:08,520 --> 00:39:10,080 I'VE GIVING AN INTRODUCTION TO 771 00:39:10,080 --> 00:39:13,160 THE WORK AND I'M RELATIVELY SURE 772 00:39:13,160 --> 00:39:18,120 MANY HAVE NOT HEARD OF US AND TO 773 00:39:18,120 --> 00:39:23,360 GIVE AN OVERVIEW OF THE 774 00:39:23,360 --> 00:39:24,440 COMPLEMENT AND INFLAMMATION 775 00:39:24,440 --> 00:39:25,840 RESEARCH SECTION I'M HEADING AND 776 00:39:25,840 --> 00:39:28,040 TO GIVE A SNAPSHOT OF OUR WORK. 777 00:39:28,040 --> 00:39:30,000 WHAT TIME TRYING TO DO IN 778 00:39:30,000 --> 00:39:32,240 BETWEEN IS NOT ONLY SHOWCASE OUR 779 00:39:32,240 --> 00:39:35,600 SCIENCE BUT SHARE HOW WE OPERATE 780 00:39:35,600 --> 00:39:38,200 AS A TEAM AND RESEARCH AND 781 00:39:38,200 --> 00:39:41,160 CLINICAL TEAM AND EMBED US IN 782 00:39:41,160 --> 00:39:42,200 THE NIH WIDE COMMUNITY AND NIH 783 00:39:42,200 --> 00:39:48,560 WIDE MISSION. 784 00:39:48,560 --> 00:39:50,320 MOST HAVE HEARD THE WORD 785 00:39:50,320 --> 00:39:50,760 COMPLIMENT SYSTEM. 786 00:39:50,760 --> 00:39:53,440 IT'S A SYSTEM CIRCULATING IN 787 00:39:53,440 --> 00:39:55,600 YOUR BLOOD AND IT'S ONE OF THE 788 00:39:55,600 --> 00:40:01,320 OLDEST PARTS OF THE IMMUNE 789 00:40:01,320 --> 00:40:03,240 SYSTEM, THE INNATE IMMUNE 790 00:40:03,240 --> 00:40:04,000 SYSTEM. 791 00:40:04,000 --> 00:40:07,080 IT'S CRITICAL TO PROTECT YOU 792 00:40:07,080 --> 00:40:10,440 AGAINST THE VIRUSES AND THERE'S 793 00:40:10,440 --> 00:40:15,640 15 PROTEINS CIRCULATING IN THE 794 00:40:15,640 --> 00:40:25,640 FLUID OR KILLS PATHOGENS BY 795 00:40:25,640 --> 00:40:30,720 ACTIVATION THAT INDUCE THIS 796 00:40:30,720 --> 00:40:32,200 INFLAMMATORY REACTION IN GENERAL 797 00:40:32,200 --> 00:40:34,840 AND CRITICAL TO ADAPTIVE 798 00:40:34,840 --> 00:40:35,120 IMMUNITY. 799 00:40:35,120 --> 00:40:38,880 THE TWO CRITICAL COMPONENTS OF 800 00:40:38,880 --> 00:40:40,840 THE COMPLIMENT SYSTEM ARE HERE. 801 00:40:40,840 --> 00:40:43,320 IT'S A GOOD SYSTEM TO HAVE 802 00:40:43,320 --> 00:40:44,440 FUNCTIONING WELL. 803 00:40:44,440 --> 00:40:46,000 THE COMPLEMENT SYSTEM ALSO HAS A 804 00:40:46,000 --> 00:40:47,320 DARK SIDE. 805 00:40:47,320 --> 00:40:50,120 IF IT'S UNCONTROLLED AND THAT 806 00:40:50,120 --> 00:40:52,600 ACTION SADLY HAPPENS QUITE OFTEN 807 00:40:52,600 --> 00:40:54,560 CAN TURN AGAINST US AND WHAT IT 808 00:40:54,560 --> 00:40:57,960 THEN DOES IS CAUSES PATHOLOGICAL 809 00:40:57,960 --> 00:41:00,120 AND ACUTE AND CHRONIC 810 00:41:00,120 --> 00:41:01,520 INFLAMMATION. 811 00:41:01,520 --> 00:41:07,440 THAT UNDERS IN -- UNDER LIES A 812 00:41:07,440 --> 00:41:09,600 BROAD RANGE OF DISEASE AND 813 00:41:09,600 --> 00:41:11,840 THERE'S ONLY A SMALL LIST OF 814 00:41:11,840 --> 00:41:12,120 REASONS. 815 00:41:12,120 --> 00:41:19,400 IT MEANS WE KNOW FOR DECADES 816 00:41:19,400 --> 00:41:20,920 COMPLEMENTS IS A THERAPEUTIC 817 00:41:20,920 --> 00:41:23,400 TARGET FOR 60 TO 70 YEARS A LOT 818 00:41:23,400 --> 00:41:26,560 OF MONEY AND RESEARCH IN 819 00:41:26,560 --> 00:41:30,000 CLINICAL EFFORTS HAVE GONE TO 820 00:41:30,000 --> 00:41:30,960 DEVELOPING COMPLEMENTIVE 821 00:41:30,960 --> 00:41:32,760 TARGETED EFFORTS AND THE SUPPORT 822 00:41:32,760 --> 00:41:34,320 HAS BEEN RATHER DISAPPOINTING. 823 00:41:34,320 --> 00:41:36,720 HERE TO THE RIGHT WE SEE A 824 00:41:36,720 --> 00:41:41,040 SNAPSHOT OF PUBLICATION IN 2015 825 00:41:41,040 --> 00:41:44,440 WHERE ONLY FOUR COMPLEMENT 826 00:41:44,440 --> 00:41:46,920 TARGETS AND IF I UPDATE IT TO 827 00:41:46,920 --> 00:41:50,520 2022 THERE'S ONLY TWO MORE. 828 00:41:50,520 --> 00:41:53,080 SIX ARE IN THE CLINIC AND FDA 829 00:41:53,080 --> 00:41:56,760 APPROVED FOR COMPLEMENT MEDIATED 830 00:41:56,760 --> 00:41:57,040 DISEASES. 831 00:41:57,040 --> 00:41:59,240 AND ALMOST MORE IMPORTANTLY, THE 832 00:41:59,240 --> 00:42:02,560 DRUGS THAT WE HAVE TODAY ARE 833 00:42:02,560 --> 00:42:07,280 ONLY APPLICABLE TO RARE DISEASE 834 00:42:07,280 --> 00:42:10,360 CONDITION AND SKIN AGE AND 835 00:42:10,360 --> 00:42:13,760 SYNDROME AND SO WHAT WE ARE 836 00:42:13,760 --> 00:42:15,960 LACKING RIGHT NOW IS COMPLEMENT 837 00:42:15,960 --> 00:42:16,640 TARGETED THERAPEUTICS THAT 838 00:42:16,640 --> 00:42:19,520 TARGET BROAD HUMAN DISEASES SUCH 839 00:42:19,520 --> 00:42:22,880 AS ARTHRITIS, ATHEROSCLEROSIS 840 00:42:22,880 --> 00:42:24,120 AND IBD. 841 00:42:24,120 --> 00:42:26,200 IT'S NOT CLEAR TO THE COMMUNITY 842 00:42:26,200 --> 00:42:28,040 WHY WE HAVE BEEN UNSUCCESSFUL 843 00:42:28,040 --> 00:42:32,160 BUT I THINK POSSIBLY OUR WORK AT 844 00:42:32,160 --> 00:42:34,040 THE NIH HAS MAYBE COME UP WITH 845 00:42:34,040 --> 00:42:35,880 AGE EXPLANATION. 846 00:42:35,880 --> 00:42:38,360 WE THINK COMPLEMENT IS LIVER 847 00:42:38,360 --> 00:42:43,040 DERIVED AND CIRCULATES IN BLOOD 848 00:42:43,040 --> 00:42:44,720 AND THERE'S COMPLEMENT MORE IN 849 00:42:44,720 --> 00:42:45,200 CIRCULATION. 850 00:42:45,200 --> 00:42:47,200 I'D LIKE YOU TO TAKE ONE 851 00:42:47,200 --> 00:42:50,520 SNAPSHOT OF THE IDEA OF WHAT 852 00:42:50,520 --> 00:42:54,120 WE'RE DOING HERE AND IT WOULD BE 853 00:42:54,120 --> 00:42:57,600 THIS SLIDE. 854 00:42:57,600 --> 00:43:03,720 WHAT WE HAVE DISCOVERED THAT 855 00:43:03,720 --> 00:43:06,120 WILL EVERY CELL CARRIES IT 856 00:43:06,120 --> 00:43:11,840 COMPLEMENT SYSTEM AND WE CALL 857 00:43:11,840 --> 00:43:22,400 THIS THE COMPLOSOME IS CONCERNED 858 00:43:24,480 --> 00:43:31,680 WITH A SINGLE-CELL METABOLISM 859 00:43:31,680 --> 00:43:33,880 AND CONTROLS CELL SURVIVAL, 860 00:43:33,880 --> 00:43:40,880 HOMEOSTASIS AND FUNCTION. 861 00:43:40,880 --> 00:43:42,560 THE WAS DISCOVERED BY A POST-DOC 862 00:43:42,560 --> 00:43:46,560 IN MY LAB IN COLLABORATION WITH 863 00:43:46,560 --> 00:43:54,080 MY MENTOR AND MARTIN HAS 864 00:43:54,080 --> 00:44:00,120 DISCOVERED THAT HUMAN C3A 865 00:44:00,120 --> 00:44:05,720 POSITIVE T CELL AND THEY CONTAIN 866 00:44:05,720 --> 00:44:10,520 C3 STOREAGES IN LYSOSOMES AND 867 00:44:10,520 --> 00:44:18,160 THAT'S ACTIVATED BY A PROTEASE 868 00:44:18,160 --> 00:44:22,120 AND THE INTRACELLULARLY 869 00:44:22,120 --> 00:44:32,680 GENERATED C3A INDUCES THE MTOR 870 00:44:36,280 --> 00:44:43,120 MACHINERY IN EVERY CELL IN YOUR 871 00:44:43,120 --> 00:44:44,360 CELL AND IT'S REQUIRED TO 872 00:44:44,360 --> 00:44:48,160 SUSTAIN T CELL SURVIVAL AND 873 00:44:48,160 --> 00:44:50,120 WITHOUT THE SYSTEM THEY WILL 874 00:44:50,120 --> 00:44:50,560 DIE. 875 00:44:50,560 --> 00:44:53,000 THAT WAS AN INTERESTING FINDING 876 00:44:53,000 --> 00:44:57,520 BECAUSE 10 YEARS AGO WE DIDN'T 877 00:44:57,520 --> 00:45:02,520 REALLY THINK COMPLEMENT WAS 878 00:45:02,520 --> 00:45:03,840 INTRACELLULARLY AND HAVE A T 879 00:45:03,840 --> 00:45:04,520 CELL SURVIVAL. 880 00:45:04,520 --> 00:45:06,240 IT WENT AGAINST THE GRAIN OF 881 00:45:06,240 --> 00:45:08,280 WHAT WE KNEW ABOUT THE 882 00:45:08,280 --> 00:45:08,720 COMPLEMENT SYSTEM. 883 00:45:08,720 --> 00:45:10,960 HOWEVER, WHEN WE KEPT WORKING ON 884 00:45:10,960 --> 00:45:13,800 THIS SYSTEM, WE KIND OF PUT IT A 885 00:45:13,800 --> 00:45:15,120 LITTLE BIT BETTER INTO THE 886 00:45:15,120 --> 00:45:17,080 PICTURE OF WHAT PEOPLE USUALLY 887 00:45:17,080 --> 00:45:18,400 THOUGHT ABOUT COMPLEMENT BECAUSE 888 00:45:18,400 --> 00:45:24,240 IT IS ACTUALLY ALSO T CELLS' 889 00:45:24,240 --> 00:45:28,800 DEFENSE SYSTEM IN THE PRESENCE 890 00:45:28,800 --> 00:45:31,280 OF DANGER, THE SYSTEM IS A 891 00:45:31,280 --> 00:45:34,040 LITTLE BIT LIKE A LOADED GUN 892 00:45:34,040 --> 00:45:37,720 FLIPS TO THE OUTSIDE OF THE T 893 00:45:37,720 --> 00:45:39,880 CELL WHERE THE OTHER PORTION OF 894 00:45:39,880 --> 00:45:50,200 C3B ENGAGES THE RECEPTOR, CD426 895 00:45:50,200 --> 00:45:53,360 AND IT'S A HUMAN SPECIFIC 896 00:45:53,360 --> 00:45:55,840 MOLECULE NOT EXPRESSED IN MICE. 897 00:45:55,840 --> 00:45:59,200 THERE'S NO SMALL ANIMAL MODEL TO 898 00:45:59,200 --> 00:46:02,560 LOOK AT THIS THIS IS A HUMAN 899 00:46:02,560 --> 00:46:05,920 SPECIFIC PATHWAY. 900 00:46:05,920 --> 00:46:10,520 THE CD ENGAGEMENT HAS THE 901 00:46:10,520 --> 00:46:13,200 CANONICAL CYTOKINE TO INDUCE OR 902 00:46:13,200 --> 00:46:17,680 DENOTE TH1 RESPONSES. 903 00:46:17,680 --> 00:46:18,480 INTERESTINGLY ENOUGH, COMING 904 00:46:18,480 --> 00:46:26,560 FULL CYCLE BACK HERE THE CD46 905 00:46:26,560 --> 00:46:29,280 ENGAGEMENT DRIVES RESPONSE BUT 906 00:46:29,280 --> 00:46:32,040 ALSO MOVES INTO A STATE 907 00:46:32,040 --> 00:46:33,800 IMPORTANT TO PREVENT TISSUE 908 00:46:33,800 --> 00:46:37,040 MORPHOLOGY AND DOES SO BY 909 00:46:37,040 --> 00:46:40,840 CO-INDUCING THE INFLAMMATORY 910 00:46:40,840 --> 00:46:44,400 CYTOKINE IN TH CELLS. 911 00:46:44,400 --> 00:46:46,440 WE HAVE SHOWN WITH 912 00:46:46,440 --> 00:46:51,840 COLLABORATORS, IF YOU DON'T HAVE 913 00:46:51,840 --> 00:46:56,120 THIS SYSTEM C3 THEY CANNOT MOUNT 914 00:46:56,120 --> 00:46:58,480 RESPONSES AND SUFFER FROM 915 00:46:58,480 --> 00:47:00,320 RECURRENT VIRAL INFECTIONS OF 916 00:47:00,320 --> 00:47:03,880 THE UPPER RESPIRATORY. 917 00:47:03,880 --> 00:47:06,480 HOWEVER, IF THE SYSTEM IS 918 00:47:06,480 --> 00:47:09,800 AUGMENTED IF THE SYSTEM PRODUCES 919 00:47:09,800 --> 00:47:13,480 TOO MUCH CD3 AND GET TOO MUCH 920 00:47:13,480 --> 00:47:17,000 CD46 ENGAGEMENT YOU ARE GET 921 00:47:17,000 --> 00:47:18,680 RESPONSES CONTRIBUTE TO THE 922 00:47:18,680 --> 00:47:26,520 ARTHRITIS, SCLERO DERMA-AND 923 00:47:26,520 --> 00:47:28,720 ORGAN REJECTION WE HAVE KNOWN 924 00:47:28,720 --> 00:47:32,960 IT'S AN INTERESTING SYSTEM AND 925 00:47:32,960 --> 00:47:35,040 THERE'S A HIGH PROBABILITY AND 926 00:47:35,040 --> 00:47:38,080 WE HAVE SHOWN THAT IF WE TAKE 927 00:47:38,080 --> 00:47:39,600 THE T CELLS FROM PATIENTS 928 00:47:39,600 --> 00:47:43,160 SUFFERING FROM THESE STATES OF 929 00:47:43,160 --> 00:47:45,120 AUTOIMMUNITY FROM THE LOCATION 930 00:47:45,120 --> 00:47:46,640 OF INFLAMMATION FOR EXAMPLE, T 931 00:47:46,640 --> 00:47:49,280 CELLS FROM THE INFLAMED JOINT OF 932 00:47:49,280 --> 00:47:54,360 PATIENTS WITH ARTHRITIS AND 933 00:47:54,360 --> 00:47:59,680 CULTURE THEM IN VIVO AND EX VIVO 934 00:47:59,680 --> 00:48:01,080 AND WHAT DRIVES THE SYSTEM WE 935 00:48:01,080 --> 00:48:07,360 CAN COMPLETELY NORMALIZE 936 00:48:07,360 --> 00:48:09,160 HYPERACTIVE TH1 RESPONSE. 937 00:48:09,160 --> 00:48:12,000 THIS WAS AN EXCITING POINT. 938 00:48:12,000 --> 00:48:13,160 THINGS GOT MORE INTERESTING WHEN 939 00:48:13,160 --> 00:48:16,560 WE TRIED TO UNDERSTAND HOW 940 00:48:16,560 --> 00:48:18,800 EXACTLY IS THIS CAREER 941 00:48:18,800 --> 00:48:25,360 COMPLEMENT CD46 CONTROLLING CH1 942 00:48:25,360 --> 00:48:25,600 BIOLOGY. 943 00:48:25,600 --> 00:48:27,720 WE EXPECT THE IT CONTROLS GENE 944 00:48:27,720 --> 00:48:30,360 TRANSCRIPTION ON THAT LEVEL BUT 945 00:48:30,360 --> 00:48:36,240 WHAT WE NOTED USING T CELLS FROM 946 00:48:36,240 --> 00:48:39,080 THESE PATIENTS CD46 DOES THREE 947 00:48:39,080 --> 00:48:40,800 CORE SIGNALLING INDUCTION 948 00:48:40,800 --> 00:48:41,080 PATHWAYS. 949 00:48:41,080 --> 00:48:44,520 FIRST ONE IS IT INDUCES THE GENE 950 00:48:44,520 --> 00:48:47,000 EXPRESSION OF GENES AND CODED 951 00:48:47,000 --> 00:48:52,560 PROTEINS CRITICAL TO ALLOW THE 952 00:48:52,560 --> 00:48:54,360 ACTIVATED T CELL. 953 00:48:54,360 --> 00:48:57,240 FOR EXAMPLE, A BROAD RANGE. 954 00:48:57,240 --> 00:49:01,400 AT THE SAME TIME, CD46 INDUCE 955 00:49:01,400 --> 00:49:05,680 THE SHUNT OF THE MTOR IN THE 956 00:49:05,680 --> 00:49:07,440 METABOLIC MACHINERY THAT SENSES 957 00:49:07,440 --> 00:49:10,520 NUTRIENTS IN THE CELL TO THE 958 00:49:10,520 --> 00:49:14,600 LYSOSOMES AND THESE TOGETHER 959 00:49:14,600 --> 00:49:17,120 DRIVE THE INFECTION. 960 00:49:17,120 --> 00:49:22,440 T CELLS ALSO CONTAIN THE SYSTEM 961 00:49:22,440 --> 00:49:24,360 CD46 ACTIVATED THE SYSTEM WHICH 962 00:49:24,360 --> 00:49:30,360 THEN ENGAGES THE CELL INTRINSIC 963 00:49:30,360 --> 00:49:33,280 OR SECOND SYSTEM THE INFLAMOSOME 964 00:49:33,280 --> 00:49:35,920 DRIVING PRODUCTION AND 965 00:49:35,920 --> 00:49:38,520 CONTROLLED TH1 RESPONSES. 966 00:49:38,520 --> 00:49:44,080 IN A SIMILAR VEIN, CD46 CONTROLS 967 00:49:44,080 --> 00:49:46,360 THE SHUT DOWN BY METABOLIC 968 00:49:46,360 --> 00:49:48,960 REPROGRAMMING AND HERE IT 969 00:49:48,960 --> 00:49:53,240 INDUCES CHOLESTEROL EFFLUX AND 970 00:49:53,240 --> 00:49:55,800 INDUCES IL01 AND TH1 971 00:49:55,800 --> 00:49:57,040 CONTRACTION. 972 00:49:57,040 --> 00:49:59,200 THERE'S A SECOND ARM OF 973 00:49:59,200 --> 00:50:03,560 COMPLEMENT AND RECEPTOR 2 THAT 974 00:50:03,560 --> 00:50:07,400 ALSO AN IN AN INTRINSIC FASHION 975 00:50:07,400 --> 00:50:09,400 BLOCKS THE ACTIVATION. 976 00:50:09,400 --> 00:50:12,280 WHAT LAURA HASN'T TOLD YOU IS I 977 00:50:12,280 --> 00:50:14,200 MOVED MY LAB AFTER THESE 978 00:50:14,200 --> 00:50:16,000 DISCOVERIES IN 2017 TO NHLBI. 979 00:50:16,000 --> 00:50:20,560 WHEN I JOINED THE FACULTY HERE, 980 00:50:20,560 --> 00:50:22,560 WE KNEW THAT NORMAL BIOLOGY IS 981 00:50:22,560 --> 00:50:25,200 DEPENDENT ON AN INTRINSIC 982 00:50:25,200 --> 00:50:29,400 COMPLOSOME, THAT IT WORKS IN 983 00:50:29,400 --> 00:50:34,560 COLLABORATION WITH OTHER ANCIENT 984 00:50:34,560 --> 00:50:39,480 SYSTEMS AND IT'S CRITICAL AND 985 00:50:39,480 --> 00:50:41,320 BECAUSE IT'S NOT EXPRESSED IT'S 986 00:50:41,320 --> 00:50:43,680 THE HUMAN SPECIFIC SYSTEM. 987 00:50:43,680 --> 00:50:48,360 WE ALSO KNEW THAT PERTURBATION 988 00:50:48,360 --> 00:50:50,920 IN THE CELL INVASIVE SYSTEM 989 00:50:50,920 --> 00:50:54,800 CONTRIBUTE TO HYPER AND 990 00:50:54,800 --> 00:50:58,520 HYPOACTIVITY AND PERTURBATIONS 991 00:50:58,520 --> 00:50:59,520 AFFECT THE MODEL. 992 00:50:59,520 --> 00:51:03,080 WHAT WE DID WAS WHEN WE MOVED 993 00:51:03,080 --> 00:51:06,160 HERE WE STARTED DEVELOPING A 994 00:51:06,160 --> 00:51:07,960 BIGGER PROGRAM. 995 00:51:07,960 --> 00:51:10,880 WE WANTED TO UNDERSTAND THE 996 00:51:10,880 --> 00:51:12,640 FUNCTION OF THE COMPLOSOME WITH 997 00:51:12,640 --> 00:51:14,680 REGARDS TO OTHER ARMS OF CELL 998 00:51:14,680 --> 00:51:18,760 BIOLOGY AND WORKING ON STRESS 999 00:51:18,760 --> 00:51:20,600 SENSING AND DNR ORGANIZATION. 1000 00:51:20,600 --> 00:51:23,240 I'LL SHOW A FEW TOWARDS THE END 1001 00:51:23,240 --> 00:51:25,160 OF MY PRESENTATION. 1002 00:51:25,160 --> 00:51:26,360 IMPORTANTLY, WE NEED TO 1003 00:51:26,360 --> 00:51:27,560 UNDERSTAND HOW THE SYSTEM 1004 00:51:27,560 --> 00:51:29,840 REGULATES BECAUSE YOU'VE SEEN IF 1005 00:51:29,840 --> 00:51:31,760 IT'S DISREGULATED AND CAUSES 1006 00:51:31,760 --> 00:51:32,160 DISEASE. 1007 00:51:32,160 --> 00:51:35,160 FOR THIS WE WENT INTO TISSUE 1008 00:51:35,160 --> 00:51:36,880 BIOLOGY AND DIFFERENCE DISEASES 1009 00:51:36,880 --> 00:51:39,360 AND TRIED TO UNDERSTAND WHERE IT 1010 00:51:39,360 --> 00:51:42,080 OCCURS OR REGULATED AND IF 1011 00:51:42,080 --> 00:51:44,880 REGULATION AND OCCURRENCE IS THE 1012 00:51:44,880 --> 00:51:50,520 SAME IN ALL AND THE ULTIMATE 1013 00:51:50,520 --> 00:51:52,640 GOAL TO UNDERSTAND TO WHAT 1014 00:51:52,640 --> 00:51:55,120 DISEASE DOES DYSFUNCTION OF THE 1015 00:51:55,120 --> 00:51:58,120 SYSTEM CONTRIBUTE AND DEVELOP 1016 00:51:58,120 --> 00:52:00,320 NEW PRE-CLINICALAL MODELS AND 1017 00:52:00,320 --> 00:52:01,440 THERAPEUTIC MODULATION. 1018 00:52:01,440 --> 00:52:04,800 THIS IS A SNAPSHOT OF OUR OVER 1019 00:52:04,800 --> 00:52:06,120 ARCHING RESEARCH PROGRAM. 1020 00:52:06,120 --> 00:52:07,600 TO ADDRESS THESE QUESTIONS IT 1021 00:52:07,600 --> 00:52:09,600 LOOKS PRETTY COMPLEX. 1022 00:52:09,600 --> 00:52:12,600 WE USUALLY CHOP DOWN THINGS INTO 1023 00:52:12,600 --> 00:52:13,840 SMALLER CHUNKS WE CAN HANDLE 1024 00:52:13,840 --> 00:52:14,640 QUITE WELL. 1025 00:52:14,640 --> 00:52:17,680 WHAT WE DO NORMALLY IS WE 1026 00:52:17,680 --> 00:52:19,560 ACTUALLY TRY TO ADDRESS TWO 1027 00:52:19,560 --> 00:52:21,280 IMPORTANT AND SIMPLE QUESTIONS. 1028 00:52:21,280 --> 00:52:22,560 THE ANSWERS ARE NOT SIMPLE BUT 1029 00:52:22,560 --> 00:52:25,280 THE QUESTIONS ARE SIMPLE. 1030 00:52:25,280 --> 00:52:27,200 HOW DOES THE COMPLOSOME FUNCTION 1031 00:52:27,200 --> 00:52:27,640 AND REGULATE? 1032 00:52:27,640 --> 00:52:29,520 ONE OF THE IMMINENT QUESTIONS 1033 00:52:29,520 --> 00:52:31,760 WAS I SHOWED YOU WE HAD 1034 00:52:31,760 --> 00:52:35,800 DISCOVERED THAT IN CD4 POSITIVE 1035 00:52:35,800 --> 00:52:36,760 T CELLS. 1036 00:52:36,760 --> 00:52:38,440 IS THE SYSTEM CD4 T CELL 1037 00:52:38,440 --> 00:52:40,240 SPECIFIC OR DOES IT OCCUR IN 1038 00:52:40,240 --> 00:52:41,200 OTHER IMMUNE CELLS? 1039 00:52:41,200 --> 00:52:42,600 I'M SHOWING YOU A LITTLE BIT OF 1040 00:52:42,600 --> 00:52:44,720 THE SUMMARY OF OUR RESEARCH IN 1041 00:52:44,720 --> 00:52:46,000 THE LAST FOUR YEARS. 1042 00:52:46,000 --> 00:52:49,800 WE FIRST TRIED TO FIND OUT IS 1043 00:52:49,800 --> 00:52:52,680 THIS SYSTEM ALSO OPERATIVE AND 1044 00:52:52,680 --> 00:52:56,960 THE OTHER SUB TYPE, CD8 T CELLS 1045 00:52:56,960 --> 00:53:01,680 THAT YOU NEED TO FIGHT VIRAL 1046 00:53:01,680 --> 00:53:02,560 INFECTIONS AND THE SYSTEM 1047 00:53:02,560 --> 00:53:04,960 OPERATES IN A SIMILAR FASHION 1048 00:53:04,960 --> 00:53:06,960 WITH CD8 POSITIVE T CELLS IS 1049 00:53:06,960 --> 00:53:08,240 REQUIRED FOR NORMAL ACTIVATION 1050 00:53:08,240 --> 00:53:09,760 AND NEEDED TO PROTECT YOU 1051 00:53:09,760 --> 00:53:20,280 AGAINST RECURRENT INFECTIONS. 1052 00:53:21,640 --> 00:53:25,600 WE COLLABORATED WITH NAIMS AND 1053 00:53:25,600 --> 00:53:28,680 WHAT WAS FOUND IS THE COMPLOSOME 1054 00:53:28,680 --> 00:53:30,200 PERTURBATION IN PATIENTS WITH 1055 00:53:30,200 --> 00:53:33,240 LUPUS CROSS-CONNECTS AND 1056 00:53:33,240 --> 00:53:35,240 CROSS-TALKS WITH THE EXTRA 1057 00:53:35,240 --> 00:53:40,640 CELLULAR COMPLIMENT SYSTEM AND 1058 00:53:40,640 --> 00:53:42,520 PERTURBATIONS CONTRIBUTE TO THE 1059 00:53:42,520 --> 00:53:44,400 PHENOTYPE FORMATION UNDERLYING 1060 00:53:44,400 --> 00:53:44,760 THIS. 1061 00:53:44,760 --> 00:53:45,760 TOGETHER WITH SOME RESEARCHERS 1062 00:53:45,760 --> 00:53:48,800 ACROSS OTHER INSTITUTES, WE HAVE 1063 00:53:48,800 --> 00:53:51,480 FOUND THE SYSTEM IS ALSO REALLY 1064 00:53:51,480 --> 00:53:55,040 OPEN TO MONOCYTES AND 1065 00:53:55,040 --> 00:54:00,280 MACROPHAGES AND DENDRITIC CELLS 1066 00:54:00,280 --> 00:54:05,680 AND IF THEY MAY NOT BE ABLE TO 1067 00:54:05,680 --> 00:54:07,680 FIGHT PRO-INFLAMMATORY STATES 1068 00:54:07,680 --> 00:54:12,320 AND PATIENT WHO'S CAN'T ENGAGE 1069 00:54:12,320 --> 00:54:13,160 IN THIS SYSTEM SUFFER FROM 1070 00:54:13,160 --> 00:54:14,640 IMMUNE DEFICIENCIES. 1071 00:54:14,640 --> 00:54:18,560 WHAT WE'RE TRYING TO DO IS MOVE 1072 00:54:18,560 --> 00:54:23,200 INTO THE SPIRIT OF NHLBI AND 1073 00:54:23,200 --> 00:54:23,840 UNDERSTAND CARDIOVASCULAR 1074 00:54:23,840 --> 00:54:26,160 DISEASE BETTER OUR MOST RECENT 1075 00:54:26,160 --> 00:54:29,000 FINDING IS THIS INTRACELLULAR 1076 00:54:29,000 --> 00:54:30,600 SYSTEM AND MONOCYTES AND 1077 00:54:30,600 --> 00:54:38,560 MACROPHAGES ARE NOW DRIVEN BY 1078 00:54:38,560 --> 00:54:39,680 INFLAMMATION. 1079 00:54:39,680 --> 00:54:45,320 ACTIVITY IN THE MONOCYTES LEADS 1080 00:54:45,320 --> 00:54:47,320 TO THE DYSREGULATION OF 1081 00:54:47,320 --> 00:54:50,240 MITOCHONDRIA AND TRANSPORT CHAIN 1082 00:54:50,240 --> 00:54:54,840 AND TO THE HYPERACTIVE STATE 1083 00:54:54,840 --> 00:55:01,920 MYELOID CELLS IN ATHEROSCLEROSIS 1084 00:55:01,920 --> 00:55:07,320 AND THERE'S A PAPER SHOWING THAT 1085 00:55:07,320 --> 00:55:12,920 SYSTEM WHICH IS DISREGULATED IN 1086 00:55:12,920 --> 00:55:16,320 ATHEROSCLEROTIC DISEASE PROTECTS 1087 00:55:16,320 --> 00:55:26,800 YOU AGAINST CANDIDIASIS AND 1088 00:55:30,000 --> 00:55:33,040 THERE'S DISEASES OF AUTOIMMUNITY 1089 00:55:33,040 --> 00:55:38,200 AND CARDIOVASCULAR DISEASE. 1090 00:55:38,200 --> 00:55:44,440 WE KNOW AND CONSTITUENT WE HAVE 1091 00:55:44,440 --> 00:55:48,960 BEEN ABLE TO NORMALIZE 1092 00:55:48,960 --> 00:55:54,560 SUCCESSFULLY C3 OR C5 INCREASES 1093 00:55:54,560 --> 00:56:01,320 IN T CELLS AND MONOCYTES AND 1094 00:56:01,320 --> 00:56:08,840 MACRO PHAGES IN VITRO AND WE 1095 00:56:08,840 --> 00:56:12,440 HAVE DEVELOPED WHAT HAS PASSED 1096 00:56:12,440 --> 00:56:13,880 TOXICOLOGY TESTS IN THE ANIMALS 1097 00:56:13,880 --> 00:56:16,040 AND MOVING TO TESTING THIS 1098 00:56:16,040 --> 00:56:18,760 COMPOUND IN CARDIOVASCULAR 1099 00:56:18,760 --> 00:56:22,560 DISEASE MODELS FOR ACTIVITY IN 1100 00:56:22,560 --> 00:56:26,840 THE INTRACELLULAR COMPLEMENT 1101 00:56:26,840 --> 00:56:33,560 DURING THESE DISEASE. 1102 00:56:33,560 --> 00:56:39,840 TACKLING AN INTRACELLULAR TARGET 1103 00:56:39,840 --> 00:56:42,800 WHAT WE'RE DOING IS WE'RE TRYING 1104 00:56:42,800 --> 00:56:44,720 TO UNDERSTAND THE NOVEL BIOLOGY 1105 00:56:44,720 --> 00:56:46,000 OF THE SYSTEM AND WE'RE 1106 00:56:46,000 --> 00:56:48,680 PARTICULARLY INTERESTED IN WHAT 1107 00:56:48,680 --> 00:56:53,040 ARE THE CELL REGULATORS OF C3 1108 00:56:53,040 --> 00:56:55,160 AND C5 TRANSCRIPTION OF IMMUNE 1109 00:56:55,160 --> 00:57:02,600 CELLS BECAUSE THE CELLS TARGET 1110 00:57:02,600 --> 00:57:04,560 AND I THINK WE HAVE DONE IT 1111 00:57:04,560 --> 00:57:07,960 SUCCESSFULLY AND I'D LIKE TO 1112 00:57:07,960 --> 00:57:09,800 SHARE WITH YOU HOW SOMETIMES AN 1113 00:57:09,800 --> 00:57:11,200 UNUSUAL FINDING OR CRITIQUE IN 1114 00:57:11,200 --> 00:57:14,640 THE FIELD CAN LEAD TO 1115 00:57:14,640 --> 00:57:15,080 DISCOVERIES. 1116 00:57:15,080 --> 00:57:17,120 SO WHAT HAPPENED IS WE RECEIVED 1117 00:57:17,120 --> 00:57:21,760 A LOT OF PHONE CALLS FROM OTHER 1118 00:57:21,760 --> 00:57:23,760 RESEARCHERS THAT SAID CLAUDIA, 1119 00:57:23,760 --> 00:57:26,000 WE CAN'T SEE A LOT OF COMPLEMENT 1120 00:57:26,000 --> 00:57:33,080 ACTIVITY IN CELLS AND 1121 00:57:33,080 --> 00:57:33,640 CIRCULATION. 1122 00:57:33,640 --> 00:57:35,600 I WAS WITH MY TEAM DURING A 1123 00:57:35,600 --> 00:57:37,880 BRAIN STORMING SYSTEM AND 1124 00:57:37,880 --> 00:57:40,600 WONDERING WHY THAT MIGHT BE AND 1125 00:57:40,600 --> 00:57:46,600 WE THOUGHT THE ACTION FOR ANY 1126 00:57:46,600 --> 00:57:48,200 DISEASE IS IN THE TISSUE. 1127 00:57:48,200 --> 00:57:51,840 SO WE WERE HYPOTHESIZING MAYBE 1128 00:57:51,840 --> 00:57:53,920 THE SYSTEM IS MORE IMPORTANT IN 1129 00:57:53,920 --> 00:57:56,000 TISSUE CELLS. 1130 00:57:56,000 --> 00:57:58,160 SO WHAT WE DID WITH 1131 00:57:58,160 --> 00:58:01,840 COLLABORATORS WE SOURCED 1132 00:58:01,840 --> 00:58:07,080 PUBLICLY AVAILABLE DATA WHERE T 1133 00:58:07,080 --> 00:58:17,840 CELLS OR IMMUSOLATED HUMAN SPLE 1134 00:58:20,080 --> 00:58:22,560 AND TISSUE OF CD4 T CELLS AND 1135 00:58:22,560 --> 00:58:27,160 LOOKED AT CIRCULATING VERSUS 1136 00:58:27,160 --> 00:58:28,760 RESIDENT CELLS AND THIS PANEL I 1137 00:58:28,760 --> 00:58:30,560 RECEIVED IN MY MAILBOX TWO DAYS 1138 00:58:30,560 --> 00:58:31,080 LATER. 1139 00:58:31,080 --> 00:58:34,080 I SAID NO, NO I DIDN'T WANT KNOW 1140 00:58:34,080 --> 00:58:34,640 THE COMPLEMENT EXPRESSION 1141 00:58:34,640 --> 00:58:40,160 PROFILE, I WANTED TO KNOW THE 1142 00:58:40,160 --> 00:58:41,160 WHOLE EXPRESSION PROFILE. 1143 00:58:41,160 --> 00:58:48,800 THEY SAID THIS IS THE UNBIASSED 1144 00:58:48,800 --> 00:58:51,480 DATA AND YOU CAN SEE THE IMMUNE 1145 00:58:51,480 --> 00:58:52,200 CELLS AND TISSUES. 1146 00:58:52,200 --> 00:58:55,440 THIS IS NOT ONLY THE CASE FOR 1147 00:58:55,440 --> 00:59:02,440 CD4 POSITIVE T CELLS BUT FOR CD8 1148 00:59:02,440 --> 00:59:08,040 T CELLS AND MYELOID CELLS AND 1149 00:59:08,040 --> 00:59:11,440 WHEN YOU GO TO THE EXPRESSION OR 1150 00:59:11,440 --> 00:59:13,960 COMPLEMENT LIKE I PROPOSED IN 1151 00:59:13,960 --> 00:59:18,040 THE BEGINNING, IT'S THE FULL 1152 00:59:18,040 --> 00:59:21,720 COMPLEMENT OF THE EXPRESSED 1153 00:59:21,720 --> 00:59:21,920 CELLS. 1154 00:59:21,920 --> 00:59:24,960 BASED ON THE INITIAL FINDING WE 1155 00:59:24,960 --> 00:59:28,760 FOUND THAT THE INTEGRIN IN FA1 1156 00:59:28,760 --> 00:59:31,920 IS THE MASTER INDUCER OF THE 1157 00:59:31,920 --> 00:59:33,800 COMPLEMENT CD3 COMPONENT WHY THE 1158 00:59:33,800 --> 00:59:39,520 CELLS MOVE INTO THE TISSUE. 1159 00:59:39,520 --> 00:59:44,120 THAT ALLOWED US TO INTEGRATE THE 1160 00:59:44,120 --> 00:59:45,520 SIMPLISTIC COMPLOSOME IN CONTROL 1161 00:59:45,520 --> 00:59:48,480 MORE INTO THE BODY AND MORE INTO 1162 00:59:48,480 --> 00:59:50,560 THE TISSUE. 1163 00:59:50,560 --> 01:00:01,120 SO WE KNOW THAT THE COMPLOSOME 1164 01:00:04,440 --> 01:00:07,040 MOVE TO THE TISSUE AND THIS IS 1165 01:00:07,040 --> 01:00:11,280 ALWAYS ENGAGED DURING THE 1166 01:00:11,280 --> 01:00:13,000 DIABETES TISSUES WHICH NOW NEEDS 1167 01:00:13,000 --> 01:00:20,160 TO TRANSCRIPTION WE CALL THIS 1168 01:00:20,160 --> 01:00:24,960 CD3 AND THE EFFECTER FUNCTION 1169 01:00:24,960 --> 01:00:27,880 AND HERE YOU HAVE HIGH 1170 01:00:27,880 --> 01:00:29,920 COMPLOSOME ACTIVATION AND THE 1171 01:00:29,920 --> 01:00:31,520 DRIVING DOWN STREAM TOWARDS T 1172 01:00:31,520 --> 01:00:33,160 CELL MYELOID CELL INFECTOR 1173 01:00:33,160 --> 01:00:34,480 FUNCTION. 1174 01:00:34,480 --> 01:00:37,920 IMPORTANTLY, THE SYSTEM ALSO IS 1175 01:00:37,920 --> 01:00:42,560 IMPORTANT AND ENGAGED ONCE THE 1176 01:00:42,560 --> 01:00:45,320 DANGER AND STOP BEING AN 1177 01:00:45,320 --> 01:00:49,640 EFFECTER CELL TO PREVENT 1178 01:00:49,640 --> 01:00:49,920 MORPHOLOGY. 1179 01:00:49,920 --> 01:00:51,560 YOU SEE THE COMPLOSOME IN ALL 1180 01:00:51,560 --> 01:00:54,560 LIFE CYCLE STAGES OF IMMUNE 1181 01:00:54,560 --> 01:00:56,280 CELLS BUT LOOKS A LITTLE BIT 1182 01:00:56,280 --> 01:00:57,800 DIFFERENT AND DOES SOMETHING 1183 01:00:57,800 --> 01:00:59,560 DIFFERENT DURING ALL THE STAGES. 1184 01:00:59,560 --> 01:01:02,080 MY LAB IS PARTICULARLY 1185 01:01:02,080 --> 01:01:04,920 INTERESTED IN UNDERSTANDING THE 1186 01:01:04,920 --> 01:01:07,560 TRANSITION OF THIS STATE AND THE 1187 01:01:07,560 --> 01:01:08,240 EFFECTER TISSUE TO THE 1188 01:01:08,240 --> 01:01:16,640 CONTRACTION TISSUE. 1189 01:01:16,640 --> 01:01:18,560 AND IF WE CAN UNDERSTAND THAT 1190 01:01:18,560 --> 01:01:20,640 AND MONTHLY LATE THAT WE'LL HAVE 1191 01:01:20,640 --> 01:01:24,320 A WAY TO CONTROL IMMUNITY AND 1192 01:01:24,320 --> 01:01:28,600 CANCER VERSUS CHRONIC INFECTION. 1193 01:01:28,600 --> 01:01:31,120 IMPORTANTLY, WITH THE EXPANDING 1194 01:01:31,120 --> 01:01:31,920 UNDERSTANDING THAT THE 1195 01:01:31,920 --> 01:01:34,040 COMPLOSOME IS REALLY QUITE 1196 01:01:34,040 --> 01:01:36,640 IMPORTANT ACROSS THE IMMUNE CELL 1197 01:01:36,640 --> 01:01:38,120 ACTIVITY IT'S NOT SOMETHING VERY 1198 01:01:38,120 --> 01:01:41,040 EXCITING OUTSIDE OF THIS, LARGE 1199 01:01:41,040 --> 01:01:42,880 PROPORTIONS OF THE SCIENTIFIC 1200 01:01:42,880 --> 01:01:43,800 COMMUNITY AND ALSO COMMISSIONS 1201 01:01:43,800 --> 01:01:45,640 ARE NOW STARTING TO BUY INTO THE 1202 01:01:45,640 --> 01:01:48,760 SYSTEM AND WE KNOW NOW THAT THIS 1203 01:01:48,760 --> 01:01:51,200 IS NOT JUST AN IMMUNE CELL 1204 01:01:51,200 --> 01:01:54,560 SPECIFIC PHENOMENA BUT THE 1205 01:01:54,560 --> 01:01:56,520 COMPLOSOME OPERATES IN A CLINIC 1206 01:01:56,520 --> 01:02:02,200 ROLE AND PANCREATIC CELLS AND 1207 01:02:02,200 --> 01:02:08,160 INTESTINAL EPITHELIAL CELLS TO 1208 01:02:08,160 --> 01:02:18,680 AND IS IMPORTANT AND DISEASE CAN 1209 01:02:19,280 --> 01:02:21,680 SPREAD AND WE HAVE HELPED OTHER 1210 01:02:21,680 --> 01:02:24,120 COLLABORATORS FIND A ROLE FOR 1211 01:02:24,120 --> 01:02:26,600 THE COMPLOSOME IN COLON CANCER 1212 01:02:26,600 --> 01:02:29,080 OR IN THE HIGH INFLAMMATORY 1213 01:02:29,080 --> 01:02:32,240 STATE THE COMPLEMENT SYSTEM PUTS 1214 01:02:32,240 --> 01:02:36,920 IN THE APPLICATION. 1215 01:02:36,920 --> 01:02:38,240 THIS IS WHERE WE STAND TODAY AND 1216 01:02:38,240 --> 01:02:41,720 I'M SHARING IN THE LAST SEVEN OR 1217 01:02:41,720 --> 01:02:43,640 EIGHT MINUTES JUST SOME 1218 01:02:43,640 --> 01:02:45,640 SNAPSHOTS AND DIRECTION IN WHICH 1219 01:02:45,640 --> 01:02:46,120 WE'RE GOING. 1220 01:02:46,120 --> 01:02:48,080 THIS IS MY TEAM RIGHT NOW. 1221 01:02:48,080 --> 01:02:52,520 I HAVE TWO STAFF SCIENTISTS AND 1222 01:02:52,520 --> 01:02:55,680 POST-DOCS AND ONE VISITING 1223 01:02:55,680 --> 01:02:56,680 CLINICAL FELLOW AND TWO Ph.D. 1224 01:02:56,680 --> 01:02:57,800 STUDENTS AND ONE JOINING THE 1225 01:02:57,800 --> 01:02:58,520 LAB. 1226 01:02:58,520 --> 01:03:02,240 I DO ACTUALLY THINK THAT MY LAB 1227 01:03:02,240 --> 01:03:05,520 IS A GREAT PLACE NOT JUST FOR 1228 01:03:05,520 --> 01:03:06,560 DOING SCIENCE BUT FOR TRAINING 1229 01:03:06,560 --> 01:03:10,560 PEOPLE NOR NEXT GENERATION OF 1230 01:03:10,560 --> 01:03:12,360 BASIC OR CLINICAL BIO MEDICAL 1231 01:03:12,360 --> 01:03:12,760 RESEARCH. 1232 01:03:12,760 --> 01:03:18,160 I THINK WE HAVE CREATED AN 1233 01:03:18,160 --> 01:03:19,920 IMPORTANT NICHE OF ADAPTIVE 1234 01:03:19,920 --> 01:03:20,280 IMMUNITY. 1235 01:03:20,280 --> 01:03:21,800 MEANING THERE'S SOMETHING FOR 1236 01:03:21,800 --> 01:03:24,360 EVERYBODY INTERESTED IN CERTAIN 1237 01:03:24,360 --> 01:03:27,360 ASPECTS OF IMMUNE BIOLOGY. 1238 01:03:27,360 --> 01:03:29,760 THEY'RE VERY INTERDISCIPLINARY. 1239 01:03:29,760 --> 01:03:32,280 WE DO HAVE FOCUS BUT WE'RE STILL 1240 01:03:32,280 --> 01:03:36,160 VERY INTERDISCIPLINARY AND 1241 01:03:36,160 --> 01:03:37,640 NETWORKING HEAVY IS GOOD FOR OUR 1242 01:03:37,640 --> 01:03:38,400 TEAMS AND STUDENTS. 1243 01:03:38,400 --> 01:03:41,760 THEY NETWORK AND MEET PEOPLE. 1244 01:03:41,760 --> 01:03:44,040 WE LIKE USING CUTTING-EDGE 1245 01:03:44,040 --> 01:03:46,560 TECHNOLOGIES YOU HEARD FROM GARY 1246 01:03:46,560 --> 01:03:54,560 GIBBONS GIVEN THE STRENGTH OF 1247 01:03:54,560 --> 01:04:00,040 NIDR AND CONVEY OUR FINDING TO 1248 01:04:00,040 --> 01:04:02,240 TRANSLATIONAL ASPECT. 1249 01:04:02,240 --> 01:04:07,480 WE'RE FOCUSSING ON TWO MAIN 1250 01:04:07,480 --> 01:04:09,440 AREAS, AND I'LL SHARE WITH YOU 1251 01:04:09,440 --> 01:04:13,760 WHY WE KEEP WORKING ON THESE. 1252 01:04:13,760 --> 01:04:18,560 WE'RE MOVING INTO A NEW AREA. 1253 01:04:18,560 --> 01:04:20,320 THE COMPLOSOME AND IMMUNITY AND 1254 01:04:20,320 --> 01:04:22,600 INFLAMMATION FROM ALL THE WORK 1255 01:04:22,600 --> 01:04:26,320 I'VE SHARED. 1256 01:04:26,320 --> 01:04:29,680 JUST A QUICK OVERVIEW. 1257 01:04:29,680 --> 01:04:31,960 AND WE HAVE A POST-DOC WHO 1258 01:04:31,960 --> 01:04:35,160 JOINED IN NOVEMBER 2019. 1259 01:04:35,160 --> 01:04:40,400 JUST WHEN HE WAS READY TO GET 1260 01:04:40,400 --> 01:04:47,520 BACK TO WORK, COVID CAME AND WE 1261 01:04:47,520 --> 01:04:49,360 MOVED TO A SHUT DOWN SYSTEM AND 1262 01:04:49,360 --> 01:04:51,160 JACK WAS INTERESTED IB DEFINING 1263 01:04:51,160 --> 01:04:54,520 THE GENETIC PROFILES THAT DRIVE 1264 01:04:54,520 --> 01:04:56,800 TH1 INFECTION AND CONTRACTION IS 1265 01:04:56,800 --> 01:05:00,640 ALSO REALLY GOOD COMPUTATIONAL 1266 01:05:00,640 --> 01:05:01,080 BIOLOGIST. 1267 01:05:01,080 --> 01:05:03,960 SO WHAT JACK DECIDED TO DO WHILE 1268 01:05:03,960 --> 01:05:06,600 HE WAS SITTING AT HOME AND 1269 01:05:06,600 --> 01:05:09,440 COULDN'T BE AT THE BENCH, 1270 01:05:09,440 --> 01:05:11,880 THERE'S A GOOD PROGRAM MISSING 1271 01:05:11,880 --> 01:05:16,400 RIGHT NOW TO MY SINGLE CELL SEQ 1272 01:05:16,400 --> 01:05:18,120 DATA AND WHAT JACK DID WAS WROTE 1273 01:05:18,120 --> 01:05:21,680 A PROGRAM AND DEVELOPED A NEW 1274 01:05:21,680 --> 01:05:22,600 TOOL. 1275 01:05:22,600 --> 01:05:25,360 HE SUBMITTED AND HAS BEEN 1276 01:05:25,360 --> 01:05:26,680 REVISED AND RESUBMITTED THIS 1277 01:05:26,680 --> 01:05:31,480 WEEK AND ASKED EVERYBODY TO MINE 1278 01:05:31,480 --> 01:05:35,160 OUR RNA SEQ DATA AND NOT JUST ON 1279 01:05:35,160 --> 01:05:37,000 A SINGLE GENE. 1280 01:05:37,000 --> 01:05:41,280 HE USES THIS NEW TOOL NOW TO 1281 01:05:41,280 --> 01:05:43,600 ASSESS THE GENETIC GENE 1282 01:05:43,600 --> 01:05:47,160 EXPRESSION PROFILES THAT T CELLS 1283 01:05:47,160 --> 01:05:49,480 GO THROUGH WHEN THEY MOVE TO THE 1284 01:05:49,480 --> 01:05:51,200 IL10 CONTRACTING PHASE. 1285 01:05:51,200 --> 01:05:56,320 HERE WE FOUND SOMETHING REALLY 1286 01:05:56,320 --> 01:05:56,600 INTERESTING. 1287 01:05:56,600 --> 01:05:58,800 DOWN HERE IN THE GRAY ZONE ARE T 1288 01:05:58,800 --> 01:06:02,320 CELLS THAT ARE NOT MOVING INTO A 1289 01:06:02,320 --> 01:06:07,280 TH1 PLACE, TH172 CELLS BUT WHEN 1290 01:06:07,280 --> 01:06:08,240 WE LOOK AT THE GENE EXPRESSION 1291 01:06:08,240 --> 01:06:12,080 BETWEEN THE GROUPS THEY ALL 1292 01:06:12,080 --> 01:06:13,280 CLUSTERED IN THE SAME AREA 1293 01:06:13,280 --> 01:06:17,000 MEANING THEY REALLY DO NOT HAVE 1294 01:06:17,000 --> 01:06:20,280 MUCH DIFFERENT OR DON'T DISPLAY 1295 01:06:20,280 --> 01:06:22,120 DRAMATIC DIFFERENT EXPRESSION OF 1296 01:06:22,120 --> 01:06:22,400 GENETICS. 1297 01:06:22,400 --> 01:06:25,120 I'M NOT GOING INTO THE AREA BUT 1298 01:06:25,120 --> 01:06:26,320 WHAT WE NOW FOUND IS THIS 1299 01:06:26,320 --> 01:06:28,520 TRANSITION PHASE IS NOT 1300 01:06:28,520 --> 01:06:30,560 REGULATED ON THE TRANSCRIPTION. 1301 01:06:30,560 --> 01:06:32,440 IT'S ACTUALLY REGULATED ON THE 1302 01:06:32,440 --> 01:06:37,080 TRANSLATIONAL SIDE. 1303 01:06:37,080 --> 01:06:39,600 WHAT JACK HAS DONE HAS ANALYZED 1304 01:06:39,600 --> 01:06:41,440 PROTEIN EXPRESSION PROFILING IN 1305 01:06:41,440 --> 01:06:45,800 THESE CELLS AND FOUND A BATTERY 1306 01:06:45,800 --> 01:06:48,560 OF NEW PROTEINS WHICH HAVE 1307 01:06:48,560 --> 01:06:50,320 PREVIOUSLY NOT BEEN DESCRIBED TO 1308 01:06:50,320 --> 01:06:56,040 BE EXPRESSED IN T CELLS. 1309 01:06:56,040 --> 01:06:58,600 NOW IN THE SAME VEIN, WE'RE 1310 01:06:58,600 --> 01:07:00,920 WORKING ON OTHER METABOLIC 1311 01:07:00,920 --> 01:07:02,120 PATHWAYS TO TIP THE BALANCE 1312 01:07:02,120 --> 01:07:04,960 BETWEEN TH1 INDUCTION AND 1313 01:07:04,960 --> 01:07:08,360 CONTRACTION AND WAS FOUND THAT T 1314 01:07:08,360 --> 01:07:12,520 CELLS AND THE COMPLOSOME PRODUCE 1315 01:07:12,520 --> 01:07:14,640 WHAT HAS NOT BEEN DESCRIBED YET 1316 01:07:14,640 --> 01:07:19,840 AND THE CONTROL BALANCE BETWEEN 1317 01:07:19,840 --> 01:07:21,480 PRODUCTION TIPS THE BALANCE 1318 01:07:21,480 --> 01:07:24,840 BETWEEN TH1 PRODUCTION AND 1319 01:07:24,840 --> 01:07:25,080 REDUCTION. 1320 01:07:25,080 --> 01:07:35,640 HE DEVELOPED A MOUSE MODEL AND 1321 01:07:36,120 --> 01:07:38,560 DISSECTING THIS NOW IN 1322 01:07:38,560 --> 01:07:40,760 ANTI-INFLAMMATORY DISEASES AND 1323 01:07:40,760 --> 01:07:42,600 HE HAS SHOWN THE T CELLS THAT 1324 01:07:42,600 --> 01:07:46,600 WAS DISPUTED FOR A LONG TIME AND 1325 01:07:46,600 --> 01:07:52,480 IS WORKING THE ARGININE 1326 01:07:52,480 --> 01:07:55,760 DEFICIENT LINES IN PATIENTS 1327 01:07:55,760 --> 01:07:58,360 WHERE THEY NOT TIP THE BALANCE 1328 01:07:58,360 --> 01:08:00,720 TO IL6 CONTRACTION AND LOOKING 1329 01:08:00,720 --> 01:08:02,360 AT THE TISSUE PATHOLOGY VERSUS 1330 01:08:02,360 --> 01:08:07,920 TISSUE PROTECTION. 1331 01:08:07,920 --> 01:08:14,360 AND OTHERS ARE WORKING ON A SUB 1332 01:08:14,360 --> 01:08:19,680 2 SYSTEM AND KNOW MOVING TO AN 1333 01:08:19,680 --> 01:08:21,320 ANIMAL MODEL FOR MULTIPLE 1334 01:08:21,320 --> 01:08:28,480 SCLEROSIS AND ALSO IDENTIFIED A 1335 01:08:28,480 --> 01:08:31,440 COMPLEMENT LIKE PROTEIN AND 1336 01:08:31,440 --> 01:08:33,760 FOUND THAT THAT PROTEIN CONTROLS 1337 01:08:33,760 --> 01:08:39,240 THE DEVELOPMENT OF TH1 VERSUS 1338 01:08:39,240 --> 01:08:49,600 TH17 CELLS IN VIVO. 1339 01:08:54,560 --> 01:08:55,880 MEMORY RESPONSES ARE IMPORTANT 1340 01:08:55,880 --> 01:08:59,080 AND THERE'S VIRTUALLY NOTHING 1341 01:08:59,080 --> 01:09:06,560 KNOWN IN THE COMPLOSOME IN TH1 1342 01:09:06,560 --> 01:09:10,560 MEMORY RESPONSES AND THEY'VE 1343 01:09:10,560 --> 01:09:14,560 BEEN LOOKING AT THIS THE LAST 1344 01:09:14,560 --> 01:09:20,120 FIVE YEARS. 1345 01:09:20,120 --> 01:09:20,320 CD46. 1346 01:09:20,320 --> 01:09:21,640 SOME PEOPLE ARGUE IS A DIFFERENT 1347 01:09:21,640 --> 01:09:23,760 AREA FOR RESEARCH BECAUSE WE 1348 01:09:23,760 --> 01:09:25,920 DON'T A SMALL ANIMAL MODEL BUT 1349 01:09:25,920 --> 01:09:28,880 WE'RE KEEN ON DISSECTING THE 1350 01:09:28,880 --> 01:09:30,160 BIOLOGICAL FUNCTIONS OF THE 1351 01:09:30,160 --> 01:09:32,440 PROTEIN BECAUSE WE THINK HES 1352 01:09:32,440 --> 01:09:34,560 UTTERLY IMPORTANT TO HUMAN 1353 01:09:34,560 --> 01:09:37,600 BIOLOGY. 1354 01:09:37,600 --> 01:09:40,720 MUTATIONS IN THIS GENE ARE 1355 01:09:40,720 --> 01:09:46,320 ASSOCIATED WITH INFECTIOUS AND 1356 01:09:46,320 --> 01:09:48,360 INFLAMMATORY DISEASES PART OF 1357 01:09:48,360 --> 01:09:52,840 THE SNIPS IN THIS MODEL ARE 1358 01:09:52,840 --> 01:09:55,560 ASSOCIATED WITH DEVELOPMENT OF 1359 01:09:55,560 --> 01:10:02,600 MENTAL DISEASE, SCHIZOPHRENIA 1360 01:10:02,600 --> 01:10:04,520 AND CANCER AND INTERESTED IN THE 1361 01:10:04,520 --> 01:10:06,760 SIGNALLING PATHWAYS OF THE 1362 01:10:06,760 --> 01:10:09,680 MOLECULE AND UNDERSTANDING HOW 1363 01:10:09,680 --> 01:10:13,600 TO APPLY IT TO CANCER AND CAR T 1364 01:10:13,600 --> 01:10:14,520 CELL THERAPY. 1365 01:10:14,520 --> 01:10:17,800 THIS IS ALL DEVELOPED BY JOHN 1366 01:10:17,800 --> 01:10:21,800 ATKINS IN 1986 AND IMPORTANT TO 1367 01:10:21,800 --> 01:10:23,080 KNOW THAT IT'S EXPRESSED IN 1368 01:10:23,080 --> 01:10:25,960 DIFFERENT ISO FORMS AND CAN 1369 01:10:25,960 --> 01:10:33,600 EXPRESS TWO DIFFERENT 1370 01:10:33,600 --> 01:10:36,120 CYTOPLASMIC DOMAINS AND WHEN 1371 01:10:36,120 --> 01:10:38,400 EXPRESSED IN THE SURFACE THROUGH 1372 01:10:38,400 --> 01:10:41,440 CB3 OR SOME PATHOGENS THAT USE 1373 01:10:41,440 --> 01:10:47,640 CD46 AS A RECEPTOR AND WHEN 1374 01:10:47,640 --> 01:10:49,320 MOVED TO THE NUCLEUS AND THIS IS 1375 01:10:49,320 --> 01:10:52,560 REALLY IMPORTANT TO INDUCE THE 1376 01:10:52,560 --> 01:10:56,120 SIGNALLING ACTIVITY OF CD46 1377 01:10:56,120 --> 01:10:58,800 HOWEVER, NONE CONTAIN A DNA 1378 01:10:58,800 --> 01:11:02,040 BINDING SO THEY CANNOT FUNCTION 1379 01:11:02,040 --> 01:11:02,600 AS TRANSCRIPTION FACTORS 1380 01:11:02,600 --> 01:11:08,400 THEMSELVES. 1381 01:11:08,400 --> 01:11:10,600 SO TWO TALENTED POST-DOCS IN THE 1382 01:11:10,600 --> 01:11:12,840 LAB DECIDED TO TACKLE AND 1383 01:11:12,840 --> 01:11:15,200 DISSECT ON THE MOLECULAR LEVEL 1384 01:11:15,200 --> 01:11:19,480 HOW THE ACTION WOULD INDUCE TH1 1385 01:11:19,480 --> 01:11:20,480 RESPONSE. 1386 01:11:20,480 --> 01:11:26,360 AND LOOKING AT THE CYTOPLASM ON 1387 01:11:26,360 --> 01:11:30,560 ITS WAY TO THE NUCLEUS AND THE 1388 01:11:30,560 --> 01:11:34,560 T1 PROBABLY INTERACTS WITH 1389 01:11:34,560 --> 01:11:36,640 TRANSCRIPTION FACTORS AND THIS 1390 01:11:36,640 --> 01:11:37,720 CONTROLS THE ACTIVATION. 1391 01:11:37,720 --> 01:11:41,840 SO SHE STARTED THIS PROJECT BY A 1392 01:11:41,840 --> 01:11:45,840 SIMPLE RNA SEQ OR CUT AND RUN 1393 01:11:45,840 --> 01:11:47,480 TECHNOLOGY TO IDENTIFY 1394 01:11:47,480 --> 01:11:51,440 TRANSCRIPTION FACTORS THAT 1395 01:11:51,440 --> 01:11:54,720 INTERACT DIRECTLY AND USING THIS 1396 01:11:54,720 --> 01:12:01,440 METHOD SHE HAS FOUND TWO TWO 1397 01:12:01,440 --> 01:12:11,920 TRANSCRIPTERS INTERACT. 1398 01:12:13,480 --> 01:12:16,960 AND USING RNA SEQ AND 1399 01:12:16,960 --> 01:12:23,480 MICROSCOPY, SHE HAS FOUND THE 1400 01:12:23,480 --> 01:12:24,280 INTERACTI 1401 01:12:24,280 --> 01:12:29,000 INTERACTION NOT ONLY DRIVES THE 1402 01:12:29,000 --> 01:12:35,040 EXPRESSION OF GENES BUT T1 ALSO 1403 01:12:35,040 --> 01:12:42,880 INDUCES THE HOMO MULTIMERIZATION 1404 01:12:42,880 --> 01:12:47,480 AND SERVES PROMOTERS AND THE 1405 01:12:47,480 --> 01:12:50,400 SYSTEM CONTROLS TH1 INDUCTION. 1406 01:12:50,400 --> 01:12:54,560 MEANING CD46 IS DIRECTLY 1407 01:12:54,560 --> 01:12:59,480 INVOLVED IN CHROMATIN 1408 01:12:59,480 --> 01:13:01,080 REMODELLING. 1409 01:13:01,080 --> 01:13:04,120 MY SECOND FINAL DATA SET NOT 1410 01:13:04,120 --> 01:13:06,120 ENTIRELY CONVINCED ME WE SHOULD 1411 01:13:06,120 --> 01:13:08,360 TRY TO MAKE OUR STRIDES TOWARDS 1412 01:13:08,360 --> 01:13:11,200 DEVELOPING AN IN VIVO MODEL TO 1413 01:13:11,200 --> 01:13:14,080 UNDERSTAND THIS AND CONVINCED ME 1414 01:13:14,080 --> 01:13:22,600 TO START WORKING ON THE CD46 DE 1415 01:13:22,600 --> 01:13:26,400 EFFICIENT ZEBRAFISH AND EXPRESS 1416 01:13:26,400 --> 01:13:29,200 THE CD46 AND TOGETHER WITH 1417 01:13:29,200 --> 01:13:30,560 COLLABORATORS AND THE FACILITY 1418 01:13:30,560 --> 01:13:33,840 OF NHLBI, WHAT WE HAVE DONE IS 1419 01:13:33,840 --> 01:13:37,920 GENERATED THE CD46 DEFICIENCY 1420 01:13:37,920 --> 01:13:39,520 AND WHAT YOU CAN SEE THIS IS THE 1421 01:13:39,520 --> 01:13:43,240 FISH THAT DOES NOT EXPRESS THE 1422 01:13:43,240 --> 01:13:46,560 CD46 GENE ANYMORE AND HERE'S 1423 01:13:46,560 --> 01:13:48,280 WILD TYPE ON HETEROZYGOUS FISH 1424 01:13:48,280 --> 01:13:49,840 AND YOU CAN SEE CLEARLY RIGHT 1425 01:13:49,840 --> 01:13:52,960 AWAY THE FISH IS VERY SIMPLE. 1426 01:13:52,960 --> 01:13:55,920 INDEED THE FISH HAS A DRAMATIC 1427 01:13:55,920 --> 01:14:01,000 PHENOTYPE, SIGNIFICANTLY 1428 01:14:01,000 --> 01:14:02,080 SMALLER, FISH DYING AT 4 MONTHS 1429 01:14:02,080 --> 01:14:06,560 OF AGE AND HAVE AN OVER ALL 1430 01:14:06,560 --> 01:14:07,720 GLYCOLYSIS FITTING NICELY WITH 1431 01:14:07,720 --> 01:14:15,480 OUR SCREEN AND CD46 IS A MASTER 1432 01:14:15,480 --> 01:14:18,560 REGULATOR OF THE METABOLISM AND 1433 01:14:18,560 --> 01:14:20,400 THE FEWER FISH DEVELOPED 1434 01:14:20,400 --> 01:14:21,240 COGNITIVE MYOPATHY. 1435 01:14:21,240 --> 01:14:23,160 WE DON'T KNOW YET THE REASON AND 1436 01:14:23,160 --> 01:14:27,400 WE'RE WORKING WITH COLLABORATORS 1437 01:14:27,400 --> 01:14:29,480 ON TRYING TO POINT OUT WHAT GOES 1438 01:14:29,480 --> 01:14:34,560 WRONG WITH THE FISH TO TARGET 1439 01:14:34,560 --> 01:14:34,840 MYOPATHY. 1440 01:14:34,840 --> 01:14:37,040 MY LAST DATA SLIDE AND A NEW 1441 01:14:37,040 --> 01:14:40,400 POST-DOC IN OUR LAB AND OUR 1442 01:14:40,400 --> 01:14:43,400 STUDENT FROM ARE REALLY 1443 01:14:43,400 --> 01:14:46,560 INTERESTED IN THE VASCULAR 1444 01:14:46,560 --> 01:14:48,000 SYSTEM AND THE SYSTEM IN THE 1445 01:14:48,000 --> 01:14:53,160 BRAIN AND TOGETHER WITH THE 1446 01:14:53,160 --> 01:14:53,800 SUPERV 1447 01:14:53,800 --> 01:14:56,440 SUPERVISORS AND OTHERS CONVINCED 1448 01:14:56,440 --> 01:14:58,600 ME WE SHOULD EMBARK IN 1449 01:14:58,600 --> 01:15:01,000 UNDERSTANDING THE COMPLEMENT 1450 01:15:01,000 --> 01:15:02,240 SYSTEM IN THIS UNUSUAL PATIENT 1451 01:15:02,240 --> 01:15:09,160 AND WHAT THEY HAVE FUND SO FAR 1452 01:15:09,160 --> 01:15:15,840 AND WHEN THEY KNOCKOUT THE C3 IN 1453 01:15:15,840 --> 01:15:17,360 MYELOID CELLS IN THE BRAIN, THE 1454 01:15:17,360 --> 01:15:22,000 BRAIN OF MICE CANNOT FORM 1455 01:15:22,000 --> 01:15:28,360 IMMUNOLOGIC CELL INTERACTION AND 1456 01:15:28,360 --> 01:15:29,800 COMMUNICATION AND CANNOT CLEAR 1457 01:15:29,800 --> 01:15:30,240 THAT. 1458 01:15:30,240 --> 01:15:33,440 WHAT I HOPE I HAVE DONE BY THIS 1459 01:15:33,440 --> 01:15:35,760 A LITTLE BIT OF A TOUR OF FORCE, 1460 01:15:35,760 --> 01:15:38,200 I KNOW THAT, BUT CONVINCED YOU 1461 01:15:38,200 --> 01:15:41,600 THE FUTURE'S BRIGHT, COMPLEMENT 1462 01:15:41,600 --> 01:15:50,080 IS NOT THE MOST BORING START OF 1463 01:15:50,080 --> 01:15:51,080 IMMUNITY AND THERE'S A LOT OF 1464 01:15:51,080 --> 01:15:52,320 SURPRISES IN STORE. 1465 01:15:52,320 --> 01:15:56,440 ALSO THE DISCOVERY OF THE 1466 01:15:56,440 --> 01:15:58,400 INTRACELLULAR COMPLEMENT SYSTEM 1467 01:15:58,400 --> 01:16:00,200 MAY EXPLAIN WHY WE HAVEN'T BEEN 1468 01:16:00,200 --> 01:16:02,400 AS SUCCESSFUL AS WE SHOULD HAVE 1469 01:16:02,400 --> 01:16:04,600 BEEN TARGETING THE SYSTEM. 1470 01:16:04,600 --> 01:16:06,760 AND WE WOULD PROPOSE THAT 1471 01:16:06,760 --> 01:16:09,920 THINKING ABOUT THE INTRACELLULAR 1472 01:16:09,920 --> 01:16:10,760 SYSTEM POSSIBLY IN COMBINATION 1473 01:16:10,760 --> 01:16:13,480 DEPENDING ON THE DISEASE OF THE 1474 01:16:13,480 --> 01:16:17,200 DISEASE STATE MAY BE A WAY TO 1475 01:16:17,200 --> 01:16:18,880 CHECK ON THE SYSTEM 1476 01:16:18,880 --> 01:16:23,960 THERAPEUTICALLY AND I'M OF THE 1477 01:16:23,960 --> 01:16:25,680 CONVICTION DIR CAN DO THIS AND 1478 01:16:25,680 --> 01:16:27,240 I'D LIKE TO LEAVE YOU HERE WITH 1479 01:16:27,240 --> 01:16:29,880 THE NAMES OF ALL THE PEOPLE THAT 1480 01:16:29,880 --> 01:16:35,840 HAVE AND ARE HELPING US IN 1481 01:16:35,840 --> 01:16:42,160 DISSECT 1482 01:16:42,160 --> 01:16:44,480 DISSECTING THIS AND IT TAKES A 1483 01:16:44,480 --> 01:16:46,040 VILLAGE TO DO GOOD SCIENCE. 1484 01:16:46,040 --> 01:16:46,880 I'M HAPPY TO ANSWER QUESTIONS 1485 01:16:46,880 --> 01:16:53,480 YOU MIGHT HAVE. 1486 01:16:53,480 --> 01:16:54,880 >> THANK YOU, DR. KEMPER. 1487 01:16:54,880 --> 01:16:56,960 DOES ANYBODY HAVE ANY QUESTIONS 1488 01:16:56,960 --> 01:16:57,520 OR COMMENTS? 1489 01:16:57,520 --> 01:17:02,520 YOU CAN PUT THEM IN THE CHAT OR 1490 01:17:02,520 --> 01:17:12,920 YOU CAN RAISE YOUR HAND. 1491 01:17:24,440 --> 01:17:26,000 DR. GIBBONS THINKS YOUR WORK IS 1492 01:17:26,000 --> 01:17:30,560 SCHOOL AND WHAT IS KNOWN ABOUT 1493 01:17:30,560 --> 01:17:38,760 ANCESTRY VARIATION OF CD46? 1494 01:17:38,760 --> 01:17:41,800 >> I AVOIDED THAT. 1495 01:17:41,800 --> 01:17:46,600 THERE'S THE PATHOGEN RECEPTOR 1496 01:17:46,600 --> 01:17:49,800 AND FOR A LOT OF DISEASES 1497 01:17:49,800 --> 01:17:53,720 THERE'S ADENOVIRUS AND GENE 1498 01:17:53,720 --> 01:17:56,520 THERAPY AND MEASLES VIRUS AND 1499 01:17:56,520 --> 01:17:58,320 THERE'S A SPECIFIC EXPRESSION 1500 01:17:58,320 --> 01:18:02,840 PROFILE IN CD46 ISO FORM 1501 01:18:02,840 --> 01:18:06,560 EXPRESSION PROFILE AND PEOPLE 1502 01:18:06,560 --> 01:18:09,240 HAVE DESPERATELY TRIED TO 1503 01:18:09,240 --> 01:18:11,160 CORRELATE EXPRESSION PROFILES 1504 01:18:11,160 --> 01:18:15,160 AND ANCESTRY OF CD46 WITH 1505 01:18:15,160 --> 01:18:16,320 DISEASE ASSOCIATION OR DISEASE 1506 01:18:16,320 --> 01:18:16,960 SEVERITY ASSOCIATION. 1507 01:18:16,960 --> 01:18:18,320 IT HASN'T WORKED VERY WELL. 1508 01:18:18,320 --> 01:18:19,280 I THINK ONE REASON IS BECAUSE 1509 01:18:19,280 --> 01:18:27,080 IT'S COMPLICATED. 1510 01:18:27,080 --> 01:18:30,280 AND THERE'S A PROCESS. 1511 01:18:30,280 --> 01:18:33,080 SIMILARLY ON THE HUMAN HEALTH 1512 01:18:33,080 --> 01:18:36,160 LEVEL, WE THINK MAYBE RODENTS 1513 01:18:36,160 --> 01:18:37,120 MAY HAVE KICKED OUT THE MODEL 1514 01:18:37,120 --> 01:18:41,000 BECAUSE IT WAS TARGETED BY 1515 01:18:41,000 --> 01:18:41,280 PATHOGENS. 1516 01:18:41,280 --> 01:18:43,400 I CAN'T GIVE YOU A DEFINITIVE 1517 01:18:43,400 --> 01:18:45,520 ANSWER TO YOUR QUESTION BECAUSE 1518 01:18:45,520 --> 01:18:47,640 I THINK WE NEED TO LEARN MORE TO 1519 01:18:47,640 --> 01:18:49,920 COME BACK FULL CIRCLE AND PROBE 1520 01:18:49,920 --> 01:19:00,440 WHAT YOU JUST ASKED ME TO DO. 1521 01:19:06,640 --> 01:19:08,200 THIS IS MORE INTERESTING THAN 1522 01:19:08,200 --> 01:19:09,240 WHEN THEY TRIED TO TEACH ME THIS 1523 01:19:09,240 --> 01:19:10,320 IN SCHOOL. 1524 01:19:10,320 --> 01:19:20,800 >> THAT'S WHAT WE THINK TOO. 1525 01:19:23,480 --> 01:19:26,600 >> DR. SCHOT. 1526 01:19:26,600 --> 01:19:30,600 >> SINCE YOU DID YOUR PROFILING 1527 01:19:30,600 --> 01:19:31,960 ON RESIDENT LUNG IMMUNE CELLS 1528 01:19:31,960 --> 01:19:34,480 AND THERE'S BEEN A HUGE AMOUNT 1529 01:19:34,480 --> 01:19:37,640 OF INTEREST IN THE COAGULATION 1530 01:19:37,640 --> 01:19:38,480 PATHWAY AND COMPLEMENT PATHWAY 1531 01:19:38,480 --> 01:19:42,560 IN ARDS, SPECIFICALLY 1532 01:19:42,560 --> 01:19:46,440 COVID-RELATED ARDS. 1533 01:19:46,440 --> 01:19:49,560 HAVE YOU LOOKED AT WHETHER THE 1534 01:19:49,560 --> 01:19:52,440 PATHWAY IS UPREGULATED AND 1535 01:19:52,440 --> 01:19:58,400 DYSFUNCTIONAL IN COVID-RELATED 1536 01:19:58,400 --> 01:20:01,600 LUNG INJURY AND THOUGHTS ON 1537 01:20:01,600 --> 01:20:01,800 THAT. 1538 01:20:01,800 --> 01:20:05,360 >> WE HAVE DONE THAT AND 1539 01:20:05,360 --> 01:20:08,960 PUBLISHED IN LINE WITH THE 1540 01:20:08,960 --> 01:20:10,120 INTRACELLULAR COMPLEMENT. 1541 01:20:10,120 --> 01:20:18,560 WE HAVE SHOWN WITH A COLLABORATE 1542 01:20:20,720 --> 01:20:26,920 ERRORSS -- COLLABORATORS AND 1543 01:20:26,920 --> 01:20:30,480 SARS COV2 ACTIVATES THE TYPE 2 1544 01:20:30,480 --> 01:20:35,440 CELLS THAT THIS INTRACELLULAR C3 1545 01:20:35,440 --> 01:20:38,040 ACTIVATION CHANGE THE BEHAVIOR 1546 01:20:38,040 --> 01:20:41,840 AND SPILLS TO THE OUTSIDE AND 1547 01:20:41,840 --> 01:20:42,880 INSTRUCT THE IMMUNE CELLS TO BE 1548 01:20:42,880 --> 01:20:44,080 MORE INFLAMMATORY. 1549 01:20:44,080 --> 01:20:47,160 WE HAD PROPOSED VERY CAREFULLY 1550 01:20:47,160 --> 01:20:52,320 THAT POSSIBLY A COMBINATION AND 1551 01:20:52,320 --> 01:21:00,920 WE COULD REMEDY THAT IN EX VIVO 1552 01:21:00,920 --> 01:21:07,840 ORGANOIDS AND WE'RE EXCITED 1553 01:21:07,840 --> 01:21:12,520 ABOUT THIS AND POSSIBLY DAMP 1554 01:21:12,520 --> 01:21:14,360 ENNING THIS IN ACUTE LUNG 1555 01:21:14,360 --> 01:21:17,120 INFLAMMATION MAY BE THE WAY TO 1556 01:21:17,120 --> 01:21:17,320 GO. 1557 01:21:17,320 --> 01:21:18,760 >> AND YOU'RE TELLING ME I NEED 1558 01:21:18,760 --> 01:21:20,480 TO DO A BETTER JOB SEARCHING THE 1559 01:21:20,480 --> 01:21:28,440 LITERATURE AND READING. 1560 01:21:28,440 --> 01:21:31,000 >> WE CAN'T DO EVERYTHING. 1561 01:21:31,000 --> 01:21:33,360 THERE'S SO MUCH OUT THERE 1562 01:21:33,360 --> 01:21:33,880 SPECIFICALLY WITH COVID. 1563 01:21:33,880 --> 01:21:36,640 >> THANK YOU. 1564 01:21:36,640 --> 01:21:40,280 >> WE HAVE A COMMENT FROM GOOD 1565 01:21:40,280 --> 01:21:41,040 GILLETTE. 1566 01:21:41,040 --> 01:21:42,560 DO YOU WANT TO SAY WHAT YOU HAD 1567 01:21:42,560 --> 01:21:49,280 TO SAY? 1568 01:21:49,280 --> 01:21:53,480 >> I'M AMAZED AT WHAT YOU'RE 1569 01:21:53,480 --> 01:21:53,680 DOING? 1570 01:21:53,680 --> 01:21:54,560 WHERE THIS? 1571 01:21:54,560 --> 01:21:58,160 IT SEEMS TO ME THIS HAS THE 1572 01:21:58,160 --> 01:21:59,280 POTENTIAL NOT ONLY TO BE 1573 01:21:59,280 --> 01:22:02,280 INVOLVED IN INFECTIOUS DISEASE 1574 01:22:02,280 --> 01:22:02,880 AND AUTOIMMUNE DISORDER WE'RE 1575 01:22:02,880 --> 01:22:08,520 FAR FROM UNDERSTANDING. 1576 01:22:08,520 --> 01:22:13,800 >> THIS IS MY FORTE. 1577 01:22:13,800 --> 01:22:16,120 I STARTED WITH AUTOIMMUNE 1578 01:22:16,120 --> 01:22:18,640 DISEASE AND THE WORK WAS DRIVEN 1579 01:22:18,640 --> 01:22:26,120 BY THE PANDEMIC AND COMPLEMENT 1580 01:22:26,120 --> 01:22:32,320 AND BACK TO AUTOIMMUNITY AND THE 1581 01:22:32,320 --> 01:22:35,960 FINDINGS AND COX INHIBITERS HAVE 1582 01:22:35,960 --> 01:22:41,280 INTERESTING FINDINGS WITH REGARD 1583 01:22:41,280 --> 01:22:43,480 TO T CELL AND THERE'S TH1 1584 01:22:43,480 --> 01:22:44,640 RESPONSES. 1585 01:22:44,640 --> 01:22:46,800 NOW, THIS IS MY FORTE, 1586 01:22:46,800 --> 01:22:51,440 AUTOIMMUNE DISEASES AND WE'RE 1587 01:22:51,440 --> 01:22:56,480 WORKING ON THIS WHICH LEADS US 1588 01:22:56,480 --> 01:22:58,280 TO CANCER BECAUSE 1589 01:22:58,280 --> 01:22:58,920 ANTI-INFLAMMATORY RESPONSE IS 1590 01:22:58,920 --> 01:23:00,920 ALSO AT THE HEART OF MANY 1591 01:23:00,920 --> 01:23:02,720 CANCERS AND AUTOIMMUNITY AND 1592 01:23:02,720 --> 01:23:08,520 MOVING CAREFULLY TO ONE OF TWO 1593 01:23:08,520 --> 01:23:10,920 DIRECTIONS AND THAT'S IT. 1594 01:23:10,920 --> 01:23:21,320 I'M AN AUTOIMMUNOLOGIST. 1595 01:23:22,720 --> 01:23:25,200 >> I DON'T SEE OTHER QUESTIONS 1596 01:23:25,200 --> 01:23:26,440 OR COMMENTS IN THE CHAT AND 1597 01:23:26,440 --> 01:23:28,040 DR. KEMPER I'LL SEND YOU OFF 1598 01:23:28,040 --> 01:23:29,560 WITH A ROUND OF VIRTUAL 1599 01:23:29,560 --> 01:23:29,840 APPLAUSE. 1600 01:23:29,840 --> 01:23:32,480 I THINK IT WAS A FANTASTIC 1601 01:23:32,480 --> 01:23:33,480 SEMINAR AND APPRECIATE YOU 1602 01:23:33,480 --> 01:23:34,560 SHARING THAT INFORMATION TODAY 1603 01:23:34,560 --> 01:23:35,720 WITH US. 1604 01:23:35,720 --> 01:23:41,240 IT WAS GREAT TO HAVE YOU. 1605 01:23:41,240 --> 01:23:43,720 >> THANK YOU VERY MUCH. 1606 01:23:43,720 --> 01:23:46,240 >> ALL RIGHT. 1607 01:23:46,240 --> 01:23:48,520 SO WE ARE NOT READY YET TO START 1608 01:23:48,520 --> 01:23:51,000 THE NEXT ITEM ON THE AGENDA 1609 01:23:51,000 --> 01:23:52,440 BECAUSE WE'RE A LITTLE BIT AHEAD 1610 01:23:52,440 --> 01:23:54,200 OF SCHEDULE AND THE DECISION 1611 01:23:54,200 --> 01:23:58,200 LENS GROUP ISN'T HERE YET SO I 1612 01:23:58,200 --> 01:24:00,240 THINK PERHAPS WHAT WE'LL DO IS 1613 01:24:00,240 --> 01:24:05,080 TAKE A 10-MINUTE BREAK 1614 01:24:05,080 --> 01:24:06,680 WELCOME BACK AFTER THE BREAK, 1615 01:24:06,680 --> 01:24:09,400 EVERYBODY. 1616 01:24:09,400 --> 01:24:11,160 WE HAVE OUR DECISION LENS FOLKS 1617 01:24:11,160 --> 01:24:13,120 HERE SO WE'RE GOING TO GO INTO 1618 01:24:13,120 --> 01:24:16,280 THE NEXT PART OF OUR AGENDA. 1619 01:24:16,280 --> 01:24:17,600 IT'S ACTUALLY THE FINAL AGENDA 1620 01:24:17,600 --> 01:24:19,240 ITEM OF TODAY'S MEETING WHICH IS 1621 01:24:19,240 --> 01:24:22,160 VOTING ON THE CONCEPT SO WE HAVE 1622 01:24:22,160 --> 01:24:23,480 AN IDEA ABOUT WHAT KIND OF 1623 01:24:23,480 --> 01:24:27,240 ADVICE YOU THINK WE SHOULD 1624 01:24:27,240 --> 01:24:27,640 CONSIDER. 1625 01:24:27,640 --> 01:24:29,120 BUT BEFORE WE PROCEED WE HAVE A 1626 01:24:29,120 --> 01:24:31,000 FEW REMINDERS. 1627 01:24:31,000 --> 01:24:33,120 WHEN ADDRESSING MEETING CONCEPT 1628 01:24:33,120 --> 01:24:34,440 COMMENTS RELATED TO SCIENTIFIC 1629 01:24:34,440 --> 01:24:35,720 COMMENTS PLEASE ADDRESS ALL THE 1630 01:24:35,720 --> 01:24:37,160 PANELISTS NOT THE HOST. 1631 01:24:37,160 --> 01:24:39,120 THAT'S WHEN YOU'RE PUTTING 1632 01:24:39,120 --> 01:24:40,120 THINGS IN THE CHAT. 1633 01:24:40,120 --> 01:24:42,440 DON'T ADDRESS ALL THE PANELISTS, 1634 01:24:42,440 --> 01:24:44,120 DO ADDRESS ALL THE PANELISTS, 1635 01:24:44,120 --> 01:24:46,440 DON'T ADDRESS THE HOST BECAUSE 1636 01:24:46,440 --> 01:24:47,600 IF YOU WRITE TO THE HOST, 1637 01:24:47,600 --> 01:24:48,800 EVERYBODY ELSE WON'T BE ABLE TO 1638 01:24:48,800 --> 01:24:51,240 SEE IT. 1639 01:24:51,240 --> 01:24:53,120 IF YOU ARE ENCOUNTERING ZOOM 1640 01:24:53,120 --> 01:24:58,720 TECHNICAL ISSUES CONTACT THE 1641 01:24:58,720 --> 01:25:05,280 I.T. FOLKS THEY'RE ONLINE AND 1642 01:25:05,280 --> 01:25:08,680 READY TO ASSIST YOU AND DON'T 1643 01:25:08,680 --> 01:25:12,120 SEND IT TO THE ZOOM TEAM. 1644 01:25:12,120 --> 01:25:14,240 SIMILARLY THOUGH FOR DECISION 1645 01:25:14,240 --> 01:25:19,840 LENS ISSUES DON'T GO TO THE I.T. 1646 01:25:19,840 --> 01:25:21,880 FOLKS BECAUSE THEY HAVE TO TO 1647 01:25:21,880 --> 01:25:24,480 THE DECISION LENS 1648 01:25:24,480 --> 01:25:24,840 REPRESENTATIVES. 1649 01:25:24,840 --> 01:25:29,120 PAT WILL PROVIDE THE LIVE DEMO 1650 01:25:29,120 --> 01:25:31,440 AND TECH SUPPORT AND PROVIDE 1651 01:25:31,440 --> 01:25:33,680 PASSWORD RESETS AND LOGIN ISSUES 1652 01:25:33,680 --> 01:25:37,680 AND HELP YOU WITH DECISION LENS 1653 01:25:37,680 --> 01:25:40,840 NAVIGATION AND WE HAVE BACKUP 1654 01:25:40,840 --> 01:25:43,880 SUPPORT FOR PAT AND WILL FORWARD 1655 01:25:43,880 --> 01:25:45,520 MORE TO THE DECISION LENS TECH 1656 01:25:45,520 --> 01:25:45,960 SUPPORT. 1657 01:25:45,960 --> 01:25:47,320 THE TECH SUPPORT E-MAIL 1658 01:25:47,320 --> 01:25:48,760 ADDRESSES WILL BE ADDED TO THE 1659 01:25:48,760 --> 01:25:50,160 CHAT FOR THOSE WHO NEED 1660 01:25:50,160 --> 01:25:51,440 ASSISTANCE AND IT WOULD BE 1661 01:25:51,440 --> 01:25:53,960 HELPFUL IF YOU STATE YOUR NAME 1662 01:25:53,960 --> 01:25:57,200 AND ROLE BEFORE THE VOTING 1663 01:25:57,200 --> 01:26:05,760 SESSION BEGINS. 1664 01:26:05,760 --> 01:26:09,120 I'D LIKE TO TURN IT OVER TO THE 1665 01:26:09,120 --> 01:26:10,960 DECISION LENS COLLEAGUES TO MOVE 1666 01:26:10,960 --> 01:26:12,280 FORWARD WITH THIS PART OF THE 1667 01:26:12,280 --> 01:26:13,080 AGENDA. 1668 01:26:13,080 --> 01:26:16,920 >> THANK YOU, DR. MOEN. 1669 01:26:16,920 --> 01:26:18,920 WE'LL GIVE A BRIEF PRESENTATION 1670 01:26:18,920 --> 01:26:21,960 OF THE MODULE AND PAT QUIN WILL 1671 01:26:21,960 --> 01:26:25,160 BE DOING OUR OVERVIEW FOR TODAY. 1672 01:26:25,160 --> 01:26:28,120 PAT, WHENEVER YOU'RE READY. 1673 01:26:28,120 --> 01:26:30,040 >> THANK YOU, JEN. 1674 01:26:30,040 --> 01:26:32,240 FIRST OFF I WANTED TO SAY THANK 1675 01:26:32,240 --> 01:26:34,320 YOU FOR HAVING US SUPPORT THE 1676 01:26:34,320 --> 01:26:34,880 ADVISORY COUNCIL. 1677 01:26:34,880 --> 01:26:36,920 AS ALWAYS IT'S A PLEASURE TO 1678 01:26:36,920 --> 01:26:39,800 WORK WITH YOU ALL AND IF YOU 1679 01:26:39,800 --> 01:26:41,040 NEED TECHNICAL SUPPORT 1680 01:26:41,040 --> 01:26:42,960 THROUGHOUT THE DAY AS DR. MOEN 1681 01:26:42,960 --> 01:26:45,800 MENTIONED YOU CAN REACH OUT TO 1682 01:26:45,800 --> 01:26:47,120 MYSELF, LAURA WILL BE WITH ME 1683 01:26:47,120 --> 01:26:50,520 THE NEXT FEW HOURS. 1684 01:26:50,520 --> 01:26:52,800 WE'LL BOTH BE MONITORING THE 1685 01:26:52,800 --> 01:26:54,320 CHAT AND WE'LL HAVE THE SUPPORT 1686 01:26:54,320 --> 01:26:54,680 TEAM. 1687 01:26:54,680 --> 01:26:56,840 THEY'RE NOT IN THIS MEETING BUT 1688 01:26:56,840 --> 01:26:58,000 THEY'RE AVAILABLE TO LEND A HAND 1689 01:26:58,000 --> 01:27:05,840 IF WE DO NEED ANYTHING AS WELL. 1690 01:27:05,840 --> 01:27:08,320 WE'LL DROP THEIR E-MAIL IN THE 1691 01:27:08,320 --> 01:27:08,560 CHAT. 1692 01:27:08,560 --> 01:27:10,080 I'LL SHARE MY SCREEN AND WALK 1693 01:27:10,080 --> 01:27:13,520 THROUGH A BRIEF DEMO OF THE 1694 01:27:13,520 --> 01:27:19,000 CAPABLEABILITY -- CAPABILITIES. 1695 01:27:19,000 --> 01:27:20,040 I'VE SEEN NAMES BEFORE BUT IF 1696 01:27:20,040 --> 01:27:22,120 YOU HAVE QUESTIONS, REACH OUT. 1697 01:27:22,120 --> 01:27:23,120 THERE'S NO NEW CAPABILITIES FROM 1698 01:27:23,120 --> 01:27:24,080 THE LAST SESSION. 1699 01:27:24,080 --> 01:27:25,040 HOPEFULLY THIS IS PRETTY 1700 01:27:25,040 --> 01:27:35,440 FAMILIAR FOR EVERYBODY. 1701 01:27:38,360 --> 01:27:40,280 THIS IS A PAGE YOU LOG IN AND 1702 01:27:40,280 --> 01:27:42,720 YOU'LL HAVE A PAGE THAT LOOKS 1703 01:27:42,720 --> 01:27:43,080 SIMILAR. 1704 01:27:43,080 --> 01:27:45,600 HAVE YOU THE TOP BANNER AND WILL 1705 01:27:45,600 --> 01:27:49,840 SEE NHLBI THE INSTANCE YOU'RE IN 1706 01:27:49,840 --> 01:27:51,600 AND SUPPORT ICON AS WELL AND TWO 1707 01:27:51,600 --> 01:27:53,800 MAIN TABS. 1708 01:27:53,800 --> 01:27:56,760 WE HAVE OUR MY TASKS AND 1709 01:27:56,760 --> 01:27:57,080 PORTFOLIO. 1710 01:27:57,080 --> 01:28:01,160 IT WILL SHOW ANY PORTFOLIOS 1711 01:28:01,160 --> 01:28:07,600 YOU'RE ASSIGNED TO. 1712 01:28:07,600 --> 01:28:09,720 IN HERE WE HAVE ANY RATING 1713 01:28:09,720 --> 01:28:11,400 ASSIGNMENTS YOU'VE BEEN GIVEN 1714 01:28:11,400 --> 01:28:12,760 WHICH EVERYBODY IN HERE TODAY 1715 01:28:12,760 --> 01:28:14,640 ALL OF OUR ADVISORY COUNCIL 1716 01:28:14,640 --> 01:28:15,400 MEMBERS HAVE BEEN ASSIGNED A 1717 01:28:15,400 --> 01:28:25,120 VOTING TASK FOR TODAY. 1718 01:28:25,120 --> 01:28:29,880 AS I REMINDER WHEN YOU LOG IN 1719 01:28:29,880 --> 01:28:39,800 USE GOOGLE CHROME OR MOZILAFOX. 1720 01:28:39,800 --> 01:28:41,120 USE ONE OF THOSE TWO BROWSERS 1721 01:28:41,120 --> 01:28:42,920 WHEN YOU LOG IN TODAY. 1722 01:28:42,920 --> 01:28:45,120 AS FAR AS LOGINS ARE CONCERNED, 1723 01:28:45,120 --> 01:28:47,640 EVERYBODY IN HERE ALREADY HAS AN 1724 01:28:47,640 --> 01:28:47,840 ACCOUNT. 1725 01:28:47,840 --> 01:28:49,120 YOUR ACCOUNTS HAVE BEEN UNLOCKED 1726 01:28:49,120 --> 01:28:49,400 AS WELL. 1727 01:28:49,400 --> 01:28:52,240 IF YOU NEED TO DO A PASSWORD 1728 01:28:52,240 --> 01:28:54,480 RESET YOU CAN CLICK ON THE I 1729 01:28:54,480 --> 01:28:56,080 FORGOT MY PASSWORD BUTTON IN THE 1730 01:28:56,080 --> 01:28:57,840 LOGIN PAGE AND IT WILL SEND AN 1731 01:28:57,840 --> 01:29:00,000 E-MAIL WITH A RESET LINK AND 1732 01:29:00,000 --> 01:29:04,720 THEN ALSO AS A REMINDER, YOUR 1733 01:29:04,720 --> 01:29:07,160 USER NAME IS GOING TO BE THE 1734 01:29:07,160 --> 01:29:11,040 E-MAIL ADDRESS INCLUDED IN THE 1735 01:29:11,040 --> 01:29:12,080 NHLBI ADVISORY COUNCIL ROSTER 1736 01:29:12,080 --> 01:29:14,680 SENT OUT IN ADVANCE OF THIS 1737 01:29:14,680 --> 01:29:14,920 MEETING. 1738 01:29:14,920 --> 01:29:17,920 IF YOU DON'T REMEMBER WHAT YOUR 1739 01:29:17,920 --> 01:29:19,640 E-MAIL ADDRESS WAS, SOMETIMES 1740 01:29:19,640 --> 01:29:25,120 PEOPLE CHANGE E-MAIL ADDRESSES, 1741 01:29:25,120 --> 01:29:28,880 JUST GO AHEAD AND ACCESS THE 1742 01:29:28,880 --> 01:29:30,720 LIST AND IT SHOULD BE THE E-MAIL 1743 01:29:30,720 --> 01:29:32,720 ASSOCIATED WITH YOUR LOG IN. 1744 01:29:32,720 --> 01:29:35,120 TO BEGIN OUR RATING ASSIGNMENT, 1745 01:29:35,120 --> 01:29:37,120 WE'LL NAVIGATE HERE TO MY TASKS. 1746 01:29:37,120 --> 01:29:39,880 WE'RE GOING FIND THE BUTTON THAT 1747 01:29:39,880 --> 01:29:44,120 SAYS RATE ALTERNATIVE FOR THE 1748 01:29:44,120 --> 01:29:46,240 PORTFOLIO LABELLED IB JUNE 2022 1749 01:29:46,240 --> 01:29:48,440 COUNCIL AND CLICK ANYWHERE IN 1750 01:29:48,440 --> 01:29:48,640 HERE. 1751 01:29:48,640 --> 01:29:51,240 WHEN WE LOG IN YOU CAN SEE I'VE 1752 01:29:51,240 --> 01:29:53,920 STARTED BECAUSE I DEMOED A BIT 1753 01:29:53,920 --> 01:29:55,320 OF THE PORTFOLIO ALREADY WITH 1754 01:29:55,320 --> 01:29:58,800 THE BEE LAST TIME BUT WHEN YOU 1755 01:29:58,800 --> 01:30:01,240 COME IN YOU'LL SEE AN ORANGE 1756 01:30:01,240 --> 01:30:04,080 BUTTON THAT SAYS START RATING 1757 01:30:04,080 --> 01:30:04,400 ALTERNATIVE. 1758 01:30:04,400 --> 01:30:05,480 IF YOU HAPPEN TO BE LOGGED OUT 1759 01:30:05,480 --> 01:30:08,560 OR SOMETHING LIKE THAT LIKE YOUR 1760 01:30:08,560 --> 01:30:09,640 WEB BROWSER CRASHES OR HAVE 1761 01:30:09,640 --> 01:30:10,960 INTERNET PROBLEMS DURING THE 1762 01:30:10,960 --> 01:30:12,560 DAY, ALL YOUR PROGRESS IS 1763 01:30:12,560 --> 01:30:14,280 AUTOMATICALLY SAVED SO WHEN YOU 1764 01:30:14,280 --> 01:30:15,960 COME BACK IT WILL SHOW THE 1765 01:30:15,960 --> 01:30:19,800 PROGRESS YOU'VE ALREADY MADE AND 1766 01:30:19,800 --> 01:30:22,840 THEN TWO, IT WILL SAY CONTINUE 1767 01:30:22,840 --> 01:30:24,800 RATING ALTERNATIVES AS WELL. 1768 01:30:24,800 --> 01:30:29,480 IN HERE WE HAVE OUR LIST OF 1769 01:30:29,480 --> 01:30:30,040 ALTERNATIVES AND CRITERIA. 1770 01:30:30,040 --> 01:30:31,840 ALTERNATIVES AND DECISION LENS 1771 01:30:31,840 --> 01:30:36,720 THE CONCEPTS. 1772 01:30:36,720 --> 01:30:39,240 THIS IS THE ACTUAL PIECE YOU'LL 1773 01:30:39,240 --> 01:30:41,520 BE EVALUATING AND IN CRITERIA WE 1774 01:30:41,520 --> 01:30:42,200 HAVE THE SIX CRITERIA WE'RE 1775 01:30:42,200 --> 01:30:45,520 EVALUATING THE PROJECTS AGAINST. 1776 01:30:45,520 --> 01:30:47,960 SO JUST A REFRESHER THOSE ARE 1777 01:30:47,960 --> 01:30:49,160 WHAT YOU GOT IN HERE. 1778 01:30:49,160 --> 01:30:50,920 YOU CAN SEE LEGACY COMMENTS IN 1779 01:30:50,920 --> 01:30:51,640 HERE AS WELL. 1780 01:30:51,640 --> 01:30:53,520 IN ORDER TO GET STARTED, WE'LL 1781 01:30:53,520 --> 01:30:55,920 CLICK THE ORANGE BUTTON THAT 1782 01:30:55,920 --> 01:30:58,600 SAYS CONTINUE ALTERNATIVES IN 1783 01:30:58,600 --> 01:31:00,960 YOUR CASE IT WILL SAY START 1784 01:31:00,960 --> 01:31:02,040 RATING ALTERNATIVES AND BRING US 1785 01:31:02,040 --> 01:31:03,760 TO THE LANDING PAGE. 1786 01:31:03,760 --> 01:31:07,280 YOU'LL GET SOME YELLOW 1787 01:31:07,280 --> 01:31:07,880 NOTIFICATIONS THROUGHOUT IT'S 1788 01:31:07,880 --> 01:31:10,880 JUST A SELF-GUIDED TOUR YOU'RE 1789 01:31:10,880 --> 01:31:13,560 WELCOME TO CLICK THROUGH OR 1790 01:31:13,560 --> 01:31:18,720 CLOSING IT BUT IT HAS USEFUL 1791 01:31:18,720 --> 01:31:19,000 POINTERS. 1792 01:31:19,000 --> 01:31:21,640 WHEN YOU LOG IN YOU'LL SEE THIS 1793 01:31:21,640 --> 01:31:23,000 CALLED SINGLE VIEW. 1794 01:31:23,000 --> 01:31:24,840 THIS IS ONE PROJECT, ONE 1795 01:31:24,840 --> 01:31:25,640 ALTERNATIVE AND ONE CRITERIA. 1796 01:31:25,640 --> 01:31:30,840 YOU CAN SEE IN HERE WE HAVE 2784 1797 01:31:30,840 --> 01:31:32,600 AND IMPORTANT OF THE SCIENTIFIC 1798 01:31:32,600 --> 01:31:34,040 MEDICAL HEALTH OR RESEARCH 1799 01:31:34,040 --> 01:31:37,080 RELATED QUESTION OR OPPORTUNITY. 1800 01:31:37,080 --> 01:31:43,680 WE HAVE THE DEEPER DEFINITION OF 1801 01:31:43,680 --> 01:31:50,480 THAT CRITERIA AS WELL THEN THE 1802 01:31:50,480 --> 01:31:51,520 RATING SCHEDULE WE'RE EVALUATING 1803 01:31:51,520 --> 01:31:52,680 IT AGAINST. 1804 01:31:52,680 --> 01:31:55,320 CLICK ON HOW YOU BEST ASSESS HOW 1805 01:31:55,320 --> 01:31:57,760 THAT CONCEPT PERFORMS AGAINST 1806 01:31:57,760 --> 01:31:59,200 THE CRITERIA JUST CLICK THAT AND 1807 01:31:59,200 --> 01:32:00,520 IT WILL HIGHLIGHT IN GREEN. 1808 01:32:00,520 --> 01:32:01,560 YOU'LL SEE THE CHECK MARK AND AT 1809 01:32:01,560 --> 01:32:03,600 THE BOTTOM YOU'LL SEE THE NEXT 1810 01:32:03,600 --> 01:32:05,000 BUTTON HIGHLIGHTS ORANGE AND YOU 1811 01:32:05,000 --> 01:32:09,120 CAN GO AHEAD AND ADVANCE. 1812 01:32:09,120 --> 01:32:11,440 I'VE DEMOED THIS SO I'LL AHEAD A 1813 01:32:11,440 --> 01:32:11,880 LITTLE BIT. 1814 01:32:11,880 --> 01:32:13,360 IF YOU DO NEED TO GO BACKWARDS 1815 01:32:13,360 --> 01:32:16,160 AND CHANGE SOMETHING, YOU CAN DO 1816 01:32:16,160 --> 01:32:16,360 THAT. 1817 01:32:16,360 --> 01:32:18,840 ALL YOU HAVE TO DO IS CLICK 1818 01:32:18,840 --> 01:32:19,720 PREVIOUS AND CHANGE YOUR 1819 01:32:19,720 --> 01:32:21,280 ASSESSMENT AND IT WILL BE 1820 01:32:21,280 --> 01:32:23,880 AUTOMATICALLY SAVED AND YOU'LL 1821 01:32:23,880 --> 01:32:24,200 BE GOOD TO GO. 1822 01:32:24,200 --> 01:32:26,680 A FEW OTHER FEATURES IN HERE IF 1823 01:32:26,680 --> 01:32:29,680 YOU WANT TO SEE MORE INFORMATION 1824 01:32:29,680 --> 01:32:36,000 ON THE CONCEPT YOU CAN CLICK THE 1825 01:32:36,000 --> 01:32:44,600 BLUE TEXT RIGHT HERE AND YOU CAN 1826 01:32:44,600 --> 01:32:45,360 SEE THE DESCRIPTION AND IN 1827 01:32:45,360 --> 01:32:49,120 OTHERS THERE COULD BE MORE AS 1828 01:32:49,120 --> 01:32:50,920 WELL AS AND YOU CAN CLICK IT BY 1829 01:32:50,920 --> 01:32:52,720 BACKING OR VIEW ALTERNATIVE 1830 01:32:52,720 --> 01:32:56,520 DETAILS AS WELL. 1831 01:32:56,520 --> 01:32:58,160 THE PURPLE TEXT IS ALSO 1832 01:32:58,160 --> 01:32:58,440 CLICKABLE. 1833 01:32:58,440 --> 01:32:59,360 THIS IS THE CRITERIA YOU'RE 1834 01:32:59,360 --> 01:33:00,440 EVALUATING IT AGAINST. 1835 01:33:00,440 --> 01:33:02,160 IF YOU CLICK THIS IT WILL GIVE 1836 01:33:02,160 --> 01:33:03,720 YOU A MORE DETAILED DESCRIPTION 1837 01:33:03,720 --> 01:33:04,280 OF THE CRITERIA. 1838 01:33:04,280 --> 01:33:07,400 YOU CAN SEE HERE WE HAVE A 1839 01:33:07,400 --> 01:33:09,120 LENGTHY DESCRIPTION OF WHAT WE 1840 01:33:09,120 --> 01:33:15,880 MEAN BY THIS. 1841 01:33:15,880 --> 01:33:18,160 IT WILL GIVE MORE DESCRIPTION OF 1842 01:33:18,160 --> 01:33:21,800 THE SCALE. 1843 01:33:21,800 --> 01:33:24,640 WE TRY TO PROVIDE AS MUCH 1844 01:33:24,640 --> 01:33:26,080 CLARITY AS POSSIBLE ABOUT WHAT 1845 01:33:26,080 --> 01:33:28,160 IS MEANT BY THIS CRITERIA AND 1846 01:33:28,160 --> 01:33:30,000 THEN HOW SHOULD YOU ACTUALLY 1847 01:33:30,000 --> 01:33:31,720 EVALUATE IT AGAINST THIS. 1848 01:33:31,720 --> 01:33:34,080 THAT'S WHY WE HAVE A DETAILED 1849 01:33:34,080 --> 01:33:34,760 DESCRIPTION AND DESCRIPTION OF 1850 01:33:34,760 --> 01:33:40,800 THE RATING SCALE AS WELL. 1851 01:33:40,800 --> 01:33:42,200 IN ORDER CHLO CLOSE THAT OUT YOU 1852 01:33:42,200 --> 01:33:43,960 CAN CLICK THE PURPLE TEXT OR THE 1853 01:33:43,960 --> 01:33:46,360 THREE BARS WHERE YOU SEE THE 1854 01:33:46,360 --> 01:33:47,720 CRITERIA AND DETAILS. 1855 01:33:47,720 --> 01:33:49,240 AGAIN, IN ORDER TO MAKE THAT 1856 01:33:49,240 --> 01:33:52,800 SELECTION, CLICK NEXT, CLICK THE 1857 01:33:52,800 --> 01:33:53,480 BEST FIT, CLICK NEXT AND MOVE 1858 01:33:53,480 --> 01:34:03,720 ON. 1859 01:34:03,720 --> 01:34:07,560 YOU CAN ALSO LEAVE A COMMENT AND 1860 01:34:07,560 --> 01:34:09,120 CLICK ON THE BUBBLE THAT SAYS 1861 01:34:09,120 --> 01:34:09,640 VIEW COMMENTS. 1862 01:34:09,640 --> 01:34:12,640 IF YOU CLICK ON THAT IN HERE YOU 1863 01:34:12,640 --> 01:34:15,720 CAN VIEW OTHER COMMENTS FROM 1864 01:34:15,720 --> 01:34:16,960 OTHER COUNCIL MEMBERS OR ALSO 1865 01:34:16,960 --> 01:34:18,520 ADD YOUR OWN COMMENT AS WELL. 1866 01:34:18,520 --> 01:34:19,920 IF THERE'S OTHER COMMENTS IN 1867 01:34:19,920 --> 01:34:26,080 HERE YOU'LL HE SEE -- YOU'LL SEE 1868 01:34:26,080 --> 01:34:27,200 NOTIFICATIONS THERE'S COMMENTS 1869 01:34:27,200 --> 01:34:30,120 AND YOU CAN ADD ONE TOO AND YOU 1870 01:34:30,120 --> 01:34:35,520 CAN SELECT THE CATEGORY. 1871 01:34:35,520 --> 01:34:40,240 MAYBE THE IN INTENSITY AS WELL. 1872 01:34:40,240 --> 01:34:41,320 IN THE PAST WE'VE MADE GOOD USE 1873 01:34:41,320 --> 01:34:43,000 OF THE COMMENTS FEATURE. 1874 01:34:43,000 --> 01:34:45,960 IF YOU DO WANT TO CAPTURE MAYBE 1875 01:34:45,960 --> 01:34:47,560 SOME NUANCE THAT ISN'T ENTIRELY 1876 01:34:47,560 --> 01:34:49,120 REFLECTED IN THE RATING SCALE, 1877 01:34:49,120 --> 01:34:53,880 THIS IS A GREAT PLACE TO GO 1878 01:34:53,880 --> 01:34:55,840 AHEAD AND RECORD THAT 1879 01:34:55,840 --> 01:34:56,240 INFORMATION AS WELL. 1880 01:34:56,240 --> 01:34:59,200 AS YOU'LL SEE UP HERE TOO IN THE 1881 01:34:59,200 --> 01:35:01,120 UPPER RIGHT HAND CORNER WE HAVE 1882 01:35:01,120 --> 01:35:02,040 THE PROGRESS BAR. 1883 01:35:02,040 --> 01:35:05,120 IT WILL SHOW EVERY CLICK YOU 1884 01:35:05,120 --> 01:35:06,520 HAVE TO MAKE. 1885 01:35:06,520 --> 01:35:10,120 WE'RE DOING 21 CONCEPTS AGAINST 1886 01:35:10,120 --> 01:35:10,800 SIX CRITERIA. 1887 01:35:10,800 --> 01:35:12,960 SO THAT'S GOING TO SHOW EACH 1888 01:35:12,960 --> 01:35:14,000 INDIVIDUAL CLIP YOU HAVE TO MAKE 1889 01:35:14,000 --> 01:35:15,960 SO YOU CAN SEE 10 RIGHT THERE. 1890 01:35:15,960 --> 01:35:18,160 I MAKE THE SELECTION AND I MOVE 1891 01:35:18,160 --> 01:35:21,120 ON AND NOW I'LL HAVE GONE UP TO 1892 01:35:21,120 --> 01:35:21,360 11. 1893 01:35:21,360 --> 01:35:22,240 THAT'S EVERY SINGLE INDIVIDUAL 1894 01:35:22,240 --> 01:35:26,920 CLICK YOU HAVE TO MAKE IN HERE. 1895 01:35:26,920 --> 01:35:28,120 I'M CONTINUE MOVING ON TO SHOW 1896 01:35:28,120 --> 01:35:30,240 MORE PROGRESS AS YOU CAN SEE 1897 01:35:30,240 --> 01:35:31,840 HERE IN THE BOTTOM RIGHT HAND 1898 01:35:31,840 --> 01:35:32,440 CORNER. 1899 01:35:32,440 --> 01:35:34,480 THIS IS A SPACE WHERE THERE'S 1900 01:35:34,480 --> 01:35:37,080 ALREADY COMMENTS FROM A PREVIOUS 1901 01:35:37,080 --> 01:35:37,280 RATER. 1902 01:35:37,280 --> 01:35:38,280 SO WE HAVE THAT AS WELL. 1903 01:35:38,280 --> 01:35:41,120 WE CAN GO AHEAD AND MAKE 1904 01:35:41,120 --> 01:35:43,200 SELECTIONS AND MOVE ON. 1905 01:35:43,200 --> 01:35:45,120 AND THE LAST THING I'LL SHOW IN 1906 01:35:45,120 --> 01:35:46,160 HERE AS WELL IS THERE'S ACTUALLY 1907 01:35:46,160 --> 01:35:48,280 ANOTHER WAY TO LOOK AT THIS 1908 01:35:48,280 --> 01:35:48,640 MENU. 1909 01:35:48,640 --> 01:35:50,120 RIGHT NOW WE'RE LOOKING AT 1910 01:35:50,120 --> 01:35:52,520 SINGLE VIEW WHICH IS ONE CONCEPT 1911 01:35:52,520 --> 01:35:53,600 AND ONE CRITERIA. 1912 01:35:53,600 --> 01:35:56,040 IF YOU WANT YOU CAN ALSO LOOK AT 1913 01:35:56,040 --> 01:35:57,200 IT IN WHAT IS CALLED MULTI-VIEW 1914 01:35:57,200 --> 01:35:59,080 AND THE WAY TO DO THAT IS GOING 1915 01:35:59,080 --> 01:36:04,800 TO BE TO NAVIGATE UP HERE TO THE 1916 01:36:04,800 --> 01:36:09,240 UPPER RIGHT HAND CORNER WHERE IT 1917 01:36:09,240 --> 01:36:12,480 HAS THREE DOTS AND IT WILL SAY 1918 01:36:12,480 --> 01:36:15,800 RATE IN MULTI-VIEW AND YOU CAN 1919 01:36:15,800 --> 01:36:17,320 SEE THE ONE CONCEPT AND THE 1920 01:36:17,320 --> 01:36:17,920 CRITERIA YOU'RE EVALUATING 1921 01:36:17,920 --> 01:36:18,640 AGAINST RIGHT HERE. 1922 01:36:18,640 --> 01:36:20,840 THIS IS EASIER FOR SOME PEOPLE 1923 01:36:20,840 --> 01:36:22,840 BECAUSE WE GO CONCEPT BY CONCEPT 1924 01:36:22,840 --> 01:36:27,720 AND REQUIRES YOU TO HIT THE NEXT 1925 01:36:27,720 --> 01:36:28,440 BUTTON LESS THAN THE OTHER 1926 01:36:28,440 --> 01:36:32,360 SINGLE VIEW METHODS. 1927 01:36:32,360 --> 01:36:34,920 IF WANT TO GO BACK TO THAT JUST 1928 01:36:34,920 --> 01:36:36,640 NAVIGATE UP HERE TO THE THREE 1929 01:36:36,640 --> 01:36:38,240 DOTS AND SAY RATE THE 1930 01:36:38,240 --> 01:36:40,720 ALTERNATIVE IN SINGLE VIEW AND 1931 01:36:40,720 --> 01:36:41,280 IT WILL REVERT BACK TO THE 1932 01:36:41,280 --> 01:36:43,600 ORIGINAL FORMAT. 1933 01:36:43,600 --> 01:36:45,480 ONCE YOU ARE 100% COMPLETE ON 1934 01:36:45,480 --> 01:36:47,920 YOUR RATINGS, YOU'LL KNOW THIS 1935 01:36:47,920 --> 01:36:49,440 BECAUSE ONE, YOU'VE GOT THE 1936 01:36:49,440 --> 01:36:53,160 PROGRESS BAR WILL SHOW YOU ALONG 1937 01:36:53,160 --> 01:36:56,320 THE WAY AND IT WILL CATCH 1938 01:36:56,320 --> 01:36:57,160 ANYTHING YOU MISS AND PUT IT 1939 01:36:57,160 --> 01:36:59,640 BACK IN FRONT OF YOU AT THE END. 1940 01:36:59,640 --> 01:37:01,120 YOU CAN WATCH THE PROGRESS BAR 1941 01:37:01,120 --> 01:37:03,360 AND AT THE END WHEN YOU'RE 100% 1942 01:37:03,360 --> 01:37:05,160 COMPLETE YOU'LL GET A POP-UP IN 1943 01:37:05,160 --> 01:37:07,240 THE MIDDLE OF THE SCREEN WITH A 1944 01:37:07,240 --> 01:37:08,640 GREEN CHECK MARK THAT BASICALLY 1945 01:37:08,640 --> 01:37:09,640 SAYS, THANK YOU, YOU'VE 1946 01:37:09,640 --> 01:37:10,320 COMPLETED EVERYTHING. 1947 01:37:10,320 --> 01:37:13,080 ONCE YOU HIT THAT YOU CAN EITHER 1948 01:37:13,080 --> 01:37:15,240 VIEW YOUR OWN INDIVIDUAL RESULTS 1949 01:37:15,240 --> 01:37:17,480 OR JUST LOG OUT, CLOSE OUT OF 1950 01:37:17,480 --> 01:37:18,280 YOUR BROWSER. 1951 01:37:18,280 --> 01:37:19,600 EVERYTHING YOU'VE DONE IS 1952 01:37:19,600 --> 01:37:20,400 AUTOMATICALLY SAVED. 1953 01:37:20,400 --> 01:37:23,320 AT THAT POINT, YOU CAN JUST 1954 01:37:23,320 --> 01:37:25,400 CLOSE OUT AND EVERYTHING IS 1955 01:37:25,400 --> 01:37:26,160 GOOD. 1956 01:37:26,160 --> 01:37:28,960 IF YOU DO WANT TO VIEW YOUR OWN 1957 01:37:28,960 --> 01:37:30,480 RESULTS IT WILL LOOK LIKE THIS 1958 01:37:30,480 --> 01:37:32,520 AND THIS IS JUST GOING TO SHOW 1959 01:37:32,520 --> 01:37:37,120 YOU HOW YOU INDIVIDUALLY RATED 1960 01:37:37,120 --> 01:37:41,040 THE CONCEPTS AGAINST EACH 1961 01:37:41,040 --> 01:37:41,280 CRITERIA. 1962 01:37:41,280 --> 01:37:43,080 I'LL REMIND THAT THE ACTUAL 1963 01:37:43,080 --> 01:37:45,120 OUTPUTS OF THIS ARE GOING TO BE 1964 01:37:45,120 --> 01:37:46,680 THE AGGREGATE OF EVERYBODY. 1965 01:37:46,680 --> 01:37:49,360 SO THIS ISN'T GOING TO BE THE 1966 01:37:49,360 --> 01:37:51,720 EXACT RESULTS BUT SHOW YOU HOW 1967 01:37:51,720 --> 01:37:53,360 YOU RATE THE CONCEPTS 1968 01:37:53,360 --> 01:37:54,280 INDIVIDUALLY. 1969 01:37:54,280 --> 01:37:56,480 IF YOU HAPPEN TO COME TO THIS 1970 01:37:56,480 --> 01:37:58,840 TEAM YOU CAN GO BACK BY SAYING 1971 01:37:58,840 --> 01:38:01,760 CONTINUE RATING AND GO BACK. 1972 01:38:01,760 --> 01:38:04,560 AT THIS TIME BARRING ANYTHING 1973 01:38:04,560 --> 01:38:08,800 ELSE FROM JEN, I THINK WE 1974 01:38:08,800 --> 01:38:09,240 COVERED EVERYTHING. 1975 01:38:09,240 --> 01:38:13,120 JEN, WAS THERE ANYTHING ELSE YOU 1976 01:38:13,120 --> 01:38:14,000 WANTED ME TO TOUCH ON? 1977 01:38:14,000 --> 01:38:17,040 >> THAT'S EVERYTHING, PAT. 1978 01:38:17,040 --> 01:38:18,960 NICELY DONE AND THANK YOU VERY 1979 01:38:18,960 --> 01:38:19,560 MUCH. 1980 01:38:19,560 --> 01:38:24,600 I'LL GIVE A REMINDER TO 1981 01:38:24,600 --> 01:38:26,120 EVERYBODY TO MOVE SLOWLY AND 1982 01:38:26,120 --> 01:38:27,880 CLICK ON THE CRITERIA FOR ALL 1983 01:38:27,880 --> 01:38:29,240 CONCEPTS OTHERWISE WE MAY 1984 01:38:29,240 --> 01:38:33,360 CONTINUE ON TO OUR VOTING. 1985 01:38:33,360 --> 01:38:36,040 >> THANK YOU, JEN. 1986 01:38:36,040 --> 01:38:38,640 I WANT TO REMIND EVERYBODY YOUR 1987 01:38:38,640 --> 01:38:40,680 COMMENTS MEAN A GREAT DEAL TO US 1988 01:38:40,680 --> 01:38:41,640 AS WELL AS THE NUMBERS YOU 1989 01:38:41,640 --> 01:38:44,000 ASSIGN WHEN VOTING ON THE 1990 01:38:44,000 --> 01:38:44,360 CONCEPTS. 1991 01:38:44,360 --> 01:38:46,120 FEEL FREE TO DISCUSS AND COMMENT 1992 01:38:46,120 --> 01:38:48,040 DURING THE DISCUSSION OR TO PUT 1993 01:38:48,040 --> 01:38:49,840 YOUR COMMENTS IN THAT PART OF 1994 01:38:49,840 --> 01:38:50,360 THE DECISION LENS. 1995 01:38:50,360 --> 01:38:55,760 WE'RE GOING BEGIN WITH THE 1996 01:38:55,760 --> 01:38:57,400 TRANS-NIH OR TRANS-NHLBI STATUS. 1997 01:38:57,400 --> 01:39:02,040 I GUESS THAT'S GOING TO BE 1998 01:39:02,040 --> 01:39:03,480 ACTUALLY THE LEAD DIVISION FROM 1999 01:39:03,480 --> 01:39:05,120 DCDS. 2000 01:39:05,120 --> 01:39:08,000 DAVID. 2001 01:39:08,000 --> 01:39:14,440 >> THANK YOU, LAURA. 2002 01:39:14,440 --> 01:39:15,400 GREETINGS FROM THE DIVISION OF 2003 01:39:15,400 --> 01:39:16,000 CARDIOVASCULAR SCIENCES. 2004 01:39:16,000 --> 01:39:18,640 BEFORE I GET INTO OUR CONCEPTS, 2005 01:39:18,640 --> 01:39:22,160 I WANT TO UNDER SCORE THE 2006 01:39:22,160 --> 01:39:22,840 IMPORTANCE OF THE COMMENTS YOU 2007 01:39:22,840 --> 01:39:26,680 PROVIDE ESPECIALLY THOSE THAT 2008 01:39:26,680 --> 01:39:28,440 YOU PROVIDE THROUGH DECISION 2009 01:39:28,440 --> 01:39:29,080 LENS. 2010 01:39:29,080 --> 01:39:31,280 WE USE THOSE COMMENTS NOT ONLY 2011 01:39:31,280 --> 01:39:32,720 IN THINKING ABOUT WHICH 2012 01:39:32,720 --> 01:39:35,440 INITIATIVES TO MOVE FORWARD BUT 2013 01:39:35,440 --> 01:39:37,680 ALSO IN TERMS OF EXECUTION. 2014 01:39:37,680 --> 01:39:39,760 IF AN INITIATIVE GOES FORWARD, 2015 01:39:39,760 --> 01:39:41,560 YOUR COMMENTS MAY HELP US SHAPE 2016 01:39:41,560 --> 01:39:43,360 IT, MAY HELP US SHAPE HOW WE 2017 01:39:43,360 --> 01:39:45,120 EXECUTE IT. 2018 01:39:45,120 --> 01:39:47,240 THANK YOU VERY MUCH IN ADVANCE. 2019 01:39:47,240 --> 01:39:50,000 OUR DIVISION HAS SIX CONCEPTS TO 2020 01:39:50,000 --> 01:39:52,720 BRING TO YOU TODAY FOR 2021 01:39:52,720 --> 01:39:54,200 DISCUSSION AND EVALUATION. 2022 01:39:54,200 --> 01:39:55,120 BUT THEY SUPPORT THREE EFFORTS 2023 01:39:55,120 --> 01:40:01,120 SO I'LL BE PRESENTING THEM IN 2024 01:40:01,120 --> 01:40:04,440 CLUSTERS TOGETHER AND YOU CAN 2025 01:40:04,440 --> 01:40:06,320 RATE ASSOCIATED CONCEPTS 2026 01:40:06,320 --> 01:40:07,280 TOGETHER WITHIN EACH EFFORT. 2027 01:40:07,280 --> 01:40:10,520 THE FIRST EFFORT IS A RENEWAL OF 2028 01:40:10,520 --> 01:40:12,760 OUR PEDIATRIC PART NETWORK WHICH 2029 01:40:12,760 --> 01:40:14,760 INVOLVED TWO CONCEPTS. 2030 01:40:14,760 --> 01:40:22,120 NUMBER 2773 AND 2784 WHICH WILL 2031 01:40:22,120 --> 01:40:25,120 SUPPORT THE COORDINATING CENTER 2032 01:40:25,120 --> 01:40:28,160 THROUGH A U24 MECHANISM AND UP 2033 01:40:28,160 --> 01:40:29,880 TO NINE CLINICAL CENTERS THROUGH 2034 01:40:29,880 --> 01:40:32,920 A UA1 MECHANISM. 2035 01:40:32,920 --> 01:40:35,000 NOW, CONGENITAL HEART DISEASE OR 2036 01:40:35,000 --> 01:40:37,880 CHD CONSISTS OF A NUMBER OF RARE 2037 01:40:37,880 --> 01:40:39,640 MALFORMATIONS THAT TOGETHER 2038 01:40:39,640 --> 01:40:41,680 REPRESENT THE MOST COMMON BIRTH 2039 01:40:41,680 --> 01:40:43,240 DEFECT AND THE ONE MOST LETHAL 2040 01:40:43,240 --> 01:40:45,360 IN INFANCY RESULTING IN HIGH 2041 01:40:45,360 --> 01:40:46,360 SOCIETAL ECONOMIC IMPACT. 2042 01:40:46,360 --> 01:40:49,280 THE NUMBER OF MALFORMATIONS 2043 01:40:49,280 --> 01:40:53,160 MAKES IT NECESSARY TO STUDY CHD 2044 01:40:53,160 --> 01:40:56,800 USING A MULTI-CENTER PLATFORM. 2045 01:40:56,800 --> 01:40:59,000 WE HAVE KEY QUESTIONS IN 2046 01:40:59,000 --> 01:41:01,120 PEDIATRIC CARDIOVASCULAR 2047 01:41:01,120 --> 01:41:01,600 DISEASE. 2048 01:41:01,600 --> 01:41:03,800 ONE OF THE PHN LANDMARK'S TRIALS 2049 01:41:03,800 --> 01:41:05,640 COMPARED TWO STRATEGIES FOR 2050 01:41:05,640 --> 01:41:08,200 NEONATAL REPAIR OF COMPLEX CHD 2051 01:41:08,200 --> 01:41:09,320 AND THAT STILL INFLUENCES 2052 01:41:09,320 --> 01:41:09,600 PRACTICE. 2053 01:41:09,600 --> 01:41:12,880 DURING THE TRIAL, SIGNIFICANT 2054 01:41:12,880 --> 01:41:14,760 PRACTICE VARIATION AND 2055 01:41:14,760 --> 01:41:16,120 RESPIRATORY SUPPORT WAS NOTED 2056 01:41:16,120 --> 01:41:16,880 ACROSS SITES. 2057 01:41:16,880 --> 01:41:22,160 THE PHN TURNED THIS INTO A 2058 01:41:22,160 --> 01:41:24,640 COLLABORATIVE LEARNING STUDY 2059 01:41:24,640 --> 01:41:28,360 WHICH FOLLOWED A MODEL FOLLOWING 2060 01:41:28,360 --> 01:41:33,440 SURGERY AND IT LEADS TO SHORTER 2061 01:41:33,440 --> 01:41:37,640 STAY AND OPIOID USING AND FOUND 2062 01:41:37,640 --> 01:41:42,440 IN THE CARDIAC CONGENITAL 2063 01:41:42,440 --> 01:41:45,040 HEADLINES AND IN THE FIRST YEARS 2064 01:41:45,040 --> 01:41:49,120 PHN CONDUCTED 13 TRIALS AND 2065 01:41:49,120 --> 01:41:51,640 OTHER OBSERVATIONAL STUDIES WITH 2066 01:41:51,640 --> 01:41:53,680 OTHERS PLANNED SOON AND 13,000 2067 01:41:53,680 --> 01:41:54,800 CHILDREN AND YOUNG ADULTS HAVE 2068 01:41:54,800 --> 01:41:57,360 BEEN ENROLLED. 2069 01:41:57,360 --> 01:41:59,840 STUDY DATA ARE REGULARLY 2070 01:41:59,840 --> 01:42:02,280 PRESENTED AND INFLUENCE 2071 01:42:02,280 --> 01:42:03,160 GUIDELINES. 2072 01:42:03,160 --> 01:42:06,440 THE PHN IS HIGHLY COLLABORATIVE 2073 01:42:06,440 --> 01:42:08,720 AND PARTNERED WITH OTHER 2074 01:42:08,720 --> 01:42:11,080 INSTITUTES AND PHARMACEUTICAL 2075 01:42:11,080 --> 01:42:14,320 STUDIED AND THE ORPHAN PRODUCTS 2076 01:42:14,320 --> 01:42:15,960 DIVISION AND ADVOCACY GROUPS AND 2077 01:42:15,960 --> 01:42:17,120 CONDUCTED TRIALS PROPOSED BY 2078 01:42:17,120 --> 01:42:21,840 NON-NETWORK INVESTIGATORS. 2079 01:42:21,840 --> 01:42:24,240 THE PHN DEMONSTRATED THE 2080 01:42:24,240 --> 01:42:25,680 NIMBLENESS AND VALUE DURING THE 2081 01:42:25,680 --> 01:42:25,920 PANDEMIC. 2082 01:42:25,920 --> 01:42:28,240 IT WAS ABLE TO PIVOT QUICKLY TO 2083 01:42:28,240 --> 01:42:31,360 CONDUCT THE LARGEST STUDY OF 2084 01:42:31,360 --> 01:42:32,280 MULTI-INFLAMMATORY SYNDROME IN 2085 01:42:32,280 --> 01:42:33,960 CHILDREN RECRUITING OVER 1200 2086 01:42:33,960 --> 01:42:36,360 CHILDREN IN ADOLESCENTS IN A 2087 01:42:36,360 --> 01:42:38,600 LITTLE OVER A YEARS. 2088 01:42:38,600 --> 01:42:41,120 THE PHN IS SHARING THE DATA WITH 2089 01:42:41,120 --> 01:42:48,680 AND PARTICIPATING IN THE RECOVER 2090 01:42:48,680 --> 01:42:50,480 INITIATIVE STUDYING PASC AND 2091 01:42:50,480 --> 01:42:53,080 THEY CONDUCTED THE FDA MANDATED 2092 01:42:53,080 --> 01:43:00,560 FOLLOW-UP STUDY ON POST-VACCINE 2093 01:43:00,560 --> 01:43:03,160 MYOCARD 2094 01:43:03,160 --> 01:43:03,480 MYOCARDITIS. 2095 01:43:03,480 --> 01:43:05,040 THEY TRAINED THE NEXT GENERATION 2096 01:43:05,040 --> 01:43:07,200 OF NURSING INVESTIGATORS AT THE 2097 01:43:07,200 --> 01:43:09,200 SCHOLARS PROGRAM HAS TRAINED 25 2098 01:43:09,200 --> 01:43:11,600 SCHOLARS AND FOUR COHORTS. 2099 01:43:11,600 --> 01:43:15,880 AND AN EVALUATION SHOWED THE 2100 01:43:15,880 --> 01:43:18,480 RETURN INVESTMENT WAS $10 IN 2101 01:43:18,480 --> 01:43:21,480 EXTRAMURAL FUNDING FOR EVERY 2102 01:43:21,480 --> 01:43:24,280 DOLLAR SPENT SUPPORTING THE PHN 2103 01:43:24,280 --> 01:43:26,000 SCHOLARS AND THEY WERE FIRST OR 2104 01:43:26,000 --> 01:43:27,760 SENIOR AUTHORS ON 109 2105 01:43:27,760 --> 01:43:28,720 MANUSCRIPTS WITHIN FIVE YEARS OF 2106 01:43:28,720 --> 01:43:31,240 THEIR SCHOLAR EXPERIENCE. 2107 01:43:31,240 --> 01:43:33,560 FOR THE RENEWAL WHICH HAS A NICE 2108 01:43:33,560 --> 01:43:36,000 GRAPHIC IN THE MATERIAL PROVIDED 2109 01:43:36,000 --> 01:43:38,920 FOR YOU OUR PLANS BUILD ON 2110 01:43:38,920 --> 01:43:41,640 SCIENCE ACROSS THE LIFE SPAN AND 2111 01:43:41,640 --> 01:43:43,880 PARTNERSHIPS AND TRAINING WHILE 2112 01:43:43,880 --> 01:43:46,000 EVOLVING THE PHN THROUGH FOCUS 2113 01:43:46,000 --> 01:43:51,480 ON THREE PILLARS, PRECISION 2114 01:43:51,480 --> 01:43:57,160 MEDICINE, DIVERSITY, EQUITY AND 2115 01:43:57,160 --> 01:44:01,720 INCLUSION AND BUILD ON EXISTING 2116 01:44:01,720 --> 01:44:03,200 COLLABORATIONS WITH THE 2117 01:44:03,200 --> 01:44:05,800 CONSORTIUM TO IMPROVE CLINICAL 2118 01:44:05,800 --> 01:44:07,760 CARE THROUGH TRIALS INFORMED BY 2119 01:44:07,760 --> 01:44:08,000 GENOMICS. 2120 01:44:08,000 --> 01:44:11,760 FOR DEI, THE FOCUS WILL BE ON 2121 01:44:11,760 --> 01:44:12,720 ADDRESSING THE STUBBORN 2122 01:44:12,720 --> 01:44:14,360 DISPARITIES IN INFANT 2123 01:44:14,360 --> 01:44:15,560 MORTALITIES DUE TO CHD 2124 01:44:15,560 --> 01:44:17,760 ASSOCIATED WITH RACE AND OTHER 2125 01:44:17,760 --> 01:44:19,200 DISPARITIES AND OUTCOMES. 2126 01:44:19,200 --> 01:44:21,120 THIS WILL BE DONE THROUGH STRONG 2127 01:44:21,120 --> 01:44:22,840 COMMUNITY ENGAGEMENT AT SITES 2128 01:44:22,840 --> 01:44:26,200 FOSTERING RESEARCH FOCUS ON 2129 01:44:26,200 --> 01:44:27,600 DIVERSITY AND SOCIAL 2130 01:44:27,600 --> 01:44:29,160 DETERMINATES AND EQUITABLE 2131 01:44:29,160 --> 01:44:31,320 IMPLEMENTATION OF THE FINDING. 2132 01:44:31,320 --> 01:44:33,400 FOR DATA SCIENCE THE PLAN IS TO 2133 01:44:33,400 --> 01:44:36,960 LEVERAGE THE INSTITUTE'S 2134 01:44:36,960 --> 01:44:38,480 CATALYST PROGRAM, SUPPORT 2135 01:44:38,480 --> 01:44:39,960 PROGRAM FOR PHYSIOLOGICAL AND 2136 01:44:39,960 --> 01:44:41,960 OTHER DATA WITH PATIENT-REPORTED 2137 01:44:41,960 --> 01:44:46,200 OUTCOMES AND ELECTRONIC HEALTH 2138 01:44:46,200 --> 01:44:47,520 RECORD DATA AND THIS WILL 2139 01:44:47,520 --> 01:44:50,800 SUPPORT A LARGE BODY OF SUPPORT 2140 01:44:50,800 --> 01:44:52,400 AND STREAMLINE CONDUCT AND 2141 01:44:52,400 --> 01:44:54,440 FACILITATE A NETWORK OF NETWORKS 2142 01:44:54,440 --> 01:44:58,880 AMONG THE PHN AND EXISTING CHD 2143 01:44:58,880 --> 01:45:01,080 REGISTRIES AND OTHER EFFORTS. 2144 01:45:01,080 --> 01:45:02,520 THESE CONCEPTS, THESE TWO 2145 01:45:02,520 --> 01:45:03,520 RELATED CONCEPTS ARE NOW OPEN 2146 01:45:03,520 --> 01:45:04,280 FOR DISCUSSION. 2147 01:45:04,280 --> 01:45:07,040 I'D BE HAPPY TO TAKE ANY 2148 01:45:07,040 --> 01:45:08,040 QUESTIONS YOU MAY HAVE. 2149 01:45:08,040 --> 01:45:09,480 IF YOU HAVE QUESTIONS, PLEASE 2150 01:45:09,480 --> 01:45:13,120 RAISE YOUR HAND OR PUT SOMETHING 2151 01:45:13,120 --> 01:45:23,360 IN THE CHAT. 2152 01:45:26,200 --> 01:45:27,800 I'M NOT SEEING HANDS RAISED OR 2153 01:45:27,800 --> 01:45:31,960 QUESTIONS IN THE CHAT SO PERHAPS 2154 01:45:31,960 --> 01:45:34,000 WE CAN MOVE TOWARDS RATING THESE 2155 01:45:34,000 --> 01:45:38,560 TWO RELATED CONCEPTS. 2156 01:45:38,560 --> 01:45:43,720 AND JEN, PLEASE LET ME KNOW WHEN 2157 01:45:43,720 --> 01:45:44,120 WE'RE ABOUT DONE. 2158 01:45:44,120 --> 01:45:46,560 >> SURE, WE'RE OFF TO A GOOD 2159 01:45:46,560 --> 01:45:47,200 START. 2160 01:45:47,200 --> 01:45:48,880 A REMINDER TO THOSE VOTING THERE 2161 01:45:48,880 --> 01:45:51,000 ARE TWO CONCEPTS TO VOTE FOR SO 2162 01:45:51,000 --> 01:45:52,480 MAKE SURE YOU ENTER THE VOTES 2163 01:45:52,480 --> 01:45:54,600 FOR EACH ONE OF THOSE. 2164 01:45:54,600 --> 01:45:56,600 AT THE MOMENT MAYBE A GOOD 2165 01:45:56,600 --> 01:46:00,520 TWO-THIRDS OF THE VOTES ARE IN 2166 01:46:00,520 --> 01:46:01,920 AS WELL AS I'LL GIVE EVERYONE A 2167 01:46:01,920 --> 01:46:02,720 MOMENT OR TWO TO DELIBERATE ON 2168 01:46:02,720 --> 01:46:05,360 THAT. 2169 01:46:05,360 --> 01:46:06,040 >> YES. 2170 01:46:06,040 --> 01:46:09,120 THERE WAS A QUESTION FROM 2171 01:46:09,120 --> 01:46:11,360 DR. CARNETHON, DO WE RATE BOTH 2172 01:46:11,360 --> 01:46:12,880 OF THESE? 2173 01:46:12,880 --> 01:46:13,080 YES. 2174 01:46:13,080 --> 01:46:16,800 WE RATE -- WE'RE ASKING TO RATE 2175 01:46:16,800 --> 01:46:18,720 BOTH CONCEPTS RELATED TO THE 2176 01:46:18,720 --> 01:46:20,520 PEDIATRIC HEART NETWORK. 2177 01:46:20,520 --> 01:46:21,360 THE REASON THEY'RE BEING 2178 01:46:21,360 --> 01:46:23,240 PRESENTED AS TWO DIFFERENT 2179 01:46:23,240 --> 01:46:24,360 CONCEPTS IS SOMETIMES THE VIEW 2180 01:46:24,360 --> 01:46:27,560 OF ONE PART OF A LARGE COMPLEX 2181 01:46:27,560 --> 01:46:30,000 INITIATE MAY BE DIFFERENT THAN 2182 01:46:30,000 --> 01:46:32,200 THE VIEW OF ANOTHER. 2183 01:46:32,200 --> 01:46:33,440 THERE WILL BE TWO DIFFERENT FOAs 2184 01:46:33,440 --> 01:46:34,240 THAT COME OUT. 2185 01:46:34,240 --> 01:46:37,440 ONE FOR THE COORDINATING CENTER 2186 01:46:37,440 --> 01:46:38,000 AND ONE NOR THE CLINICAL 2187 01:46:38,000 --> 01:46:46,560 SCIENCE. 2188 01:46:46,560 --> 01:46:51,520 >> SINCE THERE ARE TWO CONCEPTS 2189 01:46:51,520 --> 01:46:54,160 I'LL GIVE EVERYONE ANOTHER 2190 01:46:54,160 --> 01:47:04,680 MOMENT TO COMPLETE THEIR VOTES. 2191 01:47:18,280 --> 01:47:22,400 >> THE RENEWAL OF THE INITIATIVE 2192 01:47:22,400 --> 01:47:30,400 THAT'S AN R01 AND N01 AND IAA 2193 01:47:30,400 --> 01:47:33,600 INITIATIVE AND IT WILL BE AN 2194 01:47:33,600 --> 01:47:35,000 INTERAGENCY AGREEMENT. 2195 01:47:35,000 --> 01:47:38,240 THE SUDDEN DEATH AND BEYOND OR 2196 01:47:38,240 --> 01:47:40,320 SDY CASE REGISTRY WAS 2197 01:47:40,320 --> 01:47:43,160 ESTABLISHED IN 2013 IN 2198 01:47:43,160 --> 01:47:45,120 COLLABORATION WITH NINDS AND THE 2199 01:47:45,120 --> 01:47:45,440 CDC. 2200 01:47:45,440 --> 01:47:47,760 THE PROGRAM BENEFITS FROM THE 2201 01:47:47,760 --> 01:47:48,880 STRENGTHS OF EACH AGENCY. 2202 01:47:48,880 --> 01:47:53,120 THE CDC'S EXPERTISE IN PUBLIC 2203 01:47:53,120 --> 01:47:56,280 HEALTH SURVEILLANCE AND NIH's 2204 01:47:56,280 --> 01:47:57,720 EXPERT EASE AND RESEARCH AND THE 2205 01:47:57,720 --> 01:48:00,760 GOAL IS TO DESCRIBE SUDDEN DEATH 2206 01:48:00,760 --> 01:48:03,600 AND BEYOND USING 2207 01:48:03,600 --> 01:48:04,960 POPULATION-BASED SURVEILLANCE 2208 01:48:04,960 --> 01:48:07,800 AND SUPPORT RESEARCH INTO THE 2209 01:48:07,800 --> 01:48:12,120 CAUSES OF SUDDEN DEATH AND 2210 01:48:12,120 --> 01:48:15,960 BEYOND BY COMPILING PHENOTYPIC 2211 01:48:15,960 --> 01:48:17,760 DATA AND IT'S THE LARGEST 2212 01:48:17,760 --> 01:48:19,400 PROGRAM FOR SUDDEN DEATH AND 2213 01:48:19,400 --> 01:48:20,880 BEYOND IN THE U.S. AND 13 FUNDED 2214 01:48:20,880 --> 01:48:21,880 STATES AND JURISDICTIONS INCLUDE 2215 01:48:21,880 --> 01:48:25,120 ABOUT 30% OF ALL THE 2216 01:48:25,120 --> 01:48:29,120 U.S. PEDIATRIC POPULATION. 2217 01:48:29,120 --> 01:48:32,520 DATA CAN USED TO CALCULATE THE 2218 01:48:32,520 --> 01:48:36,720 SUDDEN UNEXPECTED INFANT DEATHS 2219 01:48:36,720 --> 01:48:39,360 AND ASTHMA AND SICKLE CELL 2220 01:48:39,360 --> 01:48:39,640 DISEASE. 2221 01:48:39,640 --> 01:48:40,960 OUR DATA INDICATE PEOPLE 2222 01:48:40,960 --> 01:48:45,000 EXPERIENCING POVERTY AND CERTAIN 2223 01:48:45,000 --> 01:48:48,000 GROUPS ARE DISPROPORTIONATELY 2224 01:48:48,000 --> 01:48:51,640 AFFECTED AND RATES OF SDY ARE 2225 01:48:51,640 --> 01:48:57,680 HIGHER AMONG FEMALES AND MALES. 2226 01:48:57,680 --> 01:48:58,920 ON THE SURVEILLANCE SIDE WE'LL 2227 01:48:58,920 --> 01:49:03,880 FOCUS ON HEALTH DISPARITIES AND 2228 01:49:03,880 --> 01:49:05,640 TO UNDERSTAND THE HOW AND WHY 2229 01:49:05,640 --> 01:49:08,160 AND TO OPTIMIZE THE VALUE OF THE 2230 01:49:08,160 --> 01:49:09,720 RESEARCH RESOURCE WE PROPOSE TO 2231 01:49:09,720 --> 01:49:11,880 COLLECT CARDIAC, LUNG AND AIRWAY 2232 01:49:11,880 --> 01:49:12,680 AND BRAIN TISSUE IN ADDITION TO 2233 01:49:12,680 --> 01:49:19,200 DNA. 2234 01:49:19,200 --> 01:49:21,920 TO PERFORM GENOMICS FOR 2235 01:49:21,920 --> 01:49:24,320 EFFICIENCY AND TO EMPLOY 2236 01:49:24,320 --> 01:49:25,200 ENGAGEMENT STRATEGIES TO 2237 01:49:25,200 --> 01:49:27,760 INCREASE PARTICIPATION BY UNDER 2238 01:49:27,760 --> 01:49:28,800 REPRESENTED POPULATIONS IN THE 2239 01:49:28,800 --> 01:49:30,280 RESEARCH COMPONENT AND ENHANCE 2240 01:49:30,280 --> 01:49:32,640 THE DIVERSITY OF DATA IN THE 2241 01:49:32,640 --> 01:49:33,120 REGISTRY. 2242 01:49:33,120 --> 01:49:37,800 THE RENEWAL ALSO INCLUDES A NOSI 2243 01:49:37,800 --> 01:49:39,720 OF SPECIAL INTEREST TO ENCOURAGE 2244 01:49:39,720 --> 01:49:41,440 INVESTIGATORS TO LEVERAGE THE 2245 01:49:41,440 --> 01:49:43,640 DATA AND BIO SPECIMENS TO 2246 01:49:43,640 --> 01:49:47,080 EXPLORE THE CAUSES OF SUDDEN 2247 01:49:47,080 --> 01:49:51,760 DEATH AND BEYOND. 2248 01:49:51,760 --> 01:49:54,240 WE'RE PROPOSING $12.5 MILLION 2249 01:49:54,240 --> 01:49:56,360 OVER FIVE YEARS THAT'S BEEN 2250 01:49:56,360 --> 01:49:58,320 INCREASED IN THE RENEWAL TO 2251 01:49:58,320 --> 01:49:59,720 RECOVER THE RELATED TISSUE 2252 01:49:59,720 --> 01:50:01,120 COLLECTION RELATED TO HEART, 2253 01:50:01,120 --> 01:50:01,560 LUNG, BRAIN. 2254 01:50:01,560 --> 01:50:03,600 WITH THAT I THANK YOU AND THIS 2255 01:50:03,600 --> 01:50:05,120 CONCEPT IS OPEN FOR DISCUSSION 2256 01:50:05,120 --> 01:50:09,120 OR QUESTIONS. 2257 01:50:09,120 --> 01:50:10,880 AGAIN, PLEASE RAISE YOUR HAND OR 2258 01:50:10,880 --> 01:50:12,240 PUT SOMETHING IN THE CHAT OR 2259 01:50:12,240 --> 01:50:15,760 TURN YOUR VIDEO ON. 2260 01:50:15,760 --> 01:50:26,120 WHATEVER IS MOST CONVENIENT. 2261 01:50:26,120 --> 01:50:28,120 I'M NOT SEEING ANYTHING IN THE 2262 01:50:28,120 --> 01:50:29,520 CHAT OR HANDS RAISED OR VIDEOS 2263 01:50:29,520 --> 01:50:31,360 TURNED ON SO I THINK WE MAY BE 2264 01:50:31,360 --> 01:50:33,120 ABLE TO MOVE ON TO RATING THIS 2265 01:50:33,120 --> 01:50:41,480 CONCEPT. 2266 01:50:41,480 --> 01:50:44,120 >> WE'RE NEARLY READY TO MOVE 2267 01:50:44,120 --> 01:50:44,360 ON. 2268 01:50:44,360 --> 01:50:46,520 WE'RE GIVING OUR REMAINING 2269 01:50:46,520 --> 01:50:56,720 COUNCIL MEMBERS A MOMENT VOTE. 2270 01:50:56,720 --> 01:50:58,440 >> WE'RE READY TO ADVANCE TO 2271 01:50:58,440 --> 01:51:00,520 CONCEPT 2770. 2272 01:51:00,520 --> 01:51:01,600 >> THANK YOU, JEN. 2273 01:51:01,600 --> 01:51:03,560 THE FINAL EFFORT WE'RE BRINGING 2274 01:51:03,560 --> 01:51:05,120 TO YOU TODAY FROM THE DIVISION 2275 01:51:05,120 --> 01:51:08,320 OF CARDIOVASCULAR SCIENCES IS 2276 01:51:08,320 --> 01:51:09,040 OUR PRIDE INITIATIVE. 2277 01:51:09,040 --> 01:51:11,240 IT IS SPORED BY THREE CONCEPTS 2278 01:51:11,240 --> 01:51:13,920 THAT WE'RE ASKING YOU TO 2279 01:51:13,920 --> 01:51:16,280 EVALUATE TODAY. 2280 01:51:16,280 --> 01:51:26,760 NUMBER 2770, 2771 AND 2772. 2281 01:51:28,800 --> 01:51:31,200 WE'LL BE ASKING FOR YOUR INPUT 2282 01:51:31,200 --> 01:51:34,280 ON A RENEWAL OF THE COORDINATION 2283 01:51:34,280 --> 01:51:39,760 CENTER FOR THE PRIDE PROGRAM AND 2284 01:51:39,760 --> 01:51:42,200 SUMMER INSTITUTE SITE FOR THE 2285 01:51:42,200 --> 01:51:42,680 NOSI OR ADMINISTRATIVE 2286 01:51:42,680 --> 01:51:45,120 SUPPLEMENTS FOR SMALL RESEARCH 2287 01:51:45,120 --> 01:51:45,440 PROGRAMS. 2288 01:51:45,440 --> 01:51:49,120 FOR SMALL WORK RESEARCH PILOT 2289 01:51:49,120 --> 01:51:51,280 AWARDS IN THE PRIDE PROGRAM. 2290 01:51:51,280 --> 01:51:53,120 SO THESE PROPOSALS SUPPORT 2291 01:51:53,120 --> 01:51:54,960 RENEWAL OF THE PROGRAMS TO 2292 01:51:54,960 --> 01:51:57,480 INCREASE DIVERSITY AMONG 2293 01:51:57,480 --> 01:52:01,600 INDIVIDUALS AND GAYS IN HEALTH 2294 01:52:01,600 --> 01:52:06,680 RELATED RESEARCH OR PRIDE FOR 2295 01:52:06,680 --> 01:52:07,920 RESEARCH FOCUSSED ON HEART, 2296 01:52:07,920 --> 01:52:09,720 LUNG, BLOOD AND SLEEP DISORDERS. 2297 01:52:09,720 --> 01:52:14,320 PRIDE IS COMPRISED OF SUMMER 2298 01:52:14,320 --> 01:52:18,880 INSTITUTES OF MENTORS, MENTEES A 2299 01:52:18,880 --> 01:52:20,120 COORDINATION CORE AND THE NHLBI 2300 01:52:20,120 --> 01:52:20,920 PROGRAM OFFICE. 2301 01:52:20,920 --> 01:52:21,880 THERE'S CURRENTLY NINE SUMMER 2302 01:52:21,880 --> 01:52:24,160 INSTITUTES AND EACH IS FOCUSSED 2303 01:52:24,160 --> 01:52:27,480 ON AN AREA OF SCIENCE RELEVANT 2304 01:52:27,480 --> 01:52:29,440 TO THE NHLBI MISSION FOR 2305 01:52:29,440 --> 01:52:34,600 SEQUENTIAL COHORTS OF 8 TO 12 2306 01:52:34,600 --> 01:52:34,800 MENTEES 2307 01:52:34,800 --> 01:52:35,800 THEY ATTEND AN INSTITUTE SESSION 2308 01:52:35,800 --> 01:52:38,520 FOR TWO CONSECUTIVE SUMMERS AND 2309 01:52:38,520 --> 01:52:40,640 A SHORT MID YEAR MEETING IN 2310 01:52:40,640 --> 01:52:43,160 BETWEEN AND ANNUAL PROGRAM-WIDE 2311 01:52:43,160 --> 01:52:45,120 MEETING INCLUSIVE OF ALL THE 2312 01:52:45,120 --> 01:52:46,760 SUMMER PROGRAMS. 2313 01:52:46,760 --> 01:52:50,760 THEY WORK TOGETHER TO ESTABLISH 2314 01:52:50,760 --> 01:52:51,880 MENTOR-MENTEE TEAMS MATCHED 2315 01:52:51,880 --> 01:52:54,640 BASED ON COMMON RESEARCH 2316 01:52:54,640 --> 01:52:55,720 INTERESTS. 2317 01:52:55,720 --> 01:53:00,320 AND THEY COLLABORATE TO 2318 01:53:00,320 --> 01:53:02,000 COMPLEMENT THE NEEDED EXPERT FOR 2319 01:53:02,000 --> 01:53:03,600 THE GOALS. 2320 01:53:03,600 --> 01:53:06,760 THE SPECIAL EMPHASIS ON 2321 01:53:06,760 --> 01:53:07,360 GRANTSMANSHIP AND DEVELOP 2322 01:53:07,360 --> 01:53:09,080 SPECIFIC RESEARCH PROJECTS AND 2323 01:53:09,080 --> 01:53:09,880 PROPOSALS AND ENHANCE THEIR 2324 01:53:09,880 --> 01:53:12,440 LONG-TERM FUNDABILITY. 2325 01:53:12,440 --> 01:53:14,120 MENTEES ARE SELECTED BY AN 2326 01:53:14,120 --> 01:53:15,880 APPLICATION PROCESS AS MANAGED 2327 01:53:15,880 --> 01:53:18,640 BY BOTH COORDINATION CENTER AND 2328 01:53:18,640 --> 01:53:20,760 THE SUMMER INSTITUTE PROGRAMS. 2329 01:53:20,760 --> 01:53:22,680 ELIGIBLE CANDIDATES MUST HAVE A 2330 01:53:22,680 --> 01:53:24,160 DOCTORAL DEGREE, FACULTY 2331 01:53:24,160 --> 01:53:26,040 POSITION, EARLY CAREER STATUS OR 2332 01:53:26,040 --> 01:53:27,920 NEW CAREER FOCUS AND PROTECTED 2333 01:53:27,920 --> 01:53:29,320 TIME ASSURED BY THAT OF 2334 01:53:29,320 --> 01:53:30,600 DEPARTMENT CHAIR OR DEAN. 2335 01:53:30,600 --> 01:53:33,120 IN THE CURRENT ITERATION OF 2336 01:53:33,120 --> 01:53:35,440 PRIDE ADDED THE SMALL RESEARCH 2337 01:53:35,440 --> 01:53:36,960 PROGRAM TO FUND PILOT PROGRAMS 2338 01:53:36,960 --> 01:53:40,760 LED BY PRIDE MENTEES TO 2339 01:53:40,760 --> 01:53:42,360 CONTRIBUTE TO PRELIMINARY DATA 2340 01:53:42,360 --> 01:53:45,120 TO DEVELOP A COMPETITIVE FUTURE 2341 01:53:45,120 --> 01:53:48,000 GRANT APPLICATION. 2342 01:53:48,000 --> 01:53:49,040 THE COORDINATION CENTER IS AN 2343 01:53:49,040 --> 01:53:49,920 IMPORTANT PART OF THE PROGRAM 2344 01:53:49,920 --> 01:53:51,600 AND SUPPORTS AND COMPLEMENTS THE 2345 01:53:51,600 --> 01:53:53,800 ACTIVITIES OF THE SUMMER 2346 01:53:53,800 --> 01:53:54,720 INSTITUTES AND THE PROGRAM STAFF 2347 01:53:54,720 --> 01:53:57,360 BY FACILITATING MENTEE 2348 01:53:57,360 --> 01:53:58,960 RECRUITMENT AND MATCHING WITH 2349 01:53:58,960 --> 01:54:01,120 THE SUMMER INSTITUTE SITES AND 2350 01:54:01,120 --> 01:54:03,320 MENTORS, CO-PLANNING AND 2351 01:54:03,320 --> 01:54:04,840 CO-FACILITATING PROGRAM-WIDE 2352 01:54:04,840 --> 01:54:07,280 MEETINGS AND ACTIVITIES WITH OUR 2353 01:54:07,280 --> 01:54:08,400 NHLBI PROGRAM STAFF, 2354 01:54:08,400 --> 01:54:10,440 FACILITATING REVIEW OF THE SMALL 2355 01:54:10,440 --> 01:54:13,040 RESEARCH PROGRAM PILOT AWARD 2356 01:54:13,040 --> 01:54:15,000 APPLICATIONS AND CONDUCTING 2357 01:54:15,000 --> 01:54:16,360 LONGITUDINAL DATA COLLECTION AND 2358 01:54:16,360 --> 01:54:17,880 PROGRAM-WIDE EVALUATION TO 2359 01:54:17,880 --> 01:54:18,520 BENCHMARK PROGRAM SUCCESS AND 2360 01:54:18,520 --> 01:54:24,160 OVER ALL PROGRAM IMPACT. 2361 01:54:24,160 --> 01:54:30,640 PRELIMINARY OUTCOMES SHOW 2362 01:54:30,640 --> 01:54:31,760 MEANTEES HAVE AN INCREASED 2363 01:54:31,760 --> 01:54:33,920 PUBLICATION AND GRANTS AND 50% 2364 01:54:33,920 --> 01:54:35,920 FROM EARLIER PRIDE COHORT HAVE 2365 01:54:35,920 --> 01:54:37,640 EARNED AT LEAST ONE PROMOTION IN 2366 01:54:37,640 --> 01:54:39,320 ACADEMIC RANK. 2367 01:54:39,320 --> 01:54:40,760 BASED ON THIS TRACK RECORD AND 2368 01:54:40,760 --> 01:54:42,760 WHAT WE LEARNED TO DATE, THE 2369 01:54:42,760 --> 01:54:47,200 RENEWAL AIMS TO SUSTAIN THAT 2370 01:54:47,200 --> 01:54:47,600 SUCCESS. 2371 01:54:47,600 --> 01:54:49,760 IN ADDITION TO THE CURRENTLY 2372 01:54:49,760 --> 01:54:52,280 SUPPORTED AREAS OF TRANLATIONAL 2373 01:54:52,280 --> 01:54:55,440 AND CLINICAL AND IMPLEMENTATION 2374 01:54:55,440 --> 01:54:59,160 SCIENCE AMONG HEART, LUNG, BLOOD 2375 01:54:59,160 --> 01:55:02,680 CONDITIONS AND THERE IS 2376 01:55:02,680 --> 01:55:03,800 DIVERSITY OF THE WORKFORCE 2377 01:55:03,800 --> 01:55:05,120 INCLUDING FOR EXAMPLE 2378 01:55:05,120 --> 01:55:06,240 CONTEMPORARY INTERVENTION 2379 01:55:06,240 --> 01:55:07,920 RESEARCH APPROACHES SUCH AS IVE 2380 01:55:07,920 --> 01:55:10,600 AND PRAGMATIC TRIALS, BEHAVIORAL 2381 01:55:10,600 --> 01:55:12,920 AND SOCIAL SCIENCE RESEARCH, 2382 01:55:12,920 --> 01:55:15,800 EMERGING TECHNOLOGY AND CLINICAL 2383 01:55:15,800 --> 01:55:16,920 INFORMATICS, GLOBAL HEALTH AND 2384 01:55:16,920 --> 01:55:19,760 PRECISION HEALTH. 2385 01:55:19,760 --> 01:55:21,760 SO THIS RENEWAL SUPPORTS THE 2386 01:55:21,760 --> 01:55:22,720 CONTINUATION OF THE COORDINATION 2387 01:55:22,720 --> 01:55:24,880 CORE AND SUMMER INSTITUTE AND 2388 01:55:24,880 --> 01:55:27,080 SMALL RESEARCH PROGRAM FOR A 2389 01:55:27,080 --> 01:55:27,840 FIVE-YEAR PERIOD. 2390 01:55:27,840 --> 01:55:29,200 THE CURRENT PROGRAM'S RECRUITING 2391 01:55:29,200 --> 01:55:31,280 THE LAST COHORT OF MENTEES TO 2392 01:55:31,280 --> 01:55:33,040 START THIS SUMMER AND FINISH 2393 01:55:33,040 --> 01:55:34,160 NEXT SUMMER WITH FUNDING ENDING 2394 01:55:34,160 --> 01:55:36,680 THE END OF NEXT YEAR. 2395 01:55:36,680 --> 01:55:42,680 SO THIS RENEWAL FOR FISCAL YEAR 2396 01:55:42,680 --> 01:55:47,440 '24 WELL ENABLE UNINTERRUPTED 2397 01:55:47,440 --> 01:55:48,880 PROGRAM AND THERE'S A SCIENTIFIC 2398 01:55:48,880 --> 01:55:49,640 WORKFORCE AND THE CONTINUATION 2399 01:55:49,640 --> 01:55:51,920 WILL STIMULATE THE ENTRY OF NEW 2400 01:55:51,920 --> 01:55:53,160 RESEARCH INVESTIGATORS FROM 2401 01:55:53,160 --> 01:55:55,440 HISTORICALLY EXCLUDED AND UNDER 2402 01:55:55,440 --> 01:55:56,800 REPRESENTED GROUPS INTO THE 2403 01:55:56,800 --> 01:55:58,480 PIPELINE ACROSS EXISTING AND 2404 01:55:58,480 --> 01:56:01,120 EMERGING AREAS OF SCIENCE 2405 01:56:01,120 --> 01:56:01,640 RELEVANT TO OUR MISSION. 2406 01:56:01,640 --> 01:56:04,240 WITH THAT, THESE CONCEPTS ARE 2407 01:56:04,240 --> 01:56:04,840 NOW OPEN FOR DISCUSSION OR 2408 01:56:04,840 --> 01:56:14,120 QUESTIONS. 2409 01:56:14,120 --> 01:56:15,920 >> WE'RE OFF TO A GOOD START 2410 01:56:15,920 --> 01:56:17,120 WITH THE VOTING. 2411 01:56:17,120 --> 01:56:19,080 REMEMBER THERE'S THREE 2412 01:56:19,080 --> 01:56:25,760 INDIVIDUAL CONCEPTS TO VOTE FOR. 2413 01:56:25,760 --> 01:56:27,640 >> I'M NOT SEEING QUESTIONS IN 2414 01:56:27,640 --> 01:56:31,920 THE CHAT OR HANDS RAISED OR 2415 01:56:31,920 --> 01:56:33,960 ANYONE COMING ON VIDEO SO I 2416 01:56:33,960 --> 01:56:40,480 THINK WE MAY BE PREPARED TO PASS 2417 01:56:40,480 --> 01:56:42,280 THE BATON WHEN THE VOTING IS 2418 01:56:42,280 --> 01:56:42,520 COMPLETED. 2419 01:56:42,520 --> 01:56:46,360 >> I'LL PAUSE HERE. 2420 01:56:46,360 --> 01:56:49,680 >> I SEE SOMEONE COMING ON 2421 01:56:49,680 --> 01:56:49,880 VIDEO. 2422 01:56:49,880 --> 01:56:51,920 RESPONSE HE'LL BE THE RECIPIENT 2423 01:56:51,920 --> 01:57:02,160 OF THE BATON. 2424 01:57:04,000 --> 01:57:08,920 >> I'LL TAKE A PAUSE TO VOTE ON 2425 01:57:08,920 --> 01:57:11,200 THE CONCEPTS AND I'LL LET YOU 2426 01:57:11,200 --> 01:57:12,640 KNOW WHEN WE CAN MOVE ON. 2427 01:57:12,640 --> 01:57:14,600 >> I'D LIKE TO THANK THE MEMBERS 2428 01:57:14,600 --> 01:57:15,880 FOR PROVIDING INPUT AND ANY 2429 01:57:15,880 --> 01:57:16,480 COMMENTS YOU MIGHT MAKE THROUGH 2430 01:57:16,480 --> 01:57:22,720 THE SYSTEM. 2431 01:57:22,720 --> 01:57:24,720 WE TAKE THEM SERIOUSLY IN MOVING 2432 01:57:24,720 --> 01:57:25,560 CONCEPTS FORWARD AND HOW WE 2433 01:57:25,560 --> 01:57:27,160 SHAPE AND EXECUTE THEM. 2434 01:57:27,160 --> 01:57:28,360 MANY THANKS. 2435 01:57:28,360 --> 01:57:29,080 WITH THAT I WILL GO BACK ON 2436 01:57:29,080 --> 01:57:39,200 MUTE. 2437 01:57:41,000 --> 01:57:42,000 >> WE'RE ALMOST READY TO 2438 01:57:42,000 --> 01:57:42,640 PROCEED. 2439 01:57:42,640 --> 01:57:45,120 I'M WAITING FOR ONE REMAINING 2440 01:57:45,120 --> 01:57:55,240 VOTE. 2441 01:58:07,200 --> 01:58:15,640 WE'RE NOW READY TO MOVE ON. 2442 01:58:15,640 --> 01:58:16,920 >> THANKS, JEN AND DAVID AND 2443 01:58:16,920 --> 01:58:18,760 THREW FOR THE BATON AND I'LL 2444 01:58:18,760 --> 01:58:22,200 GRAB THAT AND SEE IF WE CAN 2445 01:58:22,200 --> 01:58:23,760 CRUISE DOWN THE TRACK WITH IT. 2446 01:58:23,760 --> 01:58:27,040 THE LUNG DIVISION WILL PRESENT 2447 01:58:27,040 --> 01:58:28,760 THREE INITIATIVES THIS AFTERNOON 2448 01:58:28,760 --> 01:58:31,920 THAT WE ARE LEADING BUT AS 2449 01:58:31,920 --> 01:58:38,040 YOU'LL SEE TWO OF THEM ARE NIH 2450 01:58:38,040 --> 01:58:41,600 WIDE AND ONE IS NHLBI WIDE AND 2451 01:58:41,600 --> 01:58:42,520 THEY'RE TRANS-INITIATIVES 2452 01:58:42,520 --> 01:58:47,720 DEVELOPED BY A TEAM OF OUR STAFF 2453 01:58:47,720 --> 01:58:52,240 ACROSS THE INSTITUTE AND WOULD 2454 01:58:52,240 --> 01:58:57,880 AND HELP FROM OTHER I.C.s AS 2455 01:58:57,880 --> 01:58:59,480 WELL. 2456 01:58:59,480 --> 01:59:01,680 THIS IS ENTITLED LIMITED 2457 01:59:01,680 --> 01:59:02,120 COMPETITION. 2458 01:59:02,120 --> 01:59:03,920 THIS IS A SMALL GRANT PROGRAM 2459 01:59:03,920 --> 01:59:10,920 FOR KO1, K25 AND OTHERS AND 2460 01:59:10,920 --> 01:59:11,600 OPTIONAL. 2461 01:59:11,600 --> 01:59:12,520 YOU MAY THINK I TALKED TO YOU 2462 01:59:12,520 --> 01:59:18,600 ABOUT THIS ONE AND YOU'RE RIGHT, 2463 01:59:18,600 --> 01:59:20,720 WE PRESENTED A PROGRAM PLAN FOR 2464 01:59:20,720 --> 01:59:24,200 GRANTS THAT CAME INTO THIS 2465 01:59:24,200 --> 01:59:24,840 PARTICULAR INITIATIVE FOR THE 2466 01:59:24,840 --> 01:59:25,400 LAST ROUND. 2467 01:59:25,400 --> 01:59:25,920 THIS IS A RENEWAL OF THE 2468 01:59:25,920 --> 01:59:36,080 PROGRAM. 2469 01:59:50,800 --> 01:59:55,960 AND THERE'S KO1, K08, K23 AND 2470 01:59:55,960 --> 01:59:56,440 K25. 2471 01:59:56,440 --> 01:59:59,040 IT'S FOR SMALL GRANT SUPPORT TO 2472 01:59:59,040 --> 02:00:00,360 EXPAND THEIR K RESEARCH 2473 02:00:00,360 --> 02:00:02,080 OBJECTIVES OR TO BRANCH OUT TO A 2474 02:00:02,080 --> 02:00:04,200 NEW AREA OF RESEARCH RELATED TO 2475 02:00:04,200 --> 02:00:14,560 THEIR K AWARD STUDIES. 2476 02:00:25,520 --> 02:00:27,840 AND THERE'S ADDITIONAL SUPPORT 2477 02:00:27,840 --> 02:00:33,120 TO TRANSFER TO RESEARCH IN 2478 02:00:33,120 --> 02:00:38,120 DEPENDENCE AND RESEARCH EFFORT 2479 02:00:38,120 --> 02:00:39,280 OF THE P.I. IS REQUIRED. 2480 02:00:39,280 --> 02:00:40,920 THE PROGRAM WAS STARTED IN 2015 2481 02:00:40,920 --> 02:00:43,400 AS A PILOT AND THEN RENEWED 2482 02:00:43,400 --> 02:00:49,520 AGAIN IN 2018 AND 2020 AND SO 2483 02:00:49,520 --> 02:00:57,920 YOU THINK AND THE CURRENT 2484 02:00:57,920 --> 02:01:01,080 PROGRAM EXPIRED IN OCTOBER OF 2485 02:01:01,080 --> 02:01:01,440 '21. 2486 02:01:01,440 --> 02:01:05,040 WE AWARDED 115 NEW AWARDS 2487 02:01:05,040 --> 02:01:07,240 BETWEEN 2016 AND 2021. 2488 02:01:07,240 --> 02:01:09,480 SO THE PERIOD THAT THIS PROGRAM 2489 02:01:09,480 --> 02:01:09,800 EXISTED. 2490 02:01:09,800 --> 02:01:13,080 SO A PRETTY GOOD NUMBER OF 2491 02:01:13,080 --> 02:01:13,280 AWARDS. 2492 02:01:13,280 --> 02:01:15,920 WE HAVE LIMITED DATA BUT WE DO 2493 02:01:15,920 --> 02:01:20,680 HAVE SOME DATA TO SUGGEST THE 2494 02:01:20,680 --> 02:01:23,440 RO3 AWARDEE LIKELY TO ABSTAIN AN 2495 02:01:23,440 --> 02:01:25,040 R01 OR EQUIVALENT GRANT. 2496 02:01:25,040 --> 02:01:26,400 YOU'LL INTEREST HAVE TO TAKE MY 2497 02:01:26,400 --> 02:01:27,680 WORD FOR THAT BECAUSE I DON'T 2498 02:01:27,680 --> 02:01:28,680 HAVE TIME TO SHOW THE DATA. 2499 02:01:28,680 --> 02:01:30,240 MAYBE AT SOME POINT WE CAN BRING 2500 02:01:30,240 --> 02:01:31,280 IT TO YOU. 2501 02:01:31,280 --> 02:01:33,680 AT THIS POINT WE HAVE DONE GOOD 2502 02:01:33,680 --> 02:01:36,880 ANALYSIS OF WHAT WE HAVE AND 2503 02:01:36,880 --> 02:01:38,560 BELIEVE THE R03 PROGRAM IS 2504 02:01:38,560 --> 02:01:42,080 ACHIEVING THE STATED GOALS OF 2505 02:01:42,080 --> 02:01:43,240 ACHIEVING THE RESEARCH 2506 02:01:43,240 --> 02:01:43,760 INDEPENDENCE OR AID TO 2507 02:01:43,760 --> 02:01:49,040 TRANSITION TO THE NEXT AWARD. 2508 02:01:49,040 --> 02:01:51,240 WE WOULD LIKE TO MEET THE 2509 02:01:51,240 --> 02:01:52,680 PROGRAM AND IT'S MEETING ITS 2510 02:01:52,680 --> 02:01:53,920 GOALS FOR AN ADDITIONAL THREE 2511 02:01:53,920 --> 02:01:57,160 YEARS TO SUPPORT A TOTAL OF 90 2512 02:01:57,160 --> 02:02:02,520 NEW AWARDS WITH A DIRECT COST OF 2513 02:02:02,520 --> 02:02:03,280 75K PER YEAR. 2514 02:02:03,280 --> 02:02:04,880 SO WHAT ARE WE CHANGES FROM THE 2515 02:02:04,880 --> 02:02:06,400 PREVIOUS ONE TO NOW FROM WHAT WE 2516 02:02:06,400 --> 02:02:06,720 LEARN? 2517 02:02:06,720 --> 02:02:08,840 WE MADE A FEW MODIFICATIONS, NOT 2518 02:02:08,840 --> 02:02:12,240 MAJOR ONES BUT A COUPLE WE THINK 2519 02:02:12,240 --> 02:02:13,360 ARE GOING TO BE BENEFICIAL TO 2520 02:02:13,360 --> 02:02:16,720 THE APPLICANTS AND AWARDEES. 2521 02:02:16,720 --> 02:02:19,080 FIRST OF ALL WE'LL INCREASE THE 2522 02:02:19,080 --> 02:02:21,920 DIRECT COST FROM $50,000 TO 2523 02:02:21,920 --> 02:02:26,240 $75,000 AND HOPE TO AWARD 20 TO 2524 02:02:26,240 --> 02:02:28,760 30 PER FISCAL YEAR AND WE ADDED 2525 02:02:28,760 --> 02:02:32,720 THE K25 AS AN ELIGIBLE MECHANISM 2526 02:02:32,720 --> 02:02:35,040 FOR THIS RO3 PROGRAM. 2527 02:02:35,040 --> 02:02:37,080 SO WITH THAT BRIEF BACKGROUND 2528 02:02:37,080 --> 02:02:38,600 GIVING YOU A SENSE OF WHAT WE'RE 2529 02:02:38,600 --> 02:02:39,840 AFTER HERE WITH THE RENEWAL OF 2530 02:02:39,840 --> 02:02:42,440 THIS PROGRAM, I'LL STOP THERE. 2531 02:02:42,440 --> 02:02:44,480 I'LL BE HAPPY TO TAKE ON ANY 2532 02:02:44,480 --> 02:02:54,960 QUESTIONS THAT YOU MAY HAVE. 2533 02:02:56,120 --> 02:02:58,720 >> DOES THE AWARD THAT COME FROM 2534 02:02:58,720 --> 02:03:00,160 NHLBI OR THE RESEARCH PROPOSED 2535 02:03:00,160 --> 02:03:03,920 IN THE RO3 HAS TO BE RELEVANT TO 2536 02:03:03,920 --> 02:03:05,200 THE NHLBI? 2537 02:03:05,200 --> 02:03:07,080 >> IT'S A LIMITED COMPETITION 2538 02:03:07,080 --> 02:03:08,600 FOR NHLBI AWARDEES. 2539 02:03:08,600 --> 02:03:09,920 IF YOU HAVE A CANCER GRANT IT'S 2540 02:03:09,920 --> 02:03:12,040 NOT ELIGIBLE FOR THIS MECHANISM. 2541 02:03:12,040 --> 02:03:12,800 >> OKAY. 2542 02:03:12,800 --> 02:03:13,400 I THOUGHT I UNDERSTOOD THAT. 2543 02:03:13,400 --> 02:03:22,880 THANK YOU. 2544 02:03:22,880 --> 02:03:25,120 >> I'M NOT SEEING ANYTHING IN 2545 02:03:25,120 --> 02:03:30,760 THE CHAT BOX. 2546 02:03:30,760 --> 02:03:33,120 RAISE YOUR HAND OR SPEAK UP OR 2547 02:03:33,120 --> 02:03:43,600 ENTER ANYTHING IN THE CHAT. 2548 02:03:44,560 --> 02:03:45,960 IF NOT DO THE VOTING ON THIS 2549 02:03:45,960 --> 02:03:46,480 ONE. 2550 02:03:46,480 --> 02:03:48,040 >> THE VOTING HAS BEEN COMPLETED 2551 02:03:48,040 --> 02:03:49,120 AND WE'RE READY TO ADVANCE TO 2552 02:03:49,120 --> 02:03:59,440 THE NEXT CONCEPT. 2553 02:04:16,240 --> 02:04:16,560 AIDS PROGRAM. 2554 02:04:16,560 --> 02:04:17,680 IT'S NUMBER 2763, AND THIS ONE 2555 02:04:17,680 --> 02:04:20,320 IS SECONDARY PARTICIPATION IN 2556 02:04:20,320 --> 02:04:23,280 CATALYST AWARD FOR EARLY STAGE 2557 02:04:23,280 --> 02:04:24,600 INVESTIGATORS PURSUING RESEARCH 2558 02:04:24,600 --> 02:04:26,440 IN HIV COMORBIDITIES, 2559 02:04:26,440 --> 02:04:28,520 COINFECTIONS AND COMPLICATIONS. 2560 02:04:28,520 --> 02:04:31,480 AND THIS ONE IS GOING TO USE A 2561 02:04:31,480 --> 02:04:34,680 DP1 CLINICAL TRIAL OPTIONAL 2562 02:04:34,680 --> 02:04:39,760 MECHANISM. 2563 02:04:39,760 --> 02:04:42,080 SO OUR DESIRE IS TO SIGN ON AS A 2564 02:04:42,080 --> 02:04:45,800 SECONDARY INSTITUTE ON A 2565 02:04:45,800 --> 02:04:47,640 TRANS-NIH DP1 PROGRAM 2566 02:04:47,640 --> 02:04:48,840 ANNOUNCEMENT INITIATIVE THAT'S 2567 02:04:48,840 --> 02:04:52,240 LED BY THE NIDDK, DIABETES, 2568 02:04:52,240 --> 02:04:53,160 DIGESTIVE DISEASE AND KIDNEY 2569 02:04:53,160 --> 02:04:53,680 INSTITUTE. 2570 02:04:53,680 --> 02:04:57,280 THE GOAL HERE IS TO INCREASE 2571 02:04:57,280 --> 02:04:58,160 FUNDING OPPORTUNITIES TO PROMOTE 2572 02:04:58,160 --> 02:05:00,360 AND SUPPORT CREATIVE EARLY STAGE 2573 02:05:00,360 --> 02:05:03,520 INVESTIGATORS PROPOSING HIGH 2574 02:05:03,520 --> 02:05:03,920 IMPACT POTENTIALLY 2575 02:05:03,920 --> 02:05:06,600 TRANSFORMATIVE RESEARCH ON 2576 02:05:06,600 --> 02:05:08,480 HIV-ASSOCIATED COMORBIDITIES, 2577 02:05:08,480 --> 02:05:11,280 CO-INFECTIONS AND COMPLICATIONS. 2578 02:05:11,280 --> 02:05:12,360 SO THIS ANNOUNCEMENT, THIS 2579 02:05:12,360 --> 02:05:14,120 OPPORTUNITY WAS DEVELOPED 2580 02:05:14,120 --> 02:05:16,000 FOLLOWING A PORTFOLIO ANALYSIS 2581 02:05:16,000 --> 02:05:20,760 OF THE HIV GRANTS AT NHLBI WHICH 2582 02:05:20,760 --> 02:05:22,000 SHOW THE NUMBER OF GRANT 2583 02:05:22,000 --> 02:05:23,160 SUBMISSIONS AND AWARDS FOR THE 2584 02:05:23,160 --> 02:05:24,600 EARLY STAGE INVESTIGATORS IN 2585 02:05:24,600 --> 02:05:26,400 HIV/AIDS HAS BEEN VERY LOW OVER 2586 02:05:26,400 --> 02:05:29,240 THE PAST FEW YEARS, THREE TO 2587 02:05:29,240 --> 02:05:31,280 FOUR R01 GRANTS AWARDED ON 2588 02:05:31,280 --> 02:05:31,840 AVERAGE PER YEAR. 2589 02:05:31,840 --> 02:05:34,160 IN ADDITION, THE ESIs AND 2590 02:05:34,160 --> 02:05:36,320 HIV/AIDS ARE LESS SUCCESSFUL IN 2591 02:05:36,320 --> 02:05:38,640 GETTING R01 AWARDS THAN ESIs 2592 02:05:38,640 --> 02:05:40,600 AND OTHER FIELDS OF RESEARCH. 2593 02:05:40,600 --> 02:05:43,560 SO THIS TREND IS NOT UNIQUE TO 2594 02:05:43,560 --> 02:05:46,080 NHLBI, BUT SEEMS TO BE SIMILAR 2595 02:05:46,080 --> 02:05:47,360 ACROSS OTHER NIH INSTITUTES. 2596 02:05:47,360 --> 02:05:49,800 SO GIVEN THE SMALL NUMBER OF 2597 02:05:49,800 --> 02:05:51,400 JUNIOR INVESTIGATORS PURSUING 2598 02:05:51,400 --> 02:05:53,400 RESEARCH IN HIV/AIDS, THERE ARE 2599 02:05:53,400 --> 02:05:55,680 SOME CONCERNS THAT THE WORKFORCE 2600 02:05:55,680 --> 02:05:57,640 OF RESEARCHERS IN THIS AREA MAY 2601 02:05:57,640 --> 02:05:59,400 BE SLOWLY DECLINING. 2602 02:05:59,400 --> 02:06:01,160 AND SO TO ADDRESS THOSE 2603 02:06:01,160 --> 02:06:04,240 CONCERNS, THIS INITIATIVE WAS 2604 02:06:04,240 --> 02:06:05,560 DEVELOPED, AIMED AT INCREASING 2605 02:06:05,560 --> 02:06:08,600 THE FUNDING OPPORTUNITIES TO 2606 02:06:08,600 --> 02:06:09,600 SUPPORT OBVIOUSLY THE NEXT 2607 02:06:09,600 --> 02:06:11,880 GENERATION OF RESEARCHERS IN 2608 02:06:11,880 --> 02:06:14,160 HIV/AIDS BY ATTRACTING MORE 2609 02:06:14,160 --> 02:06:15,840 ESIs TO SUBMIT GRANT 2610 02:06:15,840 --> 02:06:17,120 APPLICATIONS AND INCREASE THE 2611 02:06:17,120 --> 02:06:18,920 NUMBER OF ESIs DOING WORK IN 2612 02:06:18,920 --> 02:06:20,240 AIDS AND HIV. 2613 02:06:20,240 --> 02:06:22,720 SO WE BELIEVE THAT THIS 2614 02:06:22,720 --> 02:06:24,760 MECHANISM, THIS DP1 MECHANISM IS 2615 02:06:24,760 --> 02:06:27,400 BETTER SUITED FOR THIS KIND OF 2616 02:06:27,400 --> 02:06:28,960 AN APPROACH COMPARED TO THE 2617 02:06:28,960 --> 02:06:31,800 STANDARD R01 MECHANISM TO 2618 02:06:31,800 --> 02:06:35,720 AUTOIMMUNE DRESS CURRENTLY -- 2619 02:06:35,720 --> 02:06:38,360 ADDRESS THE CURRENT PIPELINE 2620 02:06:38,360 --> 02:06:40,440 DOING RESEARCH IN THIS AREA. 2621 02:06:40,440 --> 02:06:42,400 DP1 AWARDS ARE GENERALLY MADE TO 2622 02:06:42,400 --> 02:06:43,720 SUPPORT CREATIVE INVESTIGATORS 2623 02:06:43,720 --> 02:06:45,360 PROPOSING HIGHLY INNOVATIVE AND 2624 02:06:45,360 --> 02:06:46,480 PIONEERING STUDIES. 2625 02:06:46,480 --> 02:06:49,160 THEY'RE NOT RENEWABLE. 2626 02:06:49,160 --> 02:06:50,840 THEY'RE SINGLE PI STUDIES ONLY, 2627 02:06:50,840 --> 02:06:52,480 AND AS SUCH, THEY FOSTER THE 2628 02:06:52,480 --> 02:06:53,560 ESTABLISHMENT OF INDEPENDENT 2629 02:06:53,560 --> 02:06:54,560 RESEARCH PROGRAMS. 2630 02:06:54,560 --> 02:06:57,040 THEY'RE USED IN OUR COMMON FUND 2631 02:06:57,040 --> 02:06:58,720 QUITE FREQUENTLY, OUR PIONEER 2632 02:06:58,720 --> 02:07:01,640 AWARDS AND OTHERS USE THIS 2633 02:07:01,640 --> 02:07:02,000 MECHANISM. 2634 02:07:02,000 --> 02:07:03,720 SO IT'S NOT A NEW MECHANISM, 2635 02:07:03,720 --> 02:07:05,360 IT'S ONE THAT'S BEEN AROUND, BUT 2636 02:07:05,360 --> 02:07:09,000 WE HAVEN'T USED IT MUCH IN OUR 2637 02:07:09,000 --> 02:07:09,760 INITIATIVES, MOSTLY BECAUSE WE 2638 02:07:09,760 --> 02:07:10,960 CAN DO IT THROUGH OTHER MEANS, 2639 02:07:10,960 --> 02:07:13,800 BUT THIS ONE MAY BE A BETTER ONE 2640 02:07:13,800 --> 02:07:15,760 FOR WHERE WE ARE WITH THE AIDS 2641 02:07:15,760 --> 02:07:18,600 PROGRAM RIGHT NOW. 2642 02:07:18,600 --> 02:07:22,120 WE'D LIKE TO FUND UP TO FOUR ESI 2643 02:07:22,120 --> 02:07:24,400 APPLICATIONS AT NHLBI IN EACH OF 2644 02:07:24,400 --> 02:07:26,480 THREE RECEIPT DATES, SO A TOTAL 2645 02:07:26,480 --> 02:07:28,160 OF ABOUT 12 APPLICATIONS IN 2646 02:07:28,160 --> 02:07:31,480 TOTAL, AND THIS WOULD AGAIN BEEF 2647 02:07:31,480 --> 02:07:35,560 UP THE POOL OF NHLBI ESIs 2648 02:07:35,560 --> 02:07:36,440 PERFORMING HIV/AIDS RESEARCH 2649 02:07:36,440 --> 02:07:37,600 BASED ON WHAT WE'VE ALREADY SEEN 2650 02:07:37,600 --> 02:07:39,600 OVER THE PAST FEW YEARS. 2651 02:07:39,600 --> 02:07:42,440 THE BUDGETS WILL BE LIMITED TO 2652 02:07:42,440 --> 02:07:44,520 350K PER YEAR DIRECT COST WITH A 2653 02:07:44,520 --> 02:07:46,600 MAXIMUM OF FIVE YEARS. 2654 02:07:46,600 --> 02:07:50,080 SO THAT PRETTY MUCH SUMMARIZES 2655 02:07:50,080 --> 02:07:51,280 WHERE WE ARE WITH THIS PROGRAM, 2656 02:07:51,280 --> 02:07:53,280 AND I'LL STOP THERE AND TRY TO 2657 02:07:53,280 --> 02:07:57,760 ANSWER QUESTIONS IF YOU HAVE 2658 02:07:57,760 --> 02:08:08,280 THEM, AND CLOSE AT THIS POINT. 2659 02:08:16,840 --> 02:08:19,840 THIS IS ALSO ONE I SHOULD MAKE 2660 02:08:19,840 --> 02:08:21,040 SURE EVERYONE REALIZES WAS 2661 02:08:21,040 --> 02:08:22,240 DEVELOPED BY OUR AIDS TEAM. 2662 02:08:22,240 --> 02:08:24,280 YOU HEARD A LITTLE FROM SHIMEON 2663 02:08:24,280 --> 02:08:25,400 THIS MORNING, SO THIS IS ONE 2664 02:08:25,400 --> 02:08:29,880 THAT WAS DEVELOPED BY A VERY 2665 02:08:29,880 --> 02:08:31,880 ESTABLISHED TEAM OF OUR STAFF IN 2666 02:08:31,880 --> 02:08:33,600 THE NHLBI THAT REALLY HAVE 2667 02:08:33,600 --> 02:08:34,600 INTERFACED WITH THE OFFICE OF 2668 02:08:34,600 --> 02:08:36,880 AIDS RESEARCH TO MAKE SURE THAT 2669 02:08:36,880 --> 02:08:38,960 ALL OF THESE THINGS ALIGN WITH 2670 02:08:38,960 --> 02:08:47,080 ALL OF OUR STRATEGIC PRIORITIES. 2671 02:08:47,080 --> 02:08:48,720 >> IF THERE ARE NO QUESTIONS FOR 2672 02:08:48,720 --> 02:08:50,120 THIS CONCEPT, WE'RE READY TO 2673 02:08:50,120 --> 02:08:51,200 ADVANCE TO THE NEXT ONE. 2674 02:08:51,200 --> 02:08:53,120 I SEE ALL THE VOTES IN DECISION 2675 02:08:53,120 --> 02:08:54,040 LENS. 2676 02:08:54,040 --> 02:08:55,080 >> OKAY. 2677 02:08:55,080 --> 02:08:55,600 VERY GOOD. 2678 02:08:55,600 --> 02:08:56,080 OKAY. 2679 02:08:56,080 --> 02:08:59,280 SO THE LAST ONE THAT THE LUNG 2680 02:08:59,280 --> 02:09:02,360 DIVISION IS LEADING IS NUMBER 2681 02:09:02,360 --> 02:09:02,560 2692. 2682 02:09:02,560 --> 02:09:04,880 THIS ONE IS ENTITLED SECONDARY 2683 02:09:04,880 --> 02:09:08,280 PARTICIPATION IN THE RENEWAL OF 2684 02:09:08,280 --> 02:09:09,960 THE TRANS-NIH PROGRAM 2685 02:09:09,960 --> 02:09:10,960 SPECIALIZED CENTER OF RESEARCH 2686 02:09:10,960 --> 02:09:12,560 EXCELLENCE ON SEX DIFFERENCES. 2687 02:09:12,560 --> 02:09:15,520 THIS IS A SCORE PROGRAM. 2688 02:09:15,520 --> 02:09:17,680 IT'S A U54 MECHANISM WHERE 2689 02:09:17,680 --> 02:09:18,640 CLINICAL TRIALS ARE OPTIONAL. 2690 02:09:18,640 --> 02:09:21,960 NOW THIS PROGRAM IS LED BY THE 2691 02:09:21,960 --> 02:09:23,240 OFFICE OF RESEARCH ON WOMEN'S 2692 02:09:23,240 --> 02:09:24,440 HEALTH, AND AGAIN, I DON'T HAVE 2693 02:09:24,440 --> 02:09:26,120 TO REPEAT MYSELF BY SAYING THAT 2694 02:09:26,120 --> 02:09:29,080 WE HAVE A REALLY TERRIFIC GROUP 2695 02:09:29,080 --> 02:09:32,320 OF STAFF WHO ARE WORKING ACROSS 2696 02:09:32,320 --> 02:09:34,280 NHLBI AS WELL AS WITH THE OFFICE 2697 02:09:34,280 --> 02:09:37,120 OF WOMEN'S HEALTH AND OUR OTHER 2698 02:09:37,120 --> 02:09:38,560 ICs TO REALLY DEVELOP THESE 2699 02:09:38,560 --> 02:09:39,680 TRANS INITIATIVES THAT ARE 2700 02:09:39,680 --> 02:09:41,720 RELEVANT TO ALL OF OUR -- ALL OF 2701 02:09:41,720 --> 02:09:42,840 THE NIH INSTITUTES. 2702 02:09:42,840 --> 02:09:44,360 SO THE CURRENT SCORE PROGRAM, 2703 02:09:44,360 --> 02:09:48,760 THIS IS A RENEWAL, SO THE 2704 02:09:48,760 --> 02:09:49,840 CURRENT ONE LEVERAGES ABOUT 15 2705 02:09:49,840 --> 02:09:51,600 YEARS OF PRIOR INVESTMENT, AND 2706 02:09:51,600 --> 02:09:53,600 REMAINS THE ONLY NIH CENTERS 2707 02:09:53,600 --> 02:09:56,960 PROGRAM SUPPORTING TRANSLATIONAL 2708 02:09:56,960 --> 02:09:57,720 RESEARCH FOCUSED ON SEX 2709 02:09:57,720 --> 02:09:58,040 DIFFERENCES. 2710 02:09:58,040 --> 02:09:59,360 SO THIS RENEWAL SEEKS TO 2711 02:09:59,360 --> 02:10:01,680 CONTINUE THIS PROGRAM FOR AN 2712 02:10:01,680 --> 02:10:03,440 ADDITIONAL FIVE YEARS TO PROMOTE 2713 02:10:03,440 --> 02:10:04,920 RESEARCH IN MAJOR MEDICAL 2714 02:10:04,920 --> 02:10:06,440 CONDITIONS AFFECTING WOMEN IN 2715 02:10:06,440 --> 02:10:07,120 THE U.S. 2716 02:10:07,120 --> 02:10:08,440 SO VERY BROAD. 2717 02:10:08,440 --> 02:10:10,720 THIS IS A TRANS NHLBI INITIATIVE 2718 02:10:10,720 --> 02:10:12,840 UNDER THE UMBRELLA OF THE NHLBI 2719 02:10:12,840 --> 02:10:15,640 WOMEN'S HEALTH WORKING GROUP. 2720 02:10:15,640 --> 02:10:16,360 APPLICATIONS WILL BE ACCEPTED 2721 02:10:16,360 --> 02:10:20,440 FROM ALL THE DIVISIONS AND WILL 2722 02:10:20,440 --> 02:10:21,320 SOLICIT APPLICATIONS ACROSS ALL 2723 02:10:21,320 --> 02:10:22,200 OF OUR MISSION AREAS. 2724 02:10:22,200 --> 02:10:24,200 SO WE THINK THIS IS A VERY 2725 02:10:24,200 --> 02:10:25,200 RELEVANT PROGRAM TO NHLBI AND WE 2726 02:10:25,200 --> 02:10:27,440 THINK WE CAN BENEFIT FROM THIS 2727 02:10:27,440 --> 02:10:29,320 PROGRAM AND WE'LL DO A GOOD JOB 2728 02:10:29,320 --> 02:10:32,520 OF TRYING TO BROADCAST WIDELY 2729 02:10:32,520 --> 02:10:33,040 ITS AVAILABILITY. 2730 02:10:33,040 --> 02:10:37,520 IT'S VERY SIMILAR TO AN NHLBI 2731 02:10:37,520 --> 02:10:39,080 PROJECT PROGRAM WITH A FOCUS ON 2732 02:10:39,080 --> 02:10:42,880 SEX DIFFERENCES AND WOMEN'S 2733 02:10:42,880 --> 02:10:44,520 HEALTH, AND WILL OPERATE AS A 2734 02:10:44,520 --> 02:10:45,920 U54 COOPERATIVE AGREEMENT WITH 2735 02:10:45,920 --> 02:10:47,160 PROGRAM STAFF OVERSIGHT. 2736 02:10:47,160 --> 02:10:48,720 SO THAT'S WHAT DIFFERENTIATES IT 2737 02:10:48,720 --> 02:10:51,640 A BIT FROM THE STANDARD P01. 2738 02:10:51,640 --> 02:10:56,640 APPLICATIONS ARE RESPONSIVE S 2739 02:10:56,640 --> 02:10:58,960 PROGRAM SHOULD INCLUDE AT LEAST 2740 02:10:58,960 --> 02:11:00,720 THREE SYNERGISTIC PROJECTS, A 2741 02:11:00,720 --> 02:11:02,800 CAREER ENHANCEMENT CORE FOR THE 2742 02:11:02,800 --> 02:11:03,840 NEXT GENERATION OF SCIENTISTS IN 2743 02:11:03,840 --> 02:11:05,640 THE STUDY OF SEX DIFFERENCES, 2744 02:11:05,640 --> 02:11:08,040 AND FINALLY AN ADMINISTRATIVE 2745 02:11:08,040 --> 02:11:12,120 CORE TO OVERSEE THE PROJECTS' 2746 02:11:12,120 --> 02:11:13,080 CAREER CORE FUNCTIONS. 2747 02:11:13,080 --> 02:11:13,880 THE PROGRAM AS I MENTIONED 2748 02:11:13,880 --> 02:11:16,120 ALREADY IS LED BY ORWH, AND THEY 2749 02:11:16,120 --> 02:11:18,520 HAVE DETERMINED THAT THIS 2750 02:11:18,520 --> 02:11:20,840 PROGRAM WOULD BENEFIT FROM FIVE 2751 02:11:20,840 --> 02:11:22,040 YEARS OF SUPPORT. 2752 02:11:22,040 --> 02:11:23,920 THE APPLICATIONS CANNOT EXCEED 2753 02:11:23,920 --> 02:11:25,640 $1 MILLION PER YEAR IN DIRECT 2754 02:11:25,640 --> 02:11:26,760 COSTS. 2755 02:11:26,760 --> 02:11:28,600 ORWH WILL SET ASIDE FUNDS TO 2756 02:11:28,600 --> 02:11:31,880 FULLY SUPPORT UP TO THREE U55 2757 02:11:31,880 --> 02:11:34,080 SCORE PROGRAMS, BUT IC 2758 02:11:34,080 --> 02:11:35,400 CO-FUNDING WOULD ALLOW THEM TO 2759 02:11:35,400 --> 02:11:36,480 FUND ADDITIONAL CENTERS. 2760 02:11:36,480 --> 02:11:38,240 SO THAT'S WHERE WE AND OTHERS 2761 02:11:38,240 --> 02:11:39,440 WILL STEP IN. 2762 02:11:39,440 --> 02:11:40,960 WITH THIS SECONDARY 2763 02:11:40,960 --> 02:11:43,480 PARTICIPATION, WE'RE REQUESTING 2764 02:11:43,480 --> 02:11:46,000 TO CO-FUND ONE NHLBI CENTER AT 2765 02:11:46,000 --> 02:11:48,720 50% FOR A TOTAL PROGRAM COST OF 2766 02:11:48,720 --> 02:11:50,120 JUST UNDER $4 MILLION. 2767 02:11:50,120 --> 02:11:52,760 SO AGAIN, VERY FOCUSED ON OUR 2768 02:11:52,760 --> 02:11:54,880 MISSION AREA AND CO-FUNDED WITH 2769 02:11:54,880 --> 02:11:56,280 ORWH, WE THINK THAT THIS IS A 2770 02:11:56,280 --> 02:11:59,680 MODEST INVESTMENT TO ALLOW US TO 2771 02:11:59,680 --> 02:12:03,600 BENEFIT FROM THIS TRANS-NIH 2772 02:12:03,600 --> 02:12:04,480 INITIATIVE. 2773 02:12:04,480 --> 02:12:06,880 IT REFLECTS THE SAME SETASIDE AS 2774 02:12:06,880 --> 02:12:07,880 OUR LAST PARTICIPATION IN THIS 2775 02:12:07,880 --> 02:12:08,200 PROGRAM. 2776 02:12:08,200 --> 02:12:09,520 AS I SAID, IT'S A RENEWAL SO 2777 02:12:09,520 --> 02:12:10,720 THIS WOULD BE NO DIFFERENT THAN 2778 02:12:10,720 --> 02:12:15,080 WHAT WE BASICALLY SPENT IN OUR 2779 02:12:15,080 --> 02:12:17,160 LAST CYCLE, AND IT WOULD BE 2780 02:12:17,160 --> 02:12:18,680 SPENT ONLY IF WE RECEIVE 2781 02:12:18,680 --> 02:12:22,120 MERITORIOUS APPLICATIONS. 2782 02:12:22,120 --> 02:12:23,000 AGAIN, VERY FOCUSED ON THE 2783 02:12:23,000 --> 02:12:23,880 MISSION AREAS OF NHLBI. 2784 02:12:23,880 --> 02:12:28,080 SO WITH THAT, I'LL STOP, SEE IF 2785 02:12:28,080 --> 02:12:29,080 THERE ARE ANY QUESTIONS AND I'LL 2786 02:12:29,080 --> 02:12:32,920 TRY TO DO MY BEST WITH THIS UP . 2787 02:12:32,920 --> 02:12:43,440 SO I'LL LET YOU ALL HAVE AT IT. 2788 02:12:46,240 --> 02:12:48,040 LOOKING FOR HANDS, VOICES OR 2789 02:12:48,040 --> 02:12:53,280 COMMENTS IN CHAT. 2790 02:12:53,280 --> 02:12:57,000 >> NOT SEEING ANYTHING. 2791 02:12:57,000 --> 02:12:59,360 >> SINCE THERE ARE NO COMMENTS, 2792 02:12:59,360 --> 02:13:03,120 IT'S OKAY TO MOVE ON TO THE NEXT 2793 02:13:03,120 --> 02:13:03,360 CONCEPT. 2794 02:13:03,360 --> 02:13:11,400 >> THANK YOU ALL VERY MUCH. 2795 02:13:11,400 --> 02:13:12,840 SO I THINK WE'RE GOING TO TURN 2796 02:13:12,840 --> 02:13:15,160 THIS OVER TO DR. MENSA. 2797 02:13:15,160 --> 02:13:16,680 HE IS GOING TO TAKE US THROUGH 2798 02:13:16,680 --> 02:13:18,000 THE NEXT COLLECTION OF 2799 02:13:18,000 --> 02:13:18,680 INITIATIVES. 2800 02:13:18,680 --> 02:13:18,920 GEORGE? 2801 02:13:18,920 --> 02:13:23,000 >> THANKS, JIM. 2802 02:13:23,000 --> 02:13:24,000 THE CENTER FOR TRANSLATIONAL 2803 02:13:24,000 --> 02:13:26,080 RESEARCH AND IMPLEMENTATION 2804 02:13:26,080 --> 02:13:29,800 SCIENCE WILL PRESENT NINE 2805 02:13:29,800 --> 02:13:30,240 CONCEPTS. 2806 02:13:30,240 --> 02:13:32,520 I PROMISE YOU I WILL NOT PRESENT 2807 02:13:32,520 --> 02:13:36,040 AND HAVE YOU VOTE ONE BY ONE FOR 2808 02:13:36,040 --> 02:13:36,440 ALL NINE. 2809 02:13:36,440 --> 02:13:40,600 THEY REALLY REPRESENT THREE 2810 02:13:40,600 --> 02:13:41,960 CLUSTERS OF THREE DISTINCT 2811 02:13:41,960 --> 02:13:45,200 EFFORTS. 2812 02:13:45,200 --> 02:13:46,520 SO I WILL TELL YOU WHEN WE NEED 2813 02:13:46,520 --> 02:13:47,200 TO VOTE. 2814 02:13:47,200 --> 02:13:49,920 THE FIRST ONE IS CONCEPT NUMBER 2815 02:13:49,920 --> 02:13:52,000 2684. 2816 02:13:52,000 --> 02:13:57,360 AND IT'S A REISSUE OF FUNDING 2817 02:13:57,360 --> 02:14:04,240 OPPORTUNITY ANNOUNCEMENT, 2818 02:14:04,240 --> 02:14:05,760 DISSEMINATION AND IMPLEMENTATION 2819 02:14:05,760 --> 02:14:06,120 RESEARCH. 2820 02:14:06,120 --> 02:14:08,640 IT SERVES AS THE PRIMARY 2821 02:14:08,640 --> 02:14:10,280 MECHANISM FOR SUPPORTING 2822 02:14:10,280 --> 02:14:12,760 DISSEMINATION AND IMPLEMENTATION 2823 02:14:12,760 --> 02:14:14,400 OR D & I RESEARCH AT NIH. 2824 02:14:14,400 --> 02:14:16,800 IT IS VERY WELL-KNOWN BY NHLBI, 2825 02:14:16,800 --> 02:14:19,000 EXTRAMURAL RESEARCH 2826 02:14:19,000 --> 02:14:21,640 INVESTIGATORS, AND NHLBI 2827 02:14:21,640 --> 02:14:23,720 LEADERSHIP AND CONTINUED 2828 02:14:23,720 --> 02:14:25,240 PARTICIPATION IN THEIR FUNDING 2829 02:14:25,240 --> 02:14:26,680 OPPORTUNITY ANNOUNCEMENT IS 2830 02:14:26,680 --> 02:14:30,080 CRUCIAL, IN FACT, OUR INSTITUTE 2831 02:14:30,080 --> 02:14:31,160 RECEIVES THE THIRD LARGEST 2832 02:14:31,160 --> 02:14:33,120 NUMBER OF APPLICATIONS TO THIS 2833 02:14:33,120 --> 02:14:33,720 FOA. 2834 02:14:33,720 --> 02:14:35,960 THE GOAL OF THE FUNDING 2835 02:14:35,960 --> 02:14:37,320 OPPORTUNITY ANNOUNCEMENT IS TO 2836 02:14:37,320 --> 02:14:40,240 SUPPORT INNOVATIVE APPROACHES 2837 02:14:40,240 --> 02:14:42,240 FOR IDENTIFYING, UNDERSTANDING, 2838 02:14:42,240 --> 02:14:45,800 AND DEVELOPING STRATEGIES THAT 2839 02:14:45,800 --> 02:14:47,000 WILL STIMULATE THE SUSTAINED 2840 02:14:47,000 --> 02:14:50,560 ADOPTION AND IMPLEMENTATION OF 2841 02:14:50,560 --> 02:14:51,520 EVIDENCE-BASED INTERVENTIONS, 2842 02:14:51,520 --> 02:14:54,880 TOOLS, STRATEGIES AND GUIDELINES 2843 02:14:54,880 --> 02:14:57,440 FOR HEART, LUNG, BLOOD AND SLEEP 2844 02:14:57,440 --> 02:14:58,840 DISEASES AND DISORDERS, 2845 02:14:58,840 --> 02:15:00,040 INCLUDING ESPECIALLY IN 2846 02:15:00,040 --> 02:15:03,200 UNDERSERVED POPULATIONS. 2847 02:15:03,200 --> 02:15:05,920 ALTHOUGH NOT OFTEN EMPHASIZED, 2848 02:15:05,920 --> 02:15:07,880 IT ALSO SUPPORTS 2849 02:15:07,880 --> 02:15:08,480 DEIMPLEMENTATION OF THE 2850 02:15:08,480 --> 02:15:11,720 DEVELOPMENT OF STRATEGIES TO 2851 02:15:11,720 --> 02:15:13,280 STOP OR REDUCE THE USE OF 2852 02:15:13,280 --> 02:15:16,440 INTERVENTIONS THAT ARE 2853 02:15:16,440 --> 02:15:17,880 INEFFECTIVE, UNPROVEN, LOW VALUE 2854 02:15:17,880 --> 02:15:19,520 OR HARMFUL. 2855 02:15:19,520 --> 02:15:22,120 IN ADDITION, STUDIES TO ADVANCE 2856 02:15:22,120 --> 02:15:25,200 DISSEMINATION AND IMPLEMENTATION 2857 02:15:25,200 --> 02:15:26,720 RESEARCH METHODOLOGY, FRAME 2858 02:15:26,720 --> 02:15:28,160 WORKS AND METHODS OF 2859 02:15:28,160 --> 02:15:29,360 IMPLEMENTATION OUTCOMES ARE 2860 02:15:29,360 --> 02:15:29,640 ENCOURAGED. 2861 02:15:29,640 --> 02:15:32,640 AS YOU KNOW, D & I RESEARCH 2862 02:15:32,640 --> 02:15:34,240 PROVIDES RIGOROUS APPROACHES TO 2863 02:15:34,240 --> 02:15:36,480 BRIDGE THE GAP BETWEEN THE 2864 02:15:36,480 --> 02:15:38,320 EVIDENCE FROM RESEARCH FROM 2865 02:15:38,320 --> 02:15:40,920 PRACTICE AND FROM POLICY BY 2866 02:15:40,920 --> 02:15:44,120 BUILDING A KNOWLEDGE BASE ABOUT 2867 02:15:44,120 --> 02:15:45,200 HOW HEALTH INFORMATION, 2868 02:15:45,200 --> 02:15:47,080 EFFECTIVE INTERVENTIONS AND NEW 2869 02:15:47,080 --> 02:15:49,240 CLINICAL PRACTICE GUIDELINES AND 2870 02:15:49,240 --> 02:15:51,960 TOOLS ARE INTEGRATED INTO 2871 02:15:51,960 --> 02:15:52,960 ROUTINE CLINICAL AND PUBLIC 2872 02:15:52,960 --> 02:15:54,360 HEALTH SETTINGS. 2873 02:15:54,360 --> 02:15:57,000 AND FOR CONTINUOUS IMPROVEMENT 2874 02:15:57,000 --> 02:15:59,000 IN THE DELIVERY OF HIGH QUALITY 2875 02:15:59,000 --> 02:16:01,840 HEALTHCARE IN A BROAD RANGE OF 2876 02:16:01,840 --> 02:16:02,440 SETTINGS. 2877 02:16:02,440 --> 02:16:04,440 THIS FOA IS CURRENTLY THE MAIN 2878 02:16:04,440 --> 02:16:06,760 MECHANISM THAT IS SPECIFICALLY 2879 02:16:06,760 --> 02:16:08,400 DESIGNED FOR 2880 02:16:08,400 --> 02:16:09,480 INVESTIGATOR-INITIATED 2881 02:16:09,480 --> 02:16:10,800 DISSEMINATION AND IMPLEMENTATION 2882 02:16:10,800 --> 02:16:11,320 RESEARCH. 2883 02:16:11,320 --> 02:16:13,200 ALMOST ALL APPLICATIONS RECEIVED 2884 02:16:13,200 --> 02:16:16,160 THROUGH THIS FOA ARE REVIEWED BY 2885 02:16:16,160 --> 02:16:17,600 A STUDY SECTION THAT IS 2886 02:16:17,600 --> 02:16:19,120 DEDICATED TO DISSEMINATION AND 2887 02:16:19,120 --> 02:16:23,480 IMPLEMENTATION RESEARCH WITH THE 2888 02:16:23,480 --> 02:16:24,240 REQUISITE EXPERTISE. 2889 02:16:24,240 --> 02:16:25,560 WE ARE CURRENTLY IN THE MIDDLE 2890 02:16:25,560 --> 02:16:28,440 OF A FORMAL PORTFOLIO ANALYSIS 2891 02:16:28,440 --> 02:16:31,400 WITH THE SUPPORT OF THE NHLBI 2892 02:16:31,400 --> 02:16:32,800 OFFICE OF PLANNING, ANALYTICS 2893 02:16:32,800 --> 02:16:34,760 AND EVALUATION, AND WE HOPE TO 2894 02:16:34,760 --> 02:16:36,960 SHARE THE PROGRAM PRODUCTIVITY 2895 02:16:36,960 --> 02:16:38,600 AND OTHER KEY FINDINGS WITH 2896 02:16:38,600 --> 02:16:42,080 COUNCIL IN THE NEAR FUTURE. 2897 02:16:42,080 --> 02:16:44,600 BUT TO GIVE YOU A FLAVOR OF SOME 2898 02:16:44,600 --> 02:16:46,280 OF THE FUNDABLE APPLICATIONS 2899 02:16:46,280 --> 02:16:50,840 RECEIVED IN THIS COUNCIL, THERE 2900 02:16:50,840 --> 02:16:52,280 IS AN APPLICATION ON INTEGRATED 2901 02:16:52,280 --> 02:16:55,360 RESPONSE PROGRAM TO ASTHMA IN 2902 02:16:55,360 --> 02:16:56,840 PUERTO RICO, THERE IS AN 2903 02:16:56,840 --> 02:16:58,720 APPLICATION ON HOW TO OPTIMIZE 2904 02:16:58,720 --> 02:17:04,200 THE IMPLEMENTATION OF MULTILEVEL 2905 02:17:04,200 --> 02:17:06,160 INTERVENTIONS IN CLINICS FOR 2906 02:17:06,160 --> 02:17:07,480 PEDIATRIC HYPERTENSION IN 2907 02:17:07,480 --> 02:17:09,320 COMMUNITY HEALTH CENTERS IN 2908 02:17:09,320 --> 02:17:12,840 CHICAGO, AND ONE FROM ABROAD, 2909 02:17:12,840 --> 02:17:14,680 HOW WE ACCELERATE THE DELIVERY 2910 02:17:14,680 --> 02:17:16,440 OF RHEUMATIC HEART DISEASE 2911 02:17:16,440 --> 02:17:17,520 PREVENTION INTERVENTIONS IN 2912 02:17:17,520 --> 02:17:18,880 UGANDA. 2913 02:17:18,880 --> 02:17:20,120 I'LL PAUSE HERE TO SEE IF YOU 2914 02:17:20,120 --> 02:17:23,760 HAVE ANY QUESTIONS, COMMENTS OR 2915 02:17:23,760 --> 02:17:34,120 SUGGESTIONS FOR US. 2916 02:17:34,640 --> 02:17:37,640 AND AGAIN, I WILL REITERATE WHAT 2917 02:17:37,640 --> 02:17:38,960 DR. MOEN HAS SAID, YOUR COMMENTS 2918 02:17:38,960 --> 02:17:41,480 REALLY ARE VERY, VERY VALUABLE 2919 02:17:41,480 --> 02:17:42,240 TO US. 2920 02:17:42,240 --> 02:17:45,440 ESPECIALLY AS WE GO INTO 2921 02:17:45,440 --> 02:17:55,840 EXECUTION OF THESE PROGRAMS. 2922 02:17:55,840 --> 02:17:57,040 JEN, I DON'T SEE ANYTHING IN THE 2923 02:17:57,040 --> 02:17:59,520 CHAT. 2924 02:17:59,520 --> 02:18:04,240 SO I'LL WAIT TO HEAR FROM YOU. 2925 02:18:04,240 --> 02:18:05,760 >> I'LL PAUSE FOR A MOMENT. 2926 02:18:05,760 --> 02:18:06,720 THERE'S ONE OR TWO 2927 02:18:06,720 --> 02:18:07,520 COUNCILMEMBERS WHO ARE STILL 2928 02:18:07,520 --> 02:18:14,000 ADDING THEIR VOTES. 2929 02:18:14,000 --> 02:18:15,280 THEY HAVE NOW COMPLETED THEM AND 2930 02:18:15,280 --> 02:18:16,720 WE CAN MOVE ON TO THE NEXT 2931 02:18:16,720 --> 02:18:16,960 CONCEPT. 2932 02:18:16,960 --> 02:18:20,320 >> GREAT. 2933 02:18:20,320 --> 02:18:24,920 THE NEXT CONCEPT IS ACTUALLY A 2934 02:18:24,920 --> 02:18:27,240 CLUSTER, AND BEFORE I BEGIN, I 2935 02:18:27,240 --> 02:18:31,560 SHOULD REALLY RECOGNIZE THE 2936 02:18:31,560 --> 02:18:33,760 OUTSTANDING WORK DONE BY BECKY 2937 02:18:33,760 --> 02:18:35,400 WILLIAMS, WHO IS NOW NHLBI 2938 02:18:35,400 --> 02:18:37,360 GLOBAL HEALTH RESEARCH PROGRAM 2939 02:18:37,360 --> 02:18:39,360 DIRECTOR, AND SEVERAL KEY STAFF 2940 02:18:39,360 --> 02:18:42,400 MEMBERS FROM ACROSS OUR NHLBI 2941 02:18:42,400 --> 02:18:43,840 DIVISIONS, INCLUDING OUR 2942 02:18:43,840 --> 02:18:47,880 DIVISION OF EXTRAMURAL RESEARCH 2943 02:18:47,880 --> 02:18:48,680 ACTIVITIES, AND ALSO A BIG THANK 2944 02:18:48,680 --> 02:18:50,240 YOU TO THE LEADERSHIP AND STAFF 2945 02:18:50,240 --> 02:18:51,920 OF THE FOGARTY INTERNATIONAL 2946 02:18:51,920 --> 02:18:56,400 CENTER, WHO HAVE HELPED MAKE 2947 02:18:56,400 --> 02:18:57,400 GLOBAL HEALTH PROGRAMS 2948 02:18:57,400 --> 02:18:57,840 SUCCESSFUL. 2949 02:18:57,840 --> 02:18:59,800 I'LL NOW PRESENT THREE RELATED 2950 02:18:59,800 --> 02:19:02,760 CONCEPTS FOR COUNCIL'S 2951 02:19:02,760 --> 02:19:05,520 CONSIDERATION OF NHLBI SECONDARY 2952 02:19:05,520 --> 02:19:06,800 PARTICIPATION IN THE NIH-WIDE 2953 02:19:06,800 --> 02:19:09,560 GLOBAL HEALTH RESEARCH CAPACITY 2954 02:19:09,560 --> 02:19:10,160 BUILDING. 2955 02:19:10,160 --> 02:19:11,400 THIS IS A FUNDING OPPORTUNITY 2956 02:19:11,400 --> 02:19:12,800 ANNOUNCEMENT ISSUED BY THE 2957 02:19:12,800 --> 02:19:18,600 FOGARTY CENTER. 2958 02:19:18,600 --> 02:19:19,720 EACH OF THE CONCEPTS REQUIRES A 2959 02:19:19,720 --> 02:19:20,800 SEPARATE VOTE, HOWEVER, THESE 2960 02:19:20,800 --> 02:19:22,200 THREE THAT I'M PRESENTING NOW 2961 02:19:22,200 --> 02:19:25,400 ARE RELATED TO TWO GLOBAL HEALTH 2962 02:19:25,400 --> 02:19:27,160 RESEARCH CAPACITY BUILDING 2963 02:19:27,160 --> 02:19:30,080 PROGRAMS THAT ARE CRUCIAL FOR 2964 02:19:30,080 --> 02:19:31,960 BUILDING A PIPELINE FROM 2965 02:19:31,960 --> 02:19:34,080 TRAINING TO INDEPENDENCE FOR 2966 02:19:34,080 --> 02:19:36,560 EARLY CAREER SCIENTISTS IN LOW 2967 02:19:36,560 --> 02:19:39,400 AND MIDDLE INCOME COUNTRIES. 2968 02:19:39,400 --> 02:19:41,920 I'LL FIRST DESCRIBE THE 2969 02:19:41,920 --> 02:19:44,040 INSTITUTIONAL D43 INITIATIVE, 2970 02:19:44,040 --> 02:19:46,960 THAT'S CONCEPT NUMBER 2677, 2971 02:19:46,960 --> 02:19:50,680 WHICH IS ALSO KNOWN AS THE NCD 2972 02:19:50,680 --> 02:19:51,840 LIFESPAN, THE CHRONIC 2973 02:19:51,840 --> 02:19:53,280 NON-COMMUNICABLE DISEASE AND 2974 02:19:53,280 --> 02:19:55,240 DISORDERS ACROSS THE LIFESPAN. 2975 02:19:55,240 --> 02:19:56,360 AND I'LL ASK YOU TO VOTE ON 2976 02:19:56,360 --> 02:19:57,640 THAT. 2977 02:19:57,640 --> 02:20:01,600 I WILL THEN DESCRIBE THE RELATED 2978 02:20:01,600 --> 02:20:04,320 INDIVIDUAL K43s WITHIN THE 2979 02:20:04,320 --> 02:20:05,680 EMERGING GLOBAL LEADER PROGRAM, 2980 02:20:05,680 --> 02:20:11,680 AND THERE ARE TWO OF THEM. 2981 02:20:11,680 --> 02:20:14,920 NUMBER 2879, AND 2878. 2982 02:20:14,920 --> 02:20:16,240 AND I'LL REMIND YOU WHICH ONES 2983 02:20:16,240 --> 02:20:18,680 THEY ARE. 2984 02:20:18,680 --> 02:20:22,400 SO FIRST THE NCD LIFESPAN. 2985 02:20:22,400 --> 02:20:26,000 THE PURPOSE OF THE 2986 02:20:26,000 --> 02:20:27,600 D43 INSTITUTIONAL NCD LIFESPAN 2987 02:20:27,600 --> 02:20:28,840 INITIATIVE IS TO SUPPORT 2988 02:20:28,840 --> 02:20:29,840 COLLABORATIVE RESEARCH TRAINING 2989 02:20:29,840 --> 02:20:32,560 BETWEEN INSTITUTIONS IN THE U.S. 2990 02:20:32,560 --> 02:20:34,080 AND THOSE IN LOW AND MIDDLE 2991 02:20:34,080 --> 02:20:36,920 INCOME COUNTRIES. 2992 02:20:36,920 --> 02:20:38,240 AND HELP SUSTAINABLY STRENGTHEN 2993 02:20:38,240 --> 02:20:41,080 THE CAPACITY OF LOW AND MIDDLE 2994 02:20:41,080 --> 02:20:42,160 INCOME COUNTRY INSTITUTION 2995 02:20:42,160 --> 02:20:43,360 INVESTIGATORS SO THAT THEY CAN 2996 02:20:43,360 --> 02:20:47,120 CONDUCT RESEARCH ON NCDs. 2997 02:20:47,120 --> 02:20:52,360 THIS INITIATIVE AIMS TO TRAIN 2998 02:20:52,360 --> 02:20:53,680 LOCAL IN-COUNTRY EXPERTS TO 2999 02:20:53,680 --> 02:20:55,760 CONDUCT RESEARCH ON CHRONIC 3000 02:20:55,760 --> 02:20:56,960 NON-COMMUNICABLE DISEASES AND 3001 02:20:56,960 --> 02:20:58,600 DISORDERS WITH THE ULTIMATE GOAL 3002 02:20:58,600 --> 02:21:02,240 OF IMPLEMENTING EVIDENCE-BASED 3003 02:21:02,240 --> 02:21:03,520 INTERVENTIONS RELEVANT TO THEIR 3004 02:21:03,520 --> 02:21:05,920 OWN COUNTRY SETTINGS. 3005 02:21:05,920 --> 02:21:08,080 AS YOU HEARD FROM DR. GIBBONS 3006 02:21:08,080 --> 02:21:10,080 EARLIER THIS MORNING, CHRONIC 3007 02:21:10,080 --> 02:21:11,720 NON-COMMUNICABLE DISEASES WITHIN 3008 02:21:11,720 --> 02:21:13,640 OUR MISSION AREA ARE STEADILY 3009 02:21:13,640 --> 02:21:15,760 INCREASING AROUND THE WORLD, 3010 02:21:15,760 --> 02:21:17,320 INCLUDING IN LOW AND MIDDLE 3011 02:21:17,320 --> 02:21:20,240 INCOME COUNTRIES, AND THEY 3012 02:21:20,240 --> 02:21:21,320 ACCOUNT FOR MORE THAN HALF OF 3013 02:21:21,320 --> 02:21:22,880 THE EXPENDITURES FOR HEALTHCARE 3014 02:21:22,880 --> 02:21:27,480 AND MORE THAN 60% OF THE 3015 02:21:27,480 --> 02:21:28,120 DISABILITY-ADJUSTED LIFE YEARS 3016 02:21:28,120 --> 02:21:31,520 IN THESE COUNTRIES. 3017 02:21:31,520 --> 02:21:33,240 THEY'VE ENDORSED A GLOBAL ACTION 3018 02:21:33,240 --> 02:21:34,200 PLAN FOR THE PREVENTION AND 3019 02:21:34,200 --> 02:21:37,000 CONTROL OF THESE DISEASES, AND 3020 02:21:37,000 --> 02:21:38,200 IT INCLUDES PROMOTION AND 3021 02:21:38,200 --> 02:21:41,040 SUPPORT OF NATIONAL CAPACITY FOR 3022 02:21:41,040 --> 02:21:43,240 HIGH QUALITY RESEARCH AND HEALTH 3023 02:21:43,240 --> 02:21:45,920 SYSTEMS DEVELOPMENT. 3024 02:21:45,920 --> 02:21:47,280 THIS INITIATIVE SUPPORTS 3025 02:21:47,280 --> 02:21:49,000 MERITORIOUS TRAINING PROGRAMS 3026 02:21:49,000 --> 02:21:51,520 THAT CAN SUSTAINABLY STRENGTHEN 3027 02:21:51,520 --> 02:21:53,360 HEART, LUNG AND BLOOD AND SLEEP 3028 02:21:53,360 --> 02:21:55,800 RESEARCH CAPACITY IN LOW AND 3029 02:21:55,800 --> 02:21:58,760 MIDDLE INCOME COUNTRIES AND IN 3030 02:21:58,760 --> 02:22:01,360 RELATED INSTITUTIONS. 3031 02:22:01,360 --> 02:22:05,360 NHLBI PARTICIPATED IN THE LAST 3032 02:22:05,360 --> 02:22:09,440 ANNOUNCEMENT, PAR18901 IN AUGUS. 3033 02:22:09,440 --> 02:22:11,760 OF THE 21 NHLBI-RELATED 3034 02:22:11,760 --> 02:22:13,840 APPLICATIONS SUBMITTED, 11 WERE 3035 02:22:13,840 --> 02:22:15,800 SCORED AND THREE HIGHLY 3036 02:22:15,800 --> 02:22:17,760 MERITORIOUS APPLICATIONS WERE 3037 02:22:17,760 --> 02:22:21,160 SELECTED FOR CO-FUNDING 3038 02:22:21,160 --> 02:22:22,360 CONSIDERATIONS. 3039 02:22:22,360 --> 02:22:23,560 THE THREE HIGHLY MERITORIOUS 3040 02:22:23,560 --> 02:22:24,560 APPLICATIONS, JUST TO GIVE YOU A 3041 02:22:24,560 --> 02:22:26,400 FLAVOR OF THESE, FOCUSED ON 3042 02:22:26,400 --> 02:22:28,040 BUILDING SUSTAINABLE AND 3043 02:22:28,040 --> 02:22:33,320 COLLABORATIVE RESEARCH TRAINING 3044 02:22:33,320 --> 02:22:35,600 INFRASTRUCTURE IN THE CARIBBEAN, 3045 02:22:35,600 --> 02:22:39,080 IN CENTRAL AMERICA, AND SOUTH 3046 02:22:39,080 --> 02:22:40,120 AMERICA. 3047 02:22:40,120 --> 02:22:43,600 IMPORTANTLY, WITHOUT NHLBI'S 3048 02:22:43,600 --> 02:22:46,240 PARTICIPATION, CRITICAL GLOBAL 3049 02:22:46,240 --> 02:22:47,640 HEART, LUNG, BLOOD, SLEEP 3050 02:22:47,640 --> 02:22:48,600 RESEARCH PROGRAMS LIKE THESE 3051 02:22:48,600 --> 02:22:51,120 WOULD NOT BE SUPPORTED DUE TO 3052 02:22:51,120 --> 02:22:52,120 FOGARTY'S LIMITED BUDGET THAT 3053 02:22:52,120 --> 02:22:54,280 NOW FOCUSES ONLY ON 3054 02:22:54,280 --> 02:22:57,720 CROSS-CUTTING HEALTH RESEARCH 3055 02:22:57,720 --> 02:22:58,480 PRIORITIES. 3056 02:22:58,480 --> 02:22:59,560 I'LL PAUSE HERE AND ENTERTAIN 3057 02:22:59,560 --> 02:23:01,720 ANY QUESTIONS OR COMMENTS AND 3058 02:23:01,720 --> 02:23:09,000 SUGGESTIONS YOU HAVE FOR US. 3059 02:23:09,000 --> 02:23:12,000 >> DR. MENSAH, I HAD A QUESTION 3060 02:23:12,000 --> 02:23:13,200 RELATED TO -- YOU SAID THIS WAS 3061 02:23:13,200 --> 02:23:14,760 LINKED WITH TWO OTHERS. 3062 02:23:14,760 --> 02:23:16,520 WHAT ARE THE OTHER TWO 3063 02:23:16,520 --> 02:23:16,840 COMPONENTS? 3064 02:23:16,840 --> 02:23:20,640 >> YES. 3065 02:23:20,640 --> 02:23:28,080 SO THE 2878 AND 2879 ARE THE D4R 3066 02:23:28,080 --> 02:23:31,520 AWARDS. 3067 02:23:31,520 --> 02:23:32,840 THE PURPOSE OF THE EMERGING 3068 02:23:32,840 --> 02:23:36,760 GLOBAL LEADER AWARD IS TO 3069 02:23:36,760 --> 02:23:39,600 PROVIDE RESEARCH SUPPORT AND 3070 02:23:39,600 --> 02:23:40,720 PROTECTED TIME ABOUT THREE TO 3071 02:23:40,720 --> 02:23:42,400 FIVE YEARS TO EARLY CAREER 3072 02:23:42,400 --> 02:23:43,440 SCIENTISTS FROM THE LOW AND 3073 02:23:43,440 --> 02:23:45,520 MIDDLE INCOME COUNTRIES WHO HOLD 3074 02:23:45,520 --> 02:23:47,720 JUNIOR FACULTY POSITIONS IN 3075 02:23:47,720 --> 02:23:49,960 ORDER TO AFFORD THEM THE TIME TO 3076 02:23:49,960 --> 02:23:53,960 DO RESEARCH. 3077 02:23:53,960 --> 02:23:57,880 2878 AND 2879, ONE BEING 3078 02:23:57,880 --> 02:24:02,480 CLINICAL TRIAL REQUIRED AND 3079 02:24:02,480 --> 02:24:03,320 CLINICAL TRIAL NOT ALLOWED. 3080 02:24:03,320 --> 02:24:13,560 >> THANK YOU. 3081 02:24:16,920 --> 02:24:19,880 >> AGAIN, 2878 REQUIRES A 3082 02:24:19,880 --> 02:24:21,960 CLINICAL TRIAL. 3083 02:24:21,960 --> 02:24:23,320 2879 DOES NOT ALLOW CLINICAL 3084 02:24:23,320 --> 02:24:33,480 TRIALS. 3085 02:24:51,880 --> 02:24:53,000 I DON'T SEE ANY QUESTIONS IN THE 3086 02:24:53,000 --> 02:24:54,320 CHAT BOX SO I'LL WAIT FOR YOUR 3087 02:24:54,320 --> 02:24:54,560 SIGNAL. 3088 02:24:54,560 --> 02:24:57,160 >> ALL THE VOTES ARE IN FOR 3089 02:24:57,160 --> 02:24:59,120 2677. 3090 02:24:59,120 --> 02:25:02,960 WAITING FOR THE ADDITIONAL VOTE 3091 02:25:02,960 --> 02:25:13,280 FOR 2678 AND 2679. 3092 02:25:22,720 --> 02:25:24,320 I HAVE NEARLY ALL THE VOTES FOR 3093 02:25:24,320 --> 02:25:25,040 ALL THREE CONCEPTS. 3094 02:25:25,040 --> 02:25:26,600 I'LL PAUSE HERE TO ALLOW THE 3095 02:25:26,600 --> 02:25:37,080 REMAINING VOTES TO COME IN. 3096 02:25:38,280 --> 02:25:39,720 WE HAVE ALL OF THEM AND CAN 3097 02:25:39,720 --> 02:25:41,280 PROCEED TO THE NEXT CONCEPT. 3098 02:25:41,280 --> 02:25:42,240 >> GREAT. 3099 02:25:42,240 --> 02:25:44,520 THANKS, JEN. 3100 02:25:44,520 --> 02:25:47,120 I WILL PRESENT FIVE CONCEPTS, 3101 02:25:47,120 --> 02:25:48,680 BECAUSE THEY ARE ALL RELATED TO 3102 02:25:48,680 --> 02:25:51,840 THE GLOBAL ALLIANCE FOR CHRONIC 3103 02:25:51,840 --> 02:25:52,560 DISEASES MULTI-MORBIDITY 3104 02:25:52,560 --> 02:25:54,480 PROGRAM. 3105 02:25:54,480 --> 02:25:56,680 YOU WILL RECALL EARLIER THIS 3106 02:25:56,680 --> 02:25:58,200 MORNING, DR. GIBBONS SHOWED YOU 3107 02:25:58,200 --> 02:26:01,480 A SLIDE OF THE GECD PROGRAM THAT 3108 02:26:01,480 --> 02:26:06,200 HAD FUNDING CALLS FOR 3109 02:26:06,200 --> 02:26:07,400 HYPERTENSION, FUNDING CALLS FOR 3110 02:26:07,400 --> 02:26:08,840 DIABETES, FOR MENTAL HEALTH, FOR 3111 02:26:08,840 --> 02:26:09,280 CANCER. 3112 02:26:09,280 --> 02:26:13,880 WE THINK WE'VE MADE SUBSTANTIAL 3113 02:26:13,880 --> 02:26:15,040 IMPROVEMENT BY MOVING AWAY FROM 3114 02:26:15,040 --> 02:26:18,760 THE SINGLE DISEASE AND SINGLE 3115 02:26:18,760 --> 02:26:20,720 RISK FACTOR CONCEPT THAT COMES 3116 02:26:20,720 --> 02:26:24,560 OUT ONE PER FUNDING CALL INTO 3117 02:26:24,560 --> 02:26:26,840 CLUSTERS THAT SHOW THE THEMES 3118 02:26:26,840 --> 02:26:31,400 AND FOCAL AREAS OF RESEARCH 3119 02:26:31,400 --> 02:26:35,400 THREE YEARS AT A TIME, AND ALSO 3120 02:26:35,400 --> 02:26:37,600 IMPORTANTLY, THEMES THAT ADDRESS 3121 02:26:37,600 --> 02:26:38,240 MULTI-MORBIDITY RATHER THAN 3122 02:26:38,240 --> 02:26:40,000 SINGLE RISK FACTORS AND SINGLE 3123 02:26:40,000 --> 02:26:40,760 DISEASES. 3124 02:26:40,760 --> 02:26:43,680 SO IN THESE FIVE CONCEPTS, I'LL 3125 02:26:43,680 --> 02:26:45,560 TELL YOU -- I'LL FIRST GIVE YOU 3126 02:26:45,560 --> 02:26:47,320 A BACKGROUND AND THEN TELL YOU 3127 02:26:47,320 --> 02:26:52,120 THE CONCEPT NUMBER AND THE THEME 3128 02:26:52,120 --> 02:26:53,320 IT ADDRESSES AND THE YEARS FOR 3129 02:26:53,320 --> 02:26:54,320 WHICH THEY'RE GOING TO BE 3130 02:26:54,320 --> 02:26:55,080 FUNDED. 3131 02:26:55,080 --> 02:26:59,160 EACH OF THE CONCEPTS REQUIRES A 3132 02:26:59,160 --> 02:27:00,360 SEPARATE VOTE. 3133 02:27:00,360 --> 02:27:02,600 HOWEVER, THEY'RE ALL RELATED TO 3134 02:27:02,600 --> 02:27:05,120 THE NIH-WIDE GLOBAL ALLIANCE FOR 3135 02:27:05,120 --> 02:27:06,000 CHRONIC DISEASES, WHICH I 3136 02:27:06,000 --> 02:27:09,080 REFERRED TO AS GECD, AND IS THE 3137 02:27:09,080 --> 02:27:10,000 MULTI-MORBIDITY RESEARCH 3138 02:27:10,000 --> 02:27:11,600 PROGRAM. 3139 02:27:11,600 --> 02:27:13,360 THE PROGRAM TARGETS CHRONIC 3140 02:27:13,360 --> 02:27:15,080 DISEASES AND MULTIPLE 3141 02:27:15,080 --> 02:27:16,520 MORBIDITIES IN LOW AND MIDDLE 3142 02:27:16,520 --> 02:27:17,600 INCOME COUNTRIES, AND VERY 3143 02:27:17,600 --> 02:27:20,680 IMPORTANTLY FOR THE FIRST TIME, 3144 02:27:20,680 --> 02:27:22,640 AMERICAN INDIAN AND ALASKA 3145 02:27:22,640 --> 02:27:23,960 NATIVE POPULATION IN THE UNITED 3146 02:27:23,960 --> 02:27:25,280 STATES. 3147 02:27:25,280 --> 02:27:27,560 I'LL PROVIDE AN OVERVIEW NEXT 3148 02:27:27,560 --> 02:27:30,640 AND THEN ASK FOR YOUR VOTE ON 3149 02:27:30,640 --> 02:27:32,720 THE CLUSTERS OF THE CONCEPTS. 3150 02:27:32,720 --> 02:27:37,960 THE PRIMARY OBJECTIVE OF THE NIH 3151 02:27:37,960 --> 02:27:40,600 WIDE GECD PROGRAM IS TO SUPPORT 3152 02:27:40,600 --> 02:27:41,560 IMPLEMENTATION RESEARCH THAT IS 3153 02:27:41,560 --> 02:27:43,520 FOCUSED ON ADDRESSING COMMON 3154 02:27:43,520 --> 02:27:45,040 RISK FACTORS FOR 3155 02:27:45,040 --> 02:27:46,680 NON-COMMUNICABLE DISEASES IN LOW 3156 02:27:46,680 --> 02:27:50,880 AND MIDDLE INCOME COUNTRIES AND 3157 02:27:50,880 --> 02:27:52,080 AMERICAN INDIAN AND ALASKA 3158 02:27:52,080 --> 02:27:53,280 NATIVE AND TRIBAL NATION 3159 02:27:53,280 --> 02:27:56,440 POPULATIONS IN THE U.S. 3160 02:27:56,440 --> 02:27:59,720 NOW, IN OTHER COUNTRIES THAT ARE 3161 02:27:59,720 --> 02:28:01,280 PARTNERS WITH US, SUCH AS 3162 02:28:01,280 --> 02:28:02,760 CANADA, AUSTRALIA AND NEW 3163 02:28:02,760 --> 02:28:04,320 ZEALAND, THEY'VE ALSO AGREED TO 3164 02:28:04,320 --> 02:28:07,800 FOCUS RESEARCH FUNDING ON 3165 02:28:07,800 --> 02:28:09,360 INDIGENOUS AND FIRST NATION 3166 02:28:09,360 --> 02:28:11,320 PEOPLES IN THEIR COUNTRIES. 3167 02:28:11,320 --> 02:28:13,800 THIS INITIATIVE IN COLLABORATION 3168 02:28:13,800 --> 02:28:16,880 WITH PARTICIPATING NIH ICs 3169 02:28:16,880 --> 02:28:19,080 SUPPORT INNOVATIVE APPROACHES TO 3170 02:28:19,080 --> 02:28:20,960 IDENTIFY, TO UNDERSTAND, 3171 02:28:20,960 --> 02:28:23,320 DEVELOP, AND IMPLEMENT 3172 02:28:23,320 --> 02:28:25,960 STRATEGIES FOR OVERCOMING 3173 02:28:25,960 --> 02:28:28,360 BARRIERS TO THE ADOPTION, 3174 02:28:28,360 --> 02:28:29,920 ADAPTATION, THE INTEGRATION AND 3175 02:28:29,920 --> 02:28:32,880 THE SCALEUP AND SPREAD AND 3176 02:28:32,880 --> 02:28:35,600 SUSTAINMENT OF EVIDENCE-BASED 3177 02:28:35,600 --> 02:28:37,880 INNOVATIONS, TOOLS, POLICIES, 3178 02:28:37,880 --> 02:28:40,320 STRATEGIES AND GUIDELINES. 3179 02:28:40,320 --> 02:28:41,800 STUDIES THAT ADVANCE 3180 02:28:41,800 --> 02:28:43,360 DISSEMINATION AND IMPLEMENTATION 3181 02:28:43,360 --> 02:28:45,440 RESEARCH METHODS AND MEASURES 3182 02:28:45,440 --> 02:28:47,000 AND THOSE THAT ENABLE 3183 02:28:47,000 --> 02:28:49,240 INCORPORATION OF DIGITAL 3184 02:28:49,240 --> 02:28:53,320 INNOVATION TOOLS ARE ENCOURAGED. 3185 02:28:53,320 --> 02:28:56,080 ESTABLISHED IN 2009, THE GECD IS 3186 02:28:56,080 --> 02:28:58,120 AN ALLIANCE OF AROUND 15 HEALTH 3187 02:28:58,120 --> 02:28:59,880 RESEARCH FUNDING AGENCIES FROM 3188 02:28:59,880 --> 02:29:02,520 AROUND THE WORLD THAT DEVELOP 3189 02:29:02,520 --> 02:29:03,840 AND FACILITATE INNOVATIVE 3190 02:29:03,840 --> 02:29:06,320 RESEARCH COLLABORATIONS BETWEEN 3191 02:29:06,320 --> 02:29:08,400 LOW AND MIDDLE INCOME COUNTRIES, 3192 02:29:08,400 --> 02:29:10,040 AND HIGH INCOME COUNTRIES IN THE 3193 02:29:10,040 --> 02:29:11,160 FIGHT AGAINST THESE CHRONIC 3194 02:29:11,160 --> 02:29:13,560 CONDITIONS. 3195 02:29:13,560 --> 02:29:15,600 NHLBI LEADERSHIP AND 3196 02:29:15,600 --> 02:29:18,920 PARTICIPATION IN THIS PROGRAM IS 3197 02:29:18,920 --> 02:29:22,000 CRUCIAL BECAUSE NEW NIH GECD 3198 02:29:22,000 --> 02:29:24,840 NICHE 3199 02:29:24,840 --> 02:29:26,160 INITIATIVES WILL HELP LEVERAGE 3200 02:29:26,160 --> 02:29:27,760 THE PROOF OF CONCEPT SUCCESSES 3201 02:29:27,760 --> 02:29:30,720 DEMONSTRATED IN EARLIER GECD 3202 02:29:30,720 --> 02:29:32,680 STUDIES WHICH IDENTIFY IDEAL 3203 02:29:32,680 --> 02:29:35,880 STRATEGIES THAT ARE RIGHT FOR 3204 02:29:35,880 --> 02:29:37,080 NATIONAL SCALEUP AND SPREAD. 3205 02:29:37,080 --> 02:29:39,480 THE STRATEGIC INVESTMENTS WE 3206 02:29:39,480 --> 02:29:41,440 MAKE AND NHLBI'S LEADERSHIP 3207 02:29:41,440 --> 02:29:43,760 WOULD LIKELY LEVERAGE ADDITIONAL 3208 02:29:43,760 --> 02:29:45,360 RESOURCES FOR GLOBAL HEALTH 3209 02:29:45,360 --> 02:29:49,840 RESEARCH FROM OTHER GECD 3210 02:29:49,840 --> 02:29:50,720 INVESTMENTS AND OTHER 3211 02:29:50,720 --> 02:29:53,040 ORGANIZATIONS SUCH AS THE 3212 02:29:53,040 --> 02:29:54,400 EUROPEAN COMMISSION AND THE 3213 02:29:54,400 --> 02:29:55,200 WORLD BANK. 3214 02:29:55,200 --> 02:29:57,520 THE NHLBI'S FACILITATION IS 3215 02:29:57,520 --> 02:29:59,920 NEEDED TO DEVELOP RESEARCH 3216 02:29:59,920 --> 02:30:01,360 CAPACITY IN THESE COUNTRIES AND 3217 02:30:01,360 --> 02:30:02,760 ESPECIALLY IN UNDERSERVED 3218 02:30:02,760 --> 02:30:03,960 POPULATIONS IN HIGH INCOME 3219 02:30:03,960 --> 02:30:07,480 COUNTRIES FOR THE PREVENTION AND 3220 02:30:07,480 --> 02:30:09,000 TREATMENT OF HEART, LUNG, BLOOD 3221 02:30:09,000 --> 02:30:10,200 AND SLEEP DISORDERS. 3222 02:30:10,200 --> 02:30:14,360 IN SUMMARY, INTEREST IN THIS 3223 02:30:14,360 --> 02:30:16,880 PROGRAM CLEARLY DRIVEN BY NHLBI 3224 02:30:16,880 --> 02:30:18,960 STRATEGIC VISION OBJECTIVE 3225 02:30:18,960 --> 02:30:20,480 6 THAT WOULD HELP OPTIMIZE 3226 02:30:20,480 --> 02:30:23,200 CLINICAL AND IMPLEMENTATION 3227 02:30:23,200 --> 02:30:26,080 RESEARCH TO IMPROVE HEALTH AND 3228 02:30:26,080 --> 02:30:26,520 REDUCE DISEASE. 3229 02:30:26,520 --> 02:30:30,520 SO FOR THE VOTING, THE FIRST 3230 02:30:30,520 --> 02:30:32,640 CONCEPT WHICH IS CONCEPT 2788, 3231 02:30:32,640 --> 02:30:36,880 IT USES THE R01 CLINICAL TRIAL 3232 02:30:36,880 --> 02:30:38,440 OPTIONAL MECHANISM AND IT 3233 02:30:38,440 --> 02:30:40,480 FOCUSES SPECIFICALLY ON CRITICAL 3234 02:30:40,480 --> 02:30:45,320 LIFE STAGES AND KEY TRANSITIONS. 3235 02:30:45,320 --> 02:30:47,600 ITS PLAN FOR FY 23 AND THE 3236 02:30:47,600 --> 02:30:49,360 FUNDING IS DESIGNED TO SUPPORT 3237 02:30:49,360 --> 02:30:53,960 RESEARCH THAT FOCUSES ON 3238 02:30:53,960 --> 02:30:55,280 ADDRESSING COMMON RISK FACTORS 3239 02:30:55,280 --> 02:30:56,920 THROUGH INNOVATIONS THAT IMPROVE 3240 02:30:56,920 --> 02:30:58,640 HEALTH OVERALL AND LIFESTYLE 3241 02:30:58,640 --> 02:31:01,400 BEHAVIORS IN INFANCY AND 3242 02:31:01,400 --> 02:31:02,680 CHILDHOOD, IN ADOLESCENCE, 3243 02:31:02,680 --> 02:31:07,720 PREGNANCY, OLDER ADULTS, ALL THE 3244 02:31:07,720 --> 02:31:09,400 RELATED TRANSITIONS ACROSS THESE 3245 02:31:09,400 --> 02:31:10,040 PHASES. 3246 02:31:10,040 --> 02:31:12,200 SO THAT'S CONCEPT 2788. 3247 02:31:12,200 --> 02:31:15,880 AND I'LL PAUSE HERE FOR ANY 3248 02:31:15,880 --> 02:31:16,800 QUESTIONS OR COMMENTS YOU HAVE 3249 02:31:16,800 --> 02:31:18,000 ON THIS CONCEPT AND FOR YOUR 3250 02:31:18,000 --> 02:31:28,120 VOTE. 3251 02:31:35,080 --> 02:31:36,640 >> SINCE I'M NOT HEARING OR 3252 02:31:36,640 --> 02:31:37,720 SEEING CONCEPTS, WE'RE ALMOST 3253 02:31:37,720 --> 02:31:39,240 READY TO MOVE ON TO THE NEXT 3254 02:31:39,240 --> 02:31:41,560 CONCEPT. 3255 02:31:41,560 --> 02:31:42,520 >> THAT'S GREAT. 3256 02:31:42,520 --> 02:31:44,080 >> I'M WAITING FOR ONE VOTE. 3257 02:31:44,080 --> 02:31:52,920 >> GREAT. 3258 02:31:52,920 --> 02:31:53,680 >> OKAY. 3259 02:31:53,680 --> 02:31:55,160 WE CAN PROCEED TO THE NEXT ONE 3260 02:31:55,160 --> 02:31:55,760 IN THIS SERIES. 3261 02:31:55,760 --> 02:32:00,880 >> I'LL PRESENT THE NEXT TWO, 3262 02:32:00,880 --> 02:32:03,840 CONCEPTS 2789, WHICH USES THE 3263 02:32:03,840 --> 02:32:07,360 R01 CLINICAL TRIALS OPTIONAL, 3264 02:32:07,360 --> 02:32:13,160 AND CONCEPT 2790. 3265 02:32:13,160 --> 02:32:15,320 THIS TIME BOTH FOCUS ON URBAN 3266 02:32:15,320 --> 02:32:17,880 ENVIRONMENTS AND CLIMATE HEALTH. 3267 02:32:17,880 --> 02:32:20,280 WITH ADDITIONAL EMPHASIS ON THE 3268 02:32:20,280 --> 02:32:23,000 RISK AND EXPOSURES LINKED TO 3269 02:32:23,000 --> 02:32:25,840 URBANIZATION AND RELATED HEALTH 3270 02:32:25,840 --> 02:32:28,000 INEQUITIES AND THE DEVELOPMENT 3271 02:32:28,000 --> 02:32:30,000 OF ENVIRONMENTALLY SUSTAINABLE 3272 02:32:30,000 --> 02:32:30,360 INTERVENTIONS. 3273 02:32:30,360 --> 02:32:32,160 SO THAT'S THE FOCUS FOR THESE 3274 02:32:32,160 --> 02:32:34,040 TWO CONCEPTS. 3275 02:32:34,040 --> 02:32:37,120 AND I'LL PAUSE HERE FOR YOUR 3276 02:32:37,120 --> 02:32:37,920 COMMENTS, YOUR SUGGESTIONS AND 3277 02:32:37,920 --> 02:32:48,080 YOUR VOTE. 3278 02:33:03,320 --> 02:33:05,480 >> WE'RE JUST ABOUT READY TO 3279 02:33:05,480 --> 02:33:08,720 MOVE ON. 3280 02:33:08,720 --> 02:33:10,240 OKAY, AND WE CAN ADVANCE TO THE 3281 02:33:10,240 --> 02:33:10,520 NEXT ONE. 3282 02:33:10,520 --> 02:33:10,800 >> GREAT. 3283 02:33:10,800 --> 02:33:12,640 THANK YOU, JEN. 3284 02:33:12,640 --> 02:33:15,800 THE FOURTH AND THE FINAL 3285 02:33:15,800 --> 02:33:20,400 CONCEPT, CONCEPT 2777 AND 2778, 3286 02:33:20,400 --> 02:33:24,360 TO BE FUNDED IN FY 2025. 3287 02:33:24,360 --> 02:33:28,720 FOCUS ON MULTI-MORBIDITIES AS A 3288 02:33:28,720 --> 02:33:30,800 WHOLE. 3289 02:33:30,800 --> 02:33:32,120 THEY ADDRESS MECHANISMS THAT 3290 02:33:32,120 --> 02:33:33,040 SUPPORT IMPLEMENTATION RESEARCH 3291 02:33:33,040 --> 02:33:36,600 ON WHEN, FOR WHOM AND UNDER WHAT 3292 02:33:36,600 --> 02:33:38,240 CIRCUMSTANCES COST-EFFECTIVE 3293 02:33:38,240 --> 02:33:42,520 PATIENT-CENTERED MODELS CAN 3294 02:33:42,520 --> 02:33:43,400 IMPROVE INTEGRATED CARE FOR 3295 02:33:43,400 --> 02:33:45,800 PATIENTS WHO HAVE NCD 3296 02:33:45,800 --> 02:33:46,760 MULTI-MORBIDITIES IN LOW AND 3297 02:33:46,760 --> 02:33:48,760 MIDDLE INCOME COUNTRIES, AND IN 3298 02:33:48,760 --> 02:33:50,400 UNDERSERVED POPULATIONS IN HIGH 3299 02:33:50,400 --> 02:33:55,640 INCOME COUNTRIES AS I DESCRIBED. 3300 02:33:55,640 --> 02:33:57,160 AGAIN, I'LL PAUSE HERE FOR YOUR 3301 02:33:57,160 --> 02:33:59,120 QUESTIONS, YOUR COMMENTS, YOUR 3302 02:33:59,120 --> 02:34:01,520 SUGGESTIONS, AND YOUR VOTE, 3303 02:34:01,520 --> 02:34:11,960 AGAIN ON 2777 AND 2778. 3304 02:34:20,720 --> 02:34:24,040 >> LOOKING GOOD FOR 2678. 3305 02:34:24,040 --> 02:34:26,040 I'LL GIVE EVERYONE A MOMENT TO 3306 02:34:26,040 --> 02:34:27,880 COMPLETE THEIR VOTE FOR THE 3307 02:34:27,880 --> 02:34:38,280 OTHER CONCEPT AS WELL. 3308 02:34:41,440 --> 02:34:44,760 THE VOTES ARE ALSO IN FOR 2678. 3309 02:34:44,760 --> 02:34:46,160 >> THANK YOU, JEN. 3310 02:34:46,160 --> 02:34:50,760 I BELIEVE THAT'S THE LAST PAIR 3311 02:34:50,760 --> 02:34:52,080 I'LL BE PRESENTING AND I'LL TURN 3312 02:34:52,080 --> 02:34:53,800 IT BACK OVER TO DR. MOEN, 3313 02:34:53,800 --> 02:34:55,040 PLEASE. 3314 02:34:55,040 --> 02:34:56,320 >> YES. 3315 02:34:56,320 --> 02:34:57,640 SO I BELIEVE SOMEBODY IS GOING 3316 02:34:57,640 --> 02:35:02,800 TO BE PRESENTING THESE FOR DARA. 3317 02:35:02,800 --> 02:35:05,880 >> I AM, DR. MOEN. 3318 02:35:05,880 --> 02:35:06,280 IT'S JULIE. 3319 02:35:06,280 --> 02:35:06,840 >> THANK YOU. 3320 02:35:06,840 --> 02:35:09,120 >> SO THE DIVISION OF EXTRAMURAL 3321 02:35:09,120 --> 02:35:10,320 RESEARCH ACTIVITIES WILL PRESENT 3322 02:35:10,320 --> 02:35:11,440 THREE INITIATIVES TODAY. 3323 02:35:11,440 --> 02:35:14,600 THE FIRST INITIATIVE, CONCEPT ID 3324 02:35:14,600 --> 02:35:16,680 NUMBER 2713 IS THE BUILDUP TRUST 3325 02:35:16,680 --> 02:35:17,680 PRIZE CHALLENGE. 3326 02:35:17,680 --> 02:35:21,080 THE OBJECTIVE -- A MAJOR 3327 02:35:21,080 --> 02:35:22,240 OBJECTIVE IS TO INCREASE 3328 02:35:22,240 --> 02:35:24,000 RESEARCH PARTICIPATION, ADOPTION 3329 02:35:24,000 --> 02:35:26,320 OF EXISTING AND NEW TOOLS, AND 3330 02:35:26,320 --> 02:35:28,280 STRATEGIES TO DETECT, TREAT AND 3331 02:35:28,280 --> 02:35:30,160 MONITOR DISEASES AND DISORDERS 3332 02:35:30,160 --> 02:35:32,080 BY IMPROVING ENGAGEMENT WITH 3333 02:35:32,080 --> 02:35:33,520 UNDERSERVED POPULATIONS. 3334 02:35:33,520 --> 02:35:37,560 I WILL DESCRIBE IN BRIEF THE 3335 02:35:37,560 --> 02:35:38,240 RATIONALE AND FORMAT. 3336 02:35:38,240 --> 02:35:39,960 BY USING A PRIZE CHALLENGE, THE 3337 02:35:39,960 --> 02:35:42,160 GOAL IS TO ENGAGE DIRECTLY WITH 3338 02:35:42,160 --> 02:35:43,280 NON-TRADITIONAL INNOVATORS SUCH 3339 02:35:43,280 --> 02:35:44,560 AS UNDERSERVED COMMUNITY 3340 02:35:44,560 --> 02:35:46,000 MEMBERS, AND TO ENGAGE WITH 3341 02:35:46,000 --> 02:35:47,320 ADVOCATES WHO DO NOT NORMALLY 3342 02:35:47,320 --> 02:35:49,520 APPLY FOR NIH GRANTS, AND TO 3343 02:35:49,520 --> 02:35:51,480 GENERATE NEW IDEAS ON ADDRESSING 3344 02:35:51,480 --> 02:35:54,640 TRUST IN UNDERSERVED 3345 02:35:54,640 --> 02:35:54,960 COMMUNITIES. 3346 02:35:54,960 --> 02:35:56,800 THE CHALLENGE CONSISTS OF TWO 3347 02:35:56,800 --> 02:35:58,160 PHASES. 3348 02:35:58,160 --> 02:35:59,120 PHASE 1 WILL SOLICIT NEW IDEAS 3349 02:35:59,120 --> 02:36:01,960 THAT WILL ADDRESS ONE OR MORE 3350 02:36:01,960 --> 02:36:03,000 BARRIERS TO TRUST IN A SPECIFIC 3351 02:36:03,000 --> 02:36:05,040 COMMUNITY TO BE REFINED BY EACH 3352 02:36:05,040 --> 02:36:06,560 SOLVER OR TEAM MEMBER. 3353 02:36:06,560 --> 02:36:09,040 IN PHASE TWO, SOLVERS WILL 3354 02:36:09,040 --> 02:36:09,600 IMPLEMENT THEIR PROPOSED 3355 02:36:09,600 --> 02:36:09,880 SOLUTION. 3356 02:36:09,880 --> 02:36:11,160 THE PHASE ONE SUBMISSION WILL 3357 02:36:11,160 --> 02:36:12,680 CONSIST OF A WHITE PAPER THAT 3358 02:36:12,680 --> 02:36:14,680 INCLUDES INFORMATION ON THE TEAM 3359 02:36:14,680 --> 02:36:15,640 MEMBERS, COMMUNITY OR GROUPS 3360 02:36:15,640 --> 02:36:17,920 THAT WILL BENEFIT FROM THE 3361 02:36:17,920 --> 02:36:18,840 PROPOSED SOLUTION, DESCRIPTION 3362 02:36:18,840 --> 02:36:21,520 OF BARRIERS, STATEMENT OF GAP 3363 02:36:21,520 --> 02:36:23,160 AND OPPORTUNITY, PROPOSED 3364 02:36:23,160 --> 02:36:24,160 SOLUTIONS, AND A PLAN TO 3365 02:36:24,160 --> 02:36:25,720 IMPLEMENT A SOLUTION AND ADDRESS 3366 02:36:25,720 --> 02:36:28,440 THE GAP. 3367 02:36:28,440 --> 02:36:31,280 PHASE ONE WILL CULMINATE IN A 3368 02:36:31,280 --> 02:36:34,240 DEMO DAY HOSTED BY THE NHLBI IN 3369 02:36:34,240 --> 02:36:35,840 WHICH THE TOP PHASE ONE SOLVERS 3370 02:36:35,840 --> 02:36:37,080 WILL BE ASKED TO PARTICIPATE. 3371 02:36:37,080 --> 02:36:38,280 THE PURPOSE IS THREE FOLD. 3372 02:36:38,280 --> 02:36:41,120 NUMBER ONE, TO SHOWCASE THE 3373 02:36:41,120 --> 02:36:43,200 EXCITING SOLUTIONS THAT WERE 3374 02:36:43,200 --> 02:36:44,040 SUBMITTED. 3375 02:36:44,040 --> 02:36:44,880 NUMBER TWO, TO PROVIDE AN 3376 02:36:44,880 --> 02:36:46,280 OPPORTUNITY FOR SOLVERS AND 3377 02:36:46,280 --> 02:36:47,680 STAKEHOLDERS TO INTERACT TO 3378 02:36:47,680 --> 02:36:49,960 SHARE IDEAS, AND NUMBER THREE, 3379 02:36:49,960 --> 02:36:54,360 TO SELECT PHASE ONE FINALISTS. 3380 02:36:54,360 --> 02:36:55,440 PHASE TWO WILL CONSIST OF A 3381 02:36:55,440 --> 02:36:56,760 REDUCTION TO PRACTICE, WHERE 3382 02:36:56,760 --> 02:36:58,160 SOLVERS ARE ASKED TO IMPLEMENT 3383 02:36:58,160 --> 02:36:59,800 THEIR PROPOSED SOLUTIONS AND 3384 02:36:59,800 --> 02:37:02,360 PROVIDE METRICS OF SUCCESS. 3385 02:37:02,360 --> 02:37:04,000 THE OPTIMAL CRITERIA FOR SUCCESS 3386 02:37:04,000 --> 02:37:05,960 WILL BE SPECIFIC TO EACH 3387 02:37:05,960 --> 02:37:06,480 SOLUTION. 3388 02:37:06,480 --> 02:37:07,920 SCORING WILL GENERALLY TAKE INTO 3389 02:37:07,920 --> 02:37:09,800 ACCOUNT FEATURES INCLUDING 3390 02:37:09,800 --> 02:37:11,840 COMPLETION OF PROPOSED PLAN, 3391 02:37:11,840 --> 02:37:14,040 DESCRIPTION OF BARRIERS 3392 02:37:14,040 --> 02:37:15,120 ENCOUNTERED AND HOW THOSE WERE 3393 02:37:15,120 --> 02:37:16,440 LAN DELLED, DESCRIPTION AND 3394 02:37:16,440 --> 02:37:17,640 DEMONSTRATION OF IMPACT AND THE 3395 02:37:17,640 --> 02:37:18,440 POSSIBILITY FOR CONTINUATION 3396 02:37:18,440 --> 02:37:20,600 INTO THE FUTURE. 3397 02:37:20,600 --> 02:37:22,240 DO ANY MEMBERS HAVE ANY 3398 02:37:22,240 --> 02:37:23,560 QUESTIONS OR WISH TO DISCUSS 3399 02:37:23,560 --> 02:37:24,320 THIS INITIATIVE? 3400 02:37:24,320 --> 02:37:25,640 IF NOT, WE CAN HAVE MEMBERS 3401 02:37:25,640 --> 02:37:33,320 VOTE. 3402 02:37:33,320 --> 02:37:34,720 SO I'M NOT HEARING OR SEEING 3403 02:37:34,720 --> 02:37:37,600 ANY, SO I THINK WE CAN GO AHEAD 3404 02:37:37,600 --> 02:37:44,600 AND VOTE. 3405 02:37:44,600 --> 02:37:45,840 >> VOTING IS TAKING PLACE RIGHT 3406 02:37:45,840 --> 02:37:46,280 NOW. 3407 02:37:46,280 --> 02:37:47,400 WE'RE JUST ABOUT READY TO MOVE 3408 02:37:47,400 --> 02:37:53,880 ON. 3409 02:37:53,880 --> 02:37:55,840 ALL THE VOTE ARE IN AND WE CAN 3410 02:37:55,840 --> 02:37:56,080 PROCEED. 3411 02:37:56,080 --> 02:37:56,400 >> THANK YOU. 3412 02:37:56,400 --> 02:37:57,480 SO THE SECOND AND THIRD 3413 02:37:57,480 --> 02:37:58,480 INITIATIVES, I WILL PRESENT 3414 02:37:58,480 --> 02:38:00,840 TOGETHER, AND THEY ARE SECONDARY 3415 02:38:00,840 --> 02:38:03,600 SIGN-ONS, CONCEPT ID NUMBER 3416 02:38:03,600 --> 02:38:06,920 2710, AND CONCEPT ID NUMBER 3417 02:38:06,920 --> 02:38:08,400 2711. 3418 02:38:08,400 --> 02:38:11,160 SBIR STTR COMMERCIALIZATION 3419 02:38:11,160 --> 02:38:12,640 READINESS PILOT PROGRAM, 3420 02:38:12,640 --> 02:38:13,800 TECHNICAL ASSISTANCE AND LATE 3421 02:38:13,800 --> 02:38:16,200 STAGE DEVELOPMENT SB1 CLINICAL 3422 02:38:16,200 --> 02:38:18,160 TRIAL NOT ALLOWED AND 3423 02:38:18,160 --> 02:38:20,640 SB1 CLINICAL TRIAL REQUIRED 3424 02:38:20,640 --> 02:38:21,960 R42 AND R44. 3425 02:38:21,960 --> 02:38:24,120 SO THE 2011 REORGANIZATION OF 3426 02:38:24,120 --> 02:38:27,680 THE SBIR/STTR PROGRAM 3427 02:38:27,680 --> 02:38:30,400 FACILITATED AN EXPANSION OF THE 3428 02:38:30,400 --> 02:38:31,480 COMMERCIALIZATION READINESS 3429 02:38:31,480 --> 02:38:33,760 PILOT PROGRAM TO THE NIH. 3430 02:38:33,760 --> 02:38:35,520 THE COMMERCIALIZATION READINESS 3431 02:38:35,520 --> 02:38:37,080 PILOT PROGRAM IS DESIGNED TO 3432 02:38:37,080 --> 02:38:38,360 FACILITATE THE TRANSITION OF 3433 02:38:38,360 --> 02:38:45,280 PREVIOUSLY FUNDED SBIR/STTR FACE 3434 02:38:45,280 --> 02:38:46,520 2B PROJECTS TO COMMERCIALIZATION 3435 02:38:46,520 --> 02:38:47,800 STAGE BY PROVIDING ADDITIONAL 3436 02:38:47,800 --> 02:38:49,080 SUPPORT FOR LATER STAGE 3437 02:38:49,080 --> 02:38:51,400 TECHNICAL ASSISTANCE AND R & D 3438 02:38:51,400 --> 02:38:51,720 ACTIVITIES. 3439 02:38:51,720 --> 02:38:55,880 AND ALSO ALLOWS PHASE TWO 2B 3440 02:38:55,880 --> 02:38:57,280 GRANTEES TO RECEIVE SUPPORT 3441 02:38:57,280 --> 02:38:57,960 CONCURRENTLY TO THE PARENT 3442 02:38:57,960 --> 02:38:58,400 AWARD. 3443 02:38:58,400 --> 02:39:01,440 DUE TO ITS UNIQUE SB1 MECHANISM, 3444 02:39:01,440 --> 02:39:03,880 AWARDS UNDER THE CRP ARE NOT 3445 02:39:03,880 --> 02:39:06,040 SUBJECT TO THE SAME 3446 02:39:06,040 --> 02:39:09,440 SUBCONTRACTING RESTRICTIONS AS 3447 02:39:09,440 --> 02:39:09,880 R42/R44 AWARDS. 3448 02:39:09,880 --> 02:39:12,720 THIS ALLOWS THE CRP AWARDS TO 3449 02:39:12,720 --> 02:39:13,680 COVER THE COST OF ACTIVITIES 3450 02:39:13,680 --> 02:39:15,120 THAT ARE NOT TYPICALLY SUPPORTED 3451 02:39:15,120 --> 02:39:17,520 THROUGH PHASE 2 OR PHASE 2B 3452 02:39:17,520 --> 02:39:18,600 GRANTS OR CONTRACTS BUT ARE 3453 02:39:18,600 --> 02:39:19,600 NECESSARY FOR PRODUCT 3454 02:39:19,600 --> 02:39:20,600 DEVELOPMENT. 3455 02:39:20,600 --> 02:39:22,240 THESE ACTIVITIES INCLUDE BUT ARE 3456 02:39:22,240 --> 02:39:26,160 NOT LIMITED TO IND IDE ENABLING 3457 02:39:26,160 --> 02:39:27,600 STUDIES, CHEMISTRY MANUFACTURING 3458 02:39:27,600 --> 02:39:29,880 AND CONTROL ACTIVITY FOR IND 3459 02:39:29,880 --> 02:39:31,760 ENABLING TESTS, DESIGN AND 3460 02:39:31,760 --> 02:39:33,200 VALIDATION STUDIES FOR DEVICES 3461 02:39:33,200 --> 02:39:35,680 AND SOFTWARE, CLINICAL TRIAL 3462 02:39:35,680 --> 02:39:37,520 DESIGN AND PLANNING, ANIMAL 3463 02:39:37,520 --> 02:39:39,160 STUDIES TO DEVELOP NEW SURGICAL 3464 02:39:39,160 --> 02:39:41,280 TECHNIQUES RELEVANT TO A NEW 3465 02:39:41,280 --> 02:39:42,360 DEVICE, AND DEVELOPMENT 3466 02:39:42,360 --> 02:39:43,680 VALIDATION OF ASSAYS FOR 3467 02:39:43,680 --> 02:39:46,760 CLINICAL TRIALS. 3468 02:39:46,760 --> 02:39:47,960 THE NHLBI STARTED PARTICIPATING 3469 02:39:47,960 --> 02:39:51,120 IN THE CRP AS EARLY AS 2015, AND 3470 02:39:51,120 --> 02:39:52,400 CONTINUED ITS PARTICIPATION WHEN 3471 02:39:52,400 --> 02:39:55,160 THE PROGRAM WAS RE-AUTHORIZED IN 3472 02:39:55,160 --> 02:39:58,360 2019 THROUGH THE JOHN S. MCCAIN 3473 02:39:58,360 --> 02:40:01,120 NATIONAL DEFENSE AUTHORIZATION 3474 02:40:01,120 --> 02:40:01,280 ACT. 3475 02:40:01,280 --> 02:40:03,040 SINCE FISCAL YEAR '20, WE HAVE 3476 02:40:03,040 --> 02:40:04,880 RECEIVED A TOTAL OF 3477 02:40:04,880 --> 02:40:06,000 44 APPLICATIONS AND MADE A TOTAL 3478 02:40:06,000 --> 02:40:08,280 OF SEVEN AWARDS THROUGH THE CRP 3479 02:40:08,280 --> 02:40:09,680 FUNDING OPPORTUNITY 3480 02:40:09,680 --> 02:40:10,560 ANNOUNCEMENTS. 3481 02:40:10,560 --> 02:40:11,440 POSITIVE OUTCOMES HAVE BEEN 3482 02:40:11,440 --> 02:40:13,320 OBSERVED FROM RECIPIENTS OF CRP 3483 02:40:13,320 --> 02:40:14,520 AWARDS. 3484 02:40:14,520 --> 02:40:17,040 FOR EXAMPLE, FOLLOWING THEIR 3485 02:40:17,040 --> 02:40:19,160 NHLBI FUNDED CRP AWARD WHICH WAS 3486 02:40:19,160 --> 02:40:20,840 USED TO DEVELOP THEIR 3487 02:40:20,840 --> 02:40:22,160 INTELLECTUAL PROPERTY STRATEGY, 3488 02:40:22,160 --> 02:40:24,240 A COMPANY FOCUSED ON DEVELOPING 3489 02:40:24,240 --> 02:40:25,440 PLATELET-BASED CELLULAR 3490 02:40:25,440 --> 02:40:26,880 THERAPIES WENT ON TO RECEIVE A 3491 02:40:26,880 --> 02:40:29,960 CONTRACT FROM BARDA, VALUED UP 3492 02:40:29,960 --> 02:40:31,680 TO $506 MILLION, TO DEVELOP 3493 02:40:31,680 --> 02:40:33,320 HUMAN STEM CELL DERIVED 3494 02:40:33,320 --> 02:40:34,320 PLATELETS AS A MEDICAL COUNCIL 3495 02:40:34,320 --> 02:40:35,960 AT THE MEASURE TO RADIOLOGICAL 3496 02:40:35,960 --> 02:40:38,000 AND NUCLEAR EXPOSURES IN 2019. 3497 02:40:38,000 --> 02:40:41,080 TWO YEARS LATER, THEY WENT ON TO 3498 02:40:41,080 --> 02:40:42,400 RAISE $75.5 MILLION IN SERIES B 3499 02:40:42,400 --> 02:40:44,960 FUNDING. 3500 02:40:44,960 --> 02:40:46,240 ANOTHER EXAMPLE WITH A COMPANY 3501 02:40:46,240 --> 02:40:48,880 WITH NHLBI FUNDING WHICH SPAWNED 3502 02:40:48,880 --> 02:40:51,480 A SPINOUT COMPANY RECENTLY 3503 02:40:51,480 --> 02:40:52,360 OBTAINED 501K CLEARANCE FOR 3504 02:40:52,360 --> 02:40:54,200 THEIR NHLBI FUNDED ULTRASOUND 3505 02:40:54,200 --> 02:40:54,960 SYSTEM. 3506 02:40:54,960 --> 02:40:57,280 THEIR NHLBI-FUNDED CRP AWARD WAS 3507 02:40:57,280 --> 02:40:59,240 USED TO SUPPORT THE 3D PRINTING 3508 02:40:59,240 --> 02:41:00,440 AND MANUFACTURING OF THE 3509 02:41:00,440 --> 02:41:04,160 COMPONENTS TO BETTER COMPLY WITH 3510 02:41:04,160 --> 02:41:05,400 FDI GUIDELINES. 3511 02:41:05,400 --> 02:41:06,560 FINALLY, A MEDICAL DEVICE 3512 02:41:06,560 --> 02:41:07,880 COMPANY FOCUSED ON THE 3513 02:41:07,880 --> 02:41:09,640 DEVELOPMENT OF BLOOD-BASED 3514 02:41:09,640 --> 02:41:11,600 DIAGNOSTICS RECEIVED THE FDA 3515 02:41:11,600 --> 02:41:13,280 ACKNOWLEDGMENT OF EMERGENCY USE 3516 02:41:13,280 --> 02:41:15,000 NOTIFICATION FOR ITS TEST FOR 3517 02:41:15,000 --> 02:41:17,520 DETECTING SARS-COV-2. 3518 02:41:17,520 --> 02:41:19,360 THE NHLBI-FUNDED CRP AWARD WAS 3519 02:41:19,360 --> 02:41:20,720 USED TO SUPPORT THE DEVELOPMENT 3520 02:41:20,720 --> 02:41:22,760 OF THE REGULATORY STRATEGY AND 3521 02:41:22,760 --> 02:41:25,400 MANUFACTURING ACTIVITY FOR THE 3522 02:41:25,400 --> 02:41:26,800 EVENTUAL COMMERCIALIZATION FOR 3523 02:41:26,800 --> 02:41:32,720 THEIR DEVICE. 3524 02:41:32,720 --> 02:41:33,600 ACOMPLETE THEIR PRODUCT 3525 02:41:33,600 --> 02:41:34,600 DEVELOPMENT ACTIVITIES AND 3526 02:41:34,600 --> 02:41:37,080 MAXIMIZE THE INSTITUTE'S EFFORTS 3527 02:41:37,080 --> 02:41:38,520 TO PROMOTE THE TRANSLATION OF 3528 02:41:38,520 --> 02:41:40,680 HEART, LUNG, BLOOD AND SLEEP 3529 02:41:40,680 --> 02:41:41,120 TECHNOLOGY. 3530 02:41:41,120 --> 02:41:42,560 WE RECOMMEND PRIORITIZING 3531 02:41:42,560 --> 02:41:43,680 CONTINUED SECONDARY 3532 02:41:43,680 --> 02:41:44,760 PARTICIPATION AND FUNDING OF 3533 02:41:44,760 --> 02:41:46,960 THIS PROGRAM. 3534 02:41:46,960 --> 02:41:48,360 I'LL STOP HERE AND DO ANY 3535 02:41:48,360 --> 02:41:49,120 MEMBERS HAVE ANY QUESTIONS OR 3536 02:41:49,120 --> 02:41:51,320 WISH TO DISCUSS THE INITIATIVE? 3537 02:41:51,320 --> 02:41:59,840 OTHERWISE WE CAN HAVE VOTING. 3538 02:41:59,840 --> 02:42:01,800 I'M NOT SEEING ANY QUESTIONS OR 3539 02:42:01,800 --> 02:42:09,400 HEARING DISCUSSION. 3540 02:42:09,400 --> 02:42:12,000 >> ALL THE VOTES ARE IN FOR 3541 02:42:12,000 --> 02:42:22,240 CONCEPT 2710. 3542 02:42:23,080 --> 02:42:24,240 I'M GOING TO PAUSE TO MAKE SURE 3543 02:42:24,240 --> 02:42:34,760 WE HAVE ALL THE VOTES FOR 2711. 3544 02:42:35,000 --> 02:42:36,840 ALL THE VOTES ARE IN FOR 2711. 3545 02:42:36,840 --> 02:42:37,440 >> GREAT. 3546 02:42:37,440 --> 02:42:38,240 THAT ENDS THAT. 3547 02:42:38,240 --> 02:42:40,640 I'LL TURN IT BACK OVER TO YOU, 3548 02:42:40,640 --> 02:42:42,080 DR. MOEN. 3549 02:42:42,080 --> 02:42:49,040 >> THANK YOU. 3550 02:42:49,040 --> 02:42:49,480 MASTERFULLY DONE. 3551 02:42:49,480 --> 02:42:50,720 BEFORE WE END THE CONCEPT 3552 02:42:50,720 --> 02:42:52,120 CLEARANCE PIECE, I JUST WANTED 3553 02:42:52,120 --> 02:42:53,720 TO LET EVERYBODY KNOW THAT IF 3554 02:42:53,720 --> 02:42:56,600 YOU HAVE ANY QUESTIONS ABOUT THE 3555 02:42:56,600 --> 02:42:57,720 CONCEPTS THAT WERE LISTED FOR 3556 02:42:57,720 --> 02:42:59,920 INFORMATION ONLY IN THE 3557 02:42:59,920 --> 02:43:02,920 MATERIALS THAT WERE PRESENTED ON 3558 02:43:02,920 --> 02:43:04,360 THE ACD, THIS IS A GOOD TIME FOR 3559 02:43:04,360 --> 02:43:05,360 YOU TO ASK ABOUT THEM. 3560 02:43:05,360 --> 02:43:06,480 THERE WERE THINGS IN THERE THAT 3561 02:43:06,480 --> 02:43:08,960 I HOPE YOU DID AT LEAST BECOME 3562 02:43:08,960 --> 02:43:10,800 AWARE OF OUR INVOLVEMENT IN THE 3563 02:43:10,800 --> 02:43:14,320 HEAL PROGRAM, OUR INVOLVEMENT IN 3564 02:43:14,320 --> 02:43:16,840 IMPROVE AND INCLUDE. 3565 02:43:16,840 --> 02:43:17,840 THERE'S A LOT OF THINGS IN THERE 3566 02:43:17,840 --> 02:43:18,920 AND THE REASON OF COURSE THAT 3567 02:43:18,920 --> 02:43:21,120 THEY'RE FOR INFORMATION ONLY IS 3568 02:43:21,120 --> 02:43:22,760 THAT THE MAJORITY OF THESE, 3569 02:43:22,760 --> 02:43:26,120 ALTHOUGH NOT ALL OF THEM, ARE 3570 02:43:26,120 --> 02:43:27,440 NIH OD PROGRAMS THAT COME FROM 3571 02:43:27,440 --> 02:43:28,760 OTHER PEOPLE'S MONEY THAT WE 3572 02:43:28,760 --> 02:43:30,520 SIGN ON TO AS PART OF BEING A 3573 02:43:30,520 --> 02:43:33,040 GOOD CITIZEN BUT ALSO FOR THE 3574 02:43:33,040 --> 02:43:35,520 NHLBI TO BE ABLE TO SUPPORT 3575 02:43:35,520 --> 02:43:38,720 THINGS IN OUR MISSION THAT FALL 3576 02:43:38,720 --> 02:43:40,240 UNDER THOSE PARTICULAR HEADINGS. 3577 02:43:40,240 --> 02:43:43,400 SO DON'T FLE GLECT NEGLECT. 3578 02:43:43,400 --> 02:43:44,520 DID ANYBODY HAVE ANY QUESTIONS 3579 02:43:44,520 --> 02:43:46,480 ABOUT THOSE? 3580 02:43:46,480 --> 02:43:50,960 NOT SEEING ANYTHING IN THE CHAT. 3581 02:43:50,960 --> 02:43:52,080 OR ANY QUESTIONS OR HANDS 3582 02:43:52,080 --> 02:43:53,600 RAISED. 3583 02:43:53,600 --> 02:43:54,600 DR. GIBBONS, DO YOU HAVE ANY 3584 02:43:54,600 --> 02:43:55,880 QUESTIONS OR ANY DIALOGUE THAT 3585 02:43:55,880 --> 02:43:58,280 YOU WISH TO ENGAGE YOUR 3586 02:43:58,280 --> 02:43:59,280 COUNCILMEMBERS ON BEFORE WE 3587 02:43:59,280 --> 02:44:09,680 ADJOURN THE MEETING? 3588 02:44:09,680 --> 02:44:11,440 I THINK YOU'RE STILL MUTED, 3589 02:44:11,440 --> 02:44:12,000 DR. GIBBONS. 3590 02:44:12,000 --> 02:44:12,800 THERE YOU GO. 3591 02:44:12,800 --> 02:44:16,560 >> THANKS. 3592 02:44:16,560 --> 02:44:18,000 FOR SOME REASON I'M NOT AS ADEPT 3593 02:44:18,000 --> 02:44:19,960 WITH THE BUTTONS ANYMORE. 3594 02:44:19,960 --> 02:44:21,240 NO, JUST -- REALLY JUST A NOTE 3595 02:44:21,240 --> 02:44:24,320 OF, AGAIN, GRATITUDE FOR SHARING 3596 02:44:24,320 --> 02:44:28,480 YOUR TIME, EXPERTISE, AND 3597 02:44:28,480 --> 02:44:29,360 ENGAGEMENT. 3598 02:44:29,360 --> 02:44:30,800 YOU'VE GIVEN SOME REALLY GOOD 3599 02:44:30,800 --> 02:44:32,960 INPUT AND ADVICE THAT WE VERY 3600 02:44:32,960 --> 02:44:35,480 MUCH APPRECIATE TO BE WITH YOUR 3601 02:44:35,480 --> 02:44:37,760 COMMENTS IN THE INITIATIVES, AND 3602 02:44:37,760 --> 02:44:39,400 SO AGAIN, THANK YOU. 3603 02:44:39,400 --> 02:44:41,640 BACK TO YOU, LAURA. 3604 02:44:41,640 --> 02:44:43,800 >> THANK YOU, DR. GIBBONS. 3605 02:44:43,800 --> 02:44:45,360 SO I ALSO WANT TO EXTEND MY 3606 02:44:45,360 --> 02:44:47,200 THANKS TO EVERYBODY AND TO THOSE 3607 02:44:47,200 --> 02:44:48,480 AD HOC MEMBERS WHO WERE WILLING 3608 02:44:48,480 --> 02:44:50,200 TO COME AND SHARE THEIR TIME 3609 02:44:50,200 --> 02:44:51,880 WITH US THIS ROUND. 3610 02:44:51,880 --> 02:44:53,840 I LOOK FORWARD TO OUR NEXT 3611 02:44:53,840 --> 02:44:54,200 MEETING. 3612 02:44:54,200 --> 02:44:56,480 I THINK I SHOULD JUST MENTION 3613 02:44:56,480 --> 02:44:59,000 THAT WE HAVE THE AUGUST MEETING 3614 02:44:59,000 --> 02:45:00,520 WHICH IS GRANTS BUSINESS ONLY SO 3615 02:45:00,520 --> 02:45:02,040 IT'S CLOSED SESSION ONLY. 3616 02:45:02,040 --> 02:45:05,560 WE'LL JUST BE DISCUSSING 3617 02:45:05,560 --> 02:45:06,120 GRANT-RELATED BUSINESS THAT 3618 02:45:06,120 --> 02:45:07,760 NEEDS TO BE CONCLUDED BEFORE THE 3619 02:45:07,760 --> 02:45:09,280 END OF THE FISCAL YEAR, BUT THE 3620 02:45:09,280 --> 02:45:11,120 BIG EVENT THAT'S COMING UP IS IN 3621 02:45:11,120 --> 02:45:12,000 SEPTEMBER, OUR COMBINED MEETING 3622 02:45:12,000 --> 02:45:14,760 WITH THE BOARD OF EXTERNAL 3623 02:45:14,760 --> 02:45:16,160 EXPERTS, AND WE ARE HOPING TO DO 3624 02:45:16,160 --> 02:45:17,920 THAT MEETING IN PERSON THIS 3625 02:45:17,920 --> 02:45:19,480 YEAR. 3626 02:45:19,480 --> 02:45:21,640 SO PLEASE DO STAY TUNED FOR 3627 02:45:21,640 --> 02:45:23,400 ADDITIONAL FUN, AND 3628 02:45:23,400 --> 02:45:24,040 ANNOUNCEMENTS. 3629 02:45:24,040 --> 02:45:25,880 I THINK WE'RE GOING TO ENJOY 3630 02:45:25,880 --> 02:45:27,640 THOSE DISCUSSIONS A GREAT DEAL, 3631 02:45:27,640 --> 02:45:30,840 AND WE'RE BUSY IN THE PLANNING 3632 02:45:30,840 --> 02:45:32,160 PHASE SO FURTHER INFORMATION 3633 02:45:32,160 --> 02:45:33,880 WILL BE FORTHCOMING. 3634 02:45:33,880 --> 02:45:34,840 DR. GIBBONS, YOU MAY CLOSE THE 3635 02:45:34,840 --> 02:45:37,720 MEETING. 3636 02:45:37,720 --> 02:45:42,680 >> WELL, THANK YOU SO MUCH TO 3637 02:45:42,680 --> 02:45:44,320 THE 297TH MEETING OF THE 3638 02:45:44,320 --> 02:45:47,440 NATIONAL HEART, LUNG AND BLOOD 3639 02:45:47,440 --> 02:45:48,240 ADVISORY COUNCIL IS NOW 3640 02:45:48,240 --> 02:45:48,600 ADJOURNED. 3641 02:45:48,600 --> 02:45:49,000 THROUGH SO MUCH. 3642 02:45:49,000 --> 02:45:51,160 >> THANKS, EVERYBODY. 3643 02:45:51,160 --> 02:45:52,360 >> BYE, ALL. 3644 02:45:52,360 --> 02:45:53,240 >> BYE. 3645 02:45:53,240 --> 02:45:54,680 THANKS, DAVID. 3646 02:45:54,680 --> 02:45:55,120 >> BYE. 3647 02:45:55,120 --> 02:45:56,000 THANK YOU. 3648 02:45:56,000 --> 02:45:57,640 >> THANK YOU, TINA. 3649 02:45:57,640 --> 02:45:58,520 >> BYE-BYE. 3650 02:45:58,520 --> 02:45:59,680 NICE TO SEE YOU ALL. 3651 02:45:59,680 --> 02:46:01,880 >> YOU TOO, MARTHA. 3652 02:46:01,880 --> 02:46:02,120 THANKS. 3653 02:46:02,120 --> 00:00:00,000 >> BYE, EVERYONE.